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Abstract
Lipid-based formulations (LBFs) are effective means for the oral delivery of poorly water-
soluble compounds. The drug is already solubilized in the formulation and, thus, the
critical dissolution step is circumvented. However, the oral bioavailability is also deter-
mined by the fate of the LBF in the gastrointestinal (GI) tract. Formulation dispersion
and lipid digestion are particularly critical steps in this regard. The ability to maintain
the drug in a solubilized state may be reduced leading to an increased risk of drug pre-
cipitation and erratic drug absorption.
The present thesis consists of five studies, which aim at improving the biopharmaceuti-
cal understanding of LBF performance in the GI tract. To this end, in vitro dispersion
and digestion assays are employed along with advanced analytical techniques and math-
ematical modeling. The findings may improve the predictability of LBF performance
upon oral administration.
In the first study, we analyzed surfactant/co-solvent systems during aqueous dilution.
A theoretical model was proposed to analyze the role of excipient interaction for drug
solubilization during dilution. This model indicated that, in undiluted formulations,
co-solvent/surfactant domains were responsible for drug solubilization. In contrast, in
diluted formulations the co-solvent partitioned out of the surfactant microstructure.
This loss of excipient interaction caused formulation-specific supersaturation, which was
indicative for the risk of drug precipitation. The analysis of excipient interactions and
drug supersaturation facilitated the identification of critical drug-loadings in LBFs that
are prone to drug precipitation.
The second study focused on the in vitro lipolysis test. We evaluated Raman spec-
troscopy as an analytical technique for real-time monitoring of lipolysis-triggered drug
precipitation. Despite the complex and varying medium composition, in-line analyt-
ics provided robust and highly time-resolved drug precipitation profiles. This allowed
further analysis of the precipitation kinetics using a theoretical nucleation and growth
model. The combination of real-time Raman spectroscopy and mathematical modeling
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provided valuable insights into the time evolution of lipolysis-triggered drug crystalliza-
tion.
The simulation of formulation digestion in an absorption environment was the purpose
of the third study. Current in vitro lipolysis tests are performed in a single compart-
ment and, therefore, they include no absorption sink. In this study, we developed a
physiologically-based model of formulation digestion in the GI tract based on in vitro
lipolysis and in vivo pharmacokinetic data. The resulting system of differential equations
allowed the calculation of drug supersaturation during the intestinal transit of LBFs.
This approach provided clear evidence that an absorption sink significantly lowers the
risk for lipolysis-triggered drug precipitation. Hence, in vitro lipolysis provides the worst
case prediction of LBF performance. Moreover, our results suggested that the intesti-
nal digestion of LBFs is less critical than expected with respect to drug precipitation,
especially with highly permeable drugs.
The fourth study focused on the solid-state of precipitated weakly basic drugs. Drug-
loaded LBFs were dispersed in a simulated intestinal medium with and without di-
gestive enzymes and the resulting precipitate was analyzed by X-ray diffraction and
re-dissolution. The study revealed that in vitro conditions can influence the solid-state
properties of precipitating weak bases. While a crystalline precipitate was observed upon
dispersion, the presence of digestive enzymes led to an amorphous precipitate. These
findings are of high practical importance for the prediction of LBF performance in vivo.
In contrast to the crystalline form, an amorphous precipitate may re-dissolve rapidly
and, hence, become again available for absorption.
Finally, in the fifth study, Raman spectroscopy and ultrasound resonator technology
were evaluated as process analytical tools for drug quantification in LBFs. This study
evidenced the excellence of Raman spectroscopy for drug quantification in complex li-
pidic matrices and was the basis for using Raman spectroscopy with biopharmaceutical
tests.
This thesis provided novel insights into the biopharmaceutical behavior of LBFs in the
GI tract. The establishment of real-time techniques allowed the examination of highly
dynamic formulation changes during dispersion and digestion. Moreover, mathematical
modeling provided key insights into biopharmaceutical processes that are hardly acces-
sible using in vitro methods. These advancements may improve the ability to predict
LBF performance in vivo.
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Chapter 1
Introduction
1.1 Background
Oral administration is generally the most convenient way for systemic drug delivery.
From a biopharmaceutical perspective, a drug has to overcome two main hurdles in order
to become systemically available. First, the drug has to dissolve in the gastrointestinal
(GI) fluids and the kinetics and extent of this dissolution are critical for poorly water-
soluble compounds. In a second step, the drug must permeate across the intestinal
membrane to reach the circulation. Good membrane permeability is fundamental at
this stage. The biopharmaceutical classification system (BCS) has been introduced to
classify pharmaceutical compounds into four types as a function of their solubility and
permeability properties [1]. BCS class II and IV compounds are particularly challenging
from a pharmaceutical perspective, but the formulation strategy can help in reducing
biopharmaceutical issues, especially with BCS class II drugs. These compounds are
poorly water-soluble but well permeable, i.e., the dissolution step is the major cause for
limited drug absorption. Drug solubilization is largely influenced by exo- and endogenous
factors such as food and bile salts, and as a consequence, the pharmacokinetic profile is
often highly variable [2, 3].
Since up to 75% of new low molecular weight compounds are poorly water-soluble [4],
the research interest toward robust and effective means for enhancing oral bioavailability
increased tremendously over the past decades. Several formulation principles have been
identified, which principally improve either the solubility or the dissolution rate of the
drug [5, 6]. This can be achieved, for example, by altering the solid-state (e.g., by
selecting superior polymorphs) or by developing more soluble salts or hydrates. Other
mechanisms include the reduction of particle size of the solid drug (i.e., variation of the
specific surface area) and the generation of solid dispersions. The dissolution step can
1
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even be entirely circumvented by administering the active compound in a solubilized
state. This strategy is applied with lipid-based formulations (LBFs) and is the main
focus of the present thesis.
LBFs are not a recent pharmaceutical innovation [7]. However, the raising number of
poorly water-soluble drug candidates notably increased the research interest toward oral
LBFs in the past decade. The successful launch of some lipid-based products, such as
Sandimmun Neoral R©, Invirase R©, and Norvir R©, has additionally promoted this formula-
tion strategy [8].
Oral LBFs are simple oil solutions or more complex mixtures of lipidic excipients, in
which the drug is incorporated in the solubilized form [9, 10]. The circumvention of
the dissolution step and the higher apparent drug solubility in GI fluids are certainly
major advantages of LBFs [11]. However, there are additional mechanisms, which can
improve the oral bioavailability. Certain lipidic excipients may interact with membrane
transporters and, thus, increase drug uptake in enterocytes [12, 13]. LBFs can also
have a protective effect against presystemic degradation. Since formulation absorption
generally occurs via the lymphatic system, first-pass metabolism is significantly reduced
[14–17].
After oral administration, LBFs experience several processing steps in the GI tract. The
aqueous environment in the stomach leads to the formation of small oil droplets, emul-
sions, and/or micellar structures. This dispersion process is generally spontaneous and
occurs rapidly on contact with the aqueous fluids. In the intestinal lumen, formulation
lipids are then digested by lipolytic enzymes. During digestion, oil droplets are reduced
to smaller colloidal structures from which drug absorption is facilitated.
Although these structural changes are necessary for promoting formulation dispersion,
in some instances they can also compromise drug absorption [11]. During dispersion,
hydrophilic excipients often migrate into the aqueous bulk, which may significantly re-
duce the drug solubilization capacity of the formulation. Similarly, excipient digestion
generates comparatively hydrophilic lipolysis products, such as monoglycerides and fatty
acids. The formulation becomes more polar, and as a consequence, the drug can precip-
itate. A poorly water-soluble compound is generally not expected to re-dissolve during
GI transit. Hence, such intralumenal precipitation is highly undesired and may seriously
compromise drug absorption.
The prediction of LBF behavior is very important for effective formulation development.
Several in vitro methods have been developed to simulate formulation dispersion and
digestion in biorelevant media [18]. However, the prediction of in vivo performance is
still poor and only a rank-order level of correlation has been evidenced so far [19–25].
It is a main focus of current LBF research to improve biopharmaceutical in vitro assays
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[26–30]. One major limitation is the lack of appropriate analytical techniques for charac-
terizing formulation changes. Formulation dispersion and digestion are highly dynamic
processes and traditional analytical instrumentations often fail in capturing these events
accurately [31, 32]. Moreover, there is increasing evidence that drug precipitation does
not necessarily impair oral bioavailability [23, 33–35]. In contrast to the crystalline form,
an amorphous precipitate may re-dissolve rapidly upon precipitation and become again
available for absorption. Hence, the solid-state of a precipitate is a major determinant
of oral bioavailability. A further critical limitation is the absence of an absorptive sink
in in vitro assays [36–38]. This is particularly relevant for poorly water-soluble drugs,
which easily attain the saturation level, especially in a closed compartment.
As a result, there is still an incomplete mechanistic understanding of LBF performance
in the digestive tract. More research is required in this field of drug delivery.
1.2 Objectives
The general aim of this thesis is to improve the biopharmaceutical understanding of
LBF performance in the GI tract using in vitro tests. To this end, advanced analytical
techniques are introduced, which provide insights into the highly dynamic processes of
formulation dispersion/digestion and drug precipitation. Moreover, mathematical mod-
els are implemented to describe the processes of drug solubilization on a mechanistic
basis. The thesis is subdivided into six chapters, which address analytical and mecha-
nistic aspects of LBF performance during in vitro dispersion and digestion.
The theoretical section (Chapter 2) aims at reviewing in vitro assays and analytical
techniques currently adopted for biopharmaceutical characterization of oral LBFs. Par-
ticular attention is also directed to the technical limitations of in vitro assays.
Chapter 3 focuses on the process of LBF dispersion of surfactant/co-solvent systems.
The aim is to elucidate the mechanism of drug solubilization upon aqueous dilution in
order to identify LBFs with a low risk for drug precipitation.
The first purpose in Chapter 4 is to implement a real-time analytical technique for
monitoring drug precipitation during in vitro lipolysis. In situ analytics is required to
reduce the temporal delay involved with off-line techniques and to obtain highly time-
resolved data. Based on this advanced analytics, the second aim is to study the kinetics
of drug crystallization using a theoretical nucleation and growth model.
The aim in Chapter 5 is to examine the effect of an absorptive sink on the extent of drug
supersaturation during formulation lipolysis. Due to the absence of multi-compartmental
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in vitro assays, we aim at developing a physiologically-based mathematical model that
simulates formulation digestion in the intestine.
The solid-state of weakly basic drugs precipitated during LBF dispersion and digestion
is the focus in Chapter 6. The purpose is to assess the influence of in vitro conditions
(dispersive versus digestive) on the solid-state properties and re-dissolution behavior of
precipitated weak bases.
Finally, Chapter 7 focuses on the application of Raman spectroscopy and ultrasound
resonator technology as process analytical tools for drug quantification in LBFs. The aim
is to identify analytical techniques which are particularly appropriate for quantitative
analyses in complex lipidic matrices.
Chapter 2
Theoretical section
2.1 Oral lipid-based formulations
Oral LBFs have gained increasing attention as a drug delivery strategy for poorly water-
soluble compounds. These formulations are mixtures of up to five excipients, including
oils, lipophilic or hydrophilic surfactants, and co-solvents [8], in which the drug is ad-
ministered in a solubilized state. In 2000, Pouton introduced the Lipid Formulation
Classification System (LFCS) that categorizes LBFs into five classes according to their
composition (Table 2.1) [9, 10]. Type I formulations are the most lipophilic formulations
and are composed from digestible oils only (e.g., Miglyol N 812, olive oil). These formu-
lations form coarse oil droplets in contact with aqueous media and have to be digested
to promote dispersion and drug absorption. Type II formulations contain additionally
a hydrophobic surfactant (e.g., Tween R© 85), which facilitates self-emulsification. They
generate coarse emulsions of 200 nm to 1 µm in diameter and digestion is often neces-
sary to reduce particle size and facilitate drug absorption. Type III formulations are
composed of lipids, hydrophilic surfactants (e.g., Cremophor R© EL, Tween R© 80), and
eventually co-solvents (e.g., ethanol, Transcutol R©). This class is subdivided into two
types to discern between formulations with larger amounts of oil (type IIIA) and formu-
lations with less than 20% w/w oil (type IIIB). The hydrophilic surfactants generally
accelerate self-emulsification and produce fine emulsions of less than 200 nm in diam-
eter. Finally, type IV formulations are lipid-free and are composed of surfactants and
co-solvents only. These systems disperse very easily forming micellar structures in aque-
ous milieu and, since surfactants are generally poorly lipolised, formulation digestion is
less relevant. Strickley [8, 39] and Hauss [18] provided thorough reviews of excipients
used in commercially available LBFs.
5
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Table 2.1: Composition of LBFs (% w/w) according to the LFCS [9, 10].
Excipient Type I Type II Type IIIA Type IIIB Type IV
Oils 100 40-80 40-80 <20 -
Lipophilic surfactants (HLB<12) - 20-60 - - 0-20
Hydrophilic surfactants (HLB>12) - - 20-40 20-50 30-80
Co-solvents - - 0-40 20-50 0-50
LBFs are developed in an empirical way to date and several procedural methods can be
found in the literature [6, 40, 41]. The development of a LBF usually starts with the
identification of excipients (oils, surfactants, and co-solvents) that provide adequate drug
solubilization [42]. This screening is performed via experimental solubility measurement
to date, but much effort is currently directed to the development of automated high-
throughput solubility assays [43] and in silico methods for solubility prediction [44–47].
Such advanced approaches are desirable since conventional solubility measurement in
lipidic and/or semi-solid matrices is labor-intensive and time-consuming.
Once adequate excipients have been identified, different mixtures of ingredients are eval-
uated in terms of miscibility via ternary phase diagrams [10, 48]. This screening allows
the identification of stable formulations that provide homogeneous drug solubilization.
Further criteria of formulation selection include toxicity and impurity issues as well as
capsule compatibility [49].
Successful formulation candidates are finally tested with respect to their biopharma-
ceutical performance. The primary aim is to assess the capacity of the formulation
to maintain the drug in the solubilized state after oral administration. Two processes
are particularly critical in this regard: formulation dispersion in the aqueous environ-
ment and formulation digestion by intestinal lipases. These processing steps can lead
to a restructuring and a change in polarity of lipidic excipients, which may affect the
microenvironment of the drug. The solubilization capacity of the formulation often
decreases, and as a result, the drug can precipitate. Because a poorly water-soluble
compound may barely re-dissolve during GI transit, such intralumenal precipitation is
highly undesired and can result in reduced and erratic drug absorption. Appropriate in
vitro tools are therefore necessary to identify viable formulation candidates.
Several in vitro methods for biopharmaceutical testing of LBFs are described in the
literature but, unfortunately, there is still a lack of standardized, compendial assays
[6, 30]. The most used in vitro assays are dilution, dispersion, and lipolysis tests. In
vitro dilution testing assesses the performance of LBFs in contact with aqueous media
qualitatively. It is a simple test, and thus, appropriate for high-throughput formulation
screening. However, the simulated environment is rather far from physiological condi-
tions. For more biorelevant characterization, other tests may be applied, as for example
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Table 2.2: Comparison of the three main in vitro assays for simulating LBF perfor-
mance in the GI tract (modified from [29]).
Dilution test Dispersion test Lipolysis test
Experimental simplicity ++ + −
Proximity to in vivo conditions −/+ + ++
Miniaturization for high-throughput
screening
++ + −
Testing of the final dosage form (e.g., cap-
sule)
− ++ −a
Quantification of the extent of precipitation −/+ ++ ++
Determination of supersaturation and kinet-
ics of precipitation
−/+ ++ ++
Solid-state analysis of precipitate −/+ ++ ++
a Limited physiological relevance.
an in vitro dispersion test. This test is usually performed in a compendial USP 2 dis-
solution apparatus and it provides the drug solubilization versus time profile of a LBF.
Due to the similarity to dissolution testing with solid dosage forms, dispersion, dissolu-
tion, and drug-release testing are often used as synonyms. However, the term dissolution
should not be used when the drug is not in a solid form in the formulation. The test
offers more standardized conditions (e.g., hydrodynamics) compared to simple in vitro
dilution. Finally, in vitro lipolysis testing is applied to characterize LBF performance in
digestive environment. This test involves a simulated intestinal medium with lipolytic
enzymes and provides the closest conditions to the in vivo physiology. However, in vitro
lipolysis is comparatively time-consuming, and thus, less adequate for high-throughput
analyses. Key aspects of in vitro dilution, dispersion, and lipolysis tests are listed in
Table 2.2.
The development of standardized in vitro assays is a major focus in current LBF re-
search [26–29]. Several limitations have been identified and much efforts were directed
to the optimization of testing protocols [26, 29, 31, 37, 50–52]. Moreover, particular at-
tention has been directed to selection of appropriate analytical instrumentation for LBF
characterization [31–33, 53]. The accurate monitoring and interpretation of formulation
properties is, indeed, the basis for any biopharmaceutical investigation.
The present theoretical section summarizes recent advancements in in vitro testing of
LBFs. First, two important parameters affecting drug absorption are discussed, i.e.,
drug supersaturation and the solid-state of a precipitate. The second part provides an
overview of current methods for in vitro dilution, drug-release, and lipolysis testing. A
particular focus is directed to the analytical techniques for biopharmaceutical charac-
terization of LBFs. Finally, current challenges of in vitro LBF testing are discussed.
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2.2 Important parameters affecting drug absorption from
LBFs
A major aim in biopharmaceutical testing of LBFs is to assess whether the drug re-
mains in solution during formulation dispersion and digestion. Drug absorption can be
significantly reduced in case of intralumenal precipitation, and thus, such biorelevant
characterization is of primary importance. In addition to the intrinsic solubilization
capacity of the LBF, oral bioavailability can also be influenced by other formulation-
and drug-related factors. Formulation-related factors include, for example, biological
effects of lipidic excipients on intestinal based efflux and lymphatic transport [14, 54].
Drug-related factors include more biophysical aspects of drug precipitation. There is a
growing realization that the occurrence of drug precipitation in vitro does not directly
imply a reduced drug absorption in vivo [36, 38, 55–62]. Important determinants are
the extent of drug supersaturation and the solid-state of precipitating material, which
will be discussed in the present section.
2.2.1 Drug supersaturation
The process of precipitation basically occurs in three stages [63]. In the initial stage, the
drug is completely solubilized, but its concentration exceeds the solubility at equilib-
rium. This so-called supersaturated state is thermodynamically unstable and provides
the driving force for drug precipitation. Once a critical degree is attained, drug molecules
begin to form small aggregates. During this nucleation phase, an initial energy barrier
must be exceeded until these aggregates grow to a critical size [64]. As soon as stable
nuclei are formed, they act as centers for crystallization and grow to larger crystals.
Crystal growth is the third stage of precipitation.
From a biopharmaceutical perspective, the initial induction period is particularly im-
portant. Supersaturated drug is thermodynamically unstable, and hence, prone to pre-
cipitation. However, the time point when nucleation begins is variable. For low degrees
of supersaturation and in the absence of external triggers, the nucleation period can be
in the order of years. In contrast, when a critical degree of supersaturation is exceeded,
the induction time reduces dramatically and nucleation may begin within seconds to
minutes [63]. This duration is particularly relevant when drug supersaturation occurs
in an absorptive environment [36]. Supersaturated drug is, indeed, still available for
absorption, and the longer the induction period, the more drug can be absorbed prior
to precipitation. In the best case, supersaturation falls below a critical level and precip-
itation is ultimately prevented.
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Four different mechanisms can basically induce drug supersaturation after oral admin-
istration of a LBF [59]. Formulation dispersion [48] and excipient digestion [56] are
certainly of major importance, but recent studies have evidenced other triggers of su-
persaturation. It was shown that the inclusion of bile salt micelles into lipid-rich mixed-
micelles containing lipolysis products decreases the solubilization capacity of basic drugs
[55, 65]. This influence is, however, assumed to be drug specific and may be less crit-
ical for neutral drugs [65]. Furthermore, supersaturation can also be generated by the
absorption of lipolysis products, and hence, the removal of solubilizing agents. Particu-
larly important is here the microenvironment at the unstirred water layer. The lower pH
favors protonation of fatty acids, the dissociation from colloidal structures, and finally,
fatty acid absorption [66].
Much attention is directed to the prevention of high degrees of supersaturation in vivo,
but supersaturation per se can also be a desirable outcome in drug delivery. Indeed,
the thermodynamic activity of a supersaturated drug is comparatively high, and thus,
the drug flux across the intestinal membrane is favored [36, 58, 67, 68]. This property
has clearly beneficial effects on drug absorption. The extent of supersaturation and the
place where supersaturation occurs within the GI lumen are particularly important in
this respect. Moderate supersaturation near to the absorptive membrane is expected to
favor drug absorption, and as a consequence, the risk of drug precipitation is rather low.
In contrast, extensive supersaturation in a poorly absorptive environment (e.g., in the
stomach) is more critical.
The potential of maintaining drug in a supersaturated state has also influenced for-
mulation strategies with poorly water-soluble compounds [69–72]. In particular, super-
saturable LBFs and supersaturated self-nanoemulsifying drug delivery systems (super-
SNEDDS) have attracted increasing attention. Supersaturable LBFs aim at generat-
ing high levels of supersaturation upon aqueous dispersion of the formulation and at
decelerating the rate of drug precipitation to enable drug absorption. To this end,
low amounts of surfactant and a polymeric precipitation inhibitor (e.g., hydroxypropyl
methylcellulose) are added to the formulation [73–75]. A similar approach is followed
with super-SNEDDS. In these formulations, the drug is incorporated at a concentration
that exceeds its solubility in the pure formulation. Hence, super-SNEDDS are ther-
modynamically unstable already in the undispersed state, but allow a higher drug-load
compared to supersaturable LBFs [23, 34].
The degree of supersaturation is generally expressed as (super-)saturation ratio, SR,
which is the ratio of the actual concentration of solubilized drug, Csol, and the equilib-
rium solubility of the drug, C∗:
SR =
Csol
C∗
(2.1)
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For SR ≤ 1, the system is thermodynamically stable, whereas for SR > 1, supersatura-
tion is reached and the drug may precipitate to restore saturation.
The extent of supersaturation can be indicative for the likelihood of drug precipitation
during LBF dispersion and digestion. This measure has therefore attracted increasing
attention in recent LBF research [28, 36, 38, 55–58, 61, 65, 70, 76, 77]. For example,
drug precipitation was shown to be unlikely on a physiologically relevant time-scale at
SR < 2, whereas rapid drug precipitation was observed at SR > 4 during in vitro disper-
sion of LBFs [48, 77]. Particularly challenging is the determination of a critical SR with
lipolysis-triggered drug precipitation. Drug solubility is here continuously changing due
to the hydrolysis of formulation lipids, and hence, the SR is not constant. Accordingly,
a formulation can be below saturation upon dispersion (without lipolysis), but then
exhibit a dramatic loss in solubilization capacity upon digestion [31]. Williams et al.
proposed a modified SR for assessing the theoretical thermodynamic instability of the
drug in digested formulation. This potential maximum supersaturation ratio, SRM , is
the ratio of the maximum theoretical concentration of solubilized drug and the minimum
drug solubility in the digest [28]:
SRM =
Max.Csol in digest
Min.C∗during digestion
(2.2)
Based on a range of compounds and LBFs, it appeared that the risk of drug precipitation
was particularly high for SRM > 3 [28, 56]. The correlation was remarkable, thus,
indicating that it is a practical approach for identifying drug-loads with an increased
risk of precipitation. However, it must be noted that the SRM value is obtained from
formulation digestion in vitro and it gives no information about the time evolution of
drug supersaturation. This can be a limitation, for example, for evaluating the risk of
drug precipitation in an absorptive environment.
2.2.2 Solid-state of precipitated drug
It was generally assumed that drug precipitation directly reduces the absorbable drug
dose because of the poor re-dissolution capacity of a poorly water-soluble substance
[10]. However, recent studies suggested that this assumption is not valid for every type
of precipitate. A significant determinant of drug absorption is the solid-state of the
precipitate, which can be either oily, amorphous, or crystalline [78].
Crystalline material is characterized by a highly periodical three-dimensional pattern
and long distance order of the molecules in the crystal lattice. This is the most stable
solid structure from a thermodynamic perspective. In an amorphous precipitate, the
molecules have no long-range order, whereas in the oil state, molecules are randomly
arranged. The oil state is considered as an additional liquid phase and is generated at
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very high degrees of supersaturation [78].
The dissolution behavior of a drug is highly dependent from its solid-state [79]. The free
energy needed to mobilize drug molecules from oil and amorphous precipitates is much
lower than for crystalline solids. Such precipitates are therefore expected to re-dissolve
notably faster and to reach higher apparent solubilities compared to crystalline drug
(Figure 2.1). Moreover, the higher apparent solubility enhances drug flux across the
intestinal membrane, which provides a further advantage for drug absorption [62].
Sassene et al. recently observed that cinnarizine precipitated in an amorphous form
during in vitro lipolysis of a self-emulsifying formulation. Subsequent re-dissolution
experiments confirmed that this precipitate dissolved much faster than the crystalline
counterpart [33]. Interestingly, a solubility advantage was also observed in vivo, where
extensive drug absorption occurred after oral administration of the LBFs [80]. However,
to confirm the causal relationship between amorphous precipitate and drug absorption,
further studies are necessary, which possibly analyze the solid-state of a precipitate
directly in intestinal aspirates. Such analyses were recently performed by Psachoulias et
al., for simple drug solutions without LBFs [61].
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Figure 2.1: Re-dissolution behavior of precipitated drug in the oil/amorphous state
(red) and in the crystalline state (blue). Although the final equilibrium solubility,
C∗eq, is equal for each solid-state, the highest apparent solubility, C
∗
app, of high energy
materials such as oil or amorphous precipitates can be a multiple of the solubility at
equilibrium (adapted from [38]).
2.3 In vitro assessment of LBF dilution/dispersion
Formulation dispersion is the first process that occurs after LBF administration and
capsule disintegration in the GI fluids. Due to the partial immiscibility of lipidic excip-
ients in polar fluids, the dispersion step often leads to a considerable restructuring of
formulation components [10, 48]. For example, the addition of small amounts of water
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to an LFCS type III formulation leads to the swelling of inverse micelles. More water
causes the formation of a water-in-oil emulsion, and in the presence of equal amounts
of water and formulation, the system becomes bicontinuous. Finally, the vehicle passes
over to an oil-in-water emulsion [10]. This restructuring can significantly impair the
drug solubilization capacity of the formulation, especially with hydrophilic systems such
as LFCS type III and IV formulations [48, 77]. The loss of drug solubilization capacity
can result in a supersaturated state and in undesired drug precipitation.
2.3.1 In vitro dilution test
In vitro dilution is a simple test that is usually applied in early formulation development.
The primary aim is to assess the spontaneity of self-emulsification and the characteristics
of the resulting dispersion. This information reveals the capacity of the LBF to form
physically stable and homogeneous emulsions upon oral administration. A second aim
is to gain first, qualitative information about the drug solubilization capacity of the
formulation in an aqueous environment.
For dilution testing, a formulation is mixed with water (or an aqueous buffer) at one to
three different dilution ratios. Experiments are perfomed at either room temperature
or 37◦C and under mild agitation conditions [81–86]. It is recommendable to select
more than one dilution ratio to learn about the LBF performance at different stages of
formulation restructuring. Low dilution ratios (e.g., 1:2 w/w) simulate the formulation
behavior near to the bicontinuous phase, whereas high dilution ratios (e.g., 1:200 w/w)
hold for the final dilution in GI fluids [77, 87].
2.3.1.1 Analytical tools for studying aqueous dilution of LBFs
In the early development of LBFs, the dilution behavior is generally evaluated with
standard analytical methods. Visual inspection is particularly important in this context
and provides first information about the spontaneity of self-emulsification and the pres-
ence of a precipitate. Instrumental methods include primarily dynamic light scattering
(DLS), turbidimetry, and conductivity measurement, which are particularly convenient
in terms of availability and costs [48, 71, 88]. DLS measures the size of dispersed parti-
cles (e.g., oil droplets) in a colloidal range [89, 90]. The sample is illuminated by a laser
beam and the backscattered light is detected at a certain angle by a photon detector.
The diffusion coefficient of particles is then used to calculate their hydrodynamic radius
via the Stokes-Einstein equation. The particle size is, however, not the only relevant
information resulting from DLS measurements. Another important parameter is the
particle size distribution, often expressed as polydispersity index (PDI), which indicates
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the uniformity of the dispersed formulation. This technique is well-established in LBF
research and has found broad application in both industrial and academic laboratories
[88, 91]. Turbidimetry is particularly appropriate to determine the spontaneity of self-
emulsification and the phase stability of an emulsion. A nephelometer is used, which
determines the forward light scattering of a sample, and hence, the degree of obscura-
tion based on the scattered signal. The possibility of in situ measurement is a great
advantage of turbidimetric analysis. Moreover, the technique can be miniaturized, and
therefore, it has found application as a high-throughput method for formulation screen-
ing [43, 92]. Turbidimetry was also proposed for flow-through analysis of the dispersion
properties of self-emulsifying formulations [83].
Conductivity measurement allows for the analysis of the phase behavior of formulations
during aqueous dilution [48, 93–95]. The phase change at the oil to water continuous/bi-
continuous region is particularly well detectable, as the conductivity notably increases
when water becomes the continuous phase in a diluted system.
Visual inspection and turbidimetry can also be used to detect drug precipitation dur-
ing formulation dilution, by direct comparison of drug-free and drug-loaded formulation
[43, 71, 72, 77]. Higher turbidity in the drug-loaded system may indicate the presence
of a precipitate. However, the clear detection of such a precipitate is sometimes chal-
lenging. Solid drug can be hardly visible due to the intrinsic turbidity of the emulsified
formulation, especially with LFCS type II and IIIA systems [29]. Other limitations are
typically the low overall amount of drug, especially at high dilution levels, and the ef-
fect of drug inclusion on the droplet size of emulsified formulations [96]. An increase in
droplet size, and thus, and increase in turbidity, may then be erroneously interpreted as
drug precipitation. In these cases, additional methods, such as optical microscopy, may
be necessary to confirm the presence of a precipitate [29].
The mechanistic elucidation of formulation behavior is more complex and sophisticated
methods are required for this purpose.
Microscopy techniques such as transmission electron microscopy (TEM) has been often
applied for studying formulation morphology in the dispersed state [94, 97–102]. Tradi-
tional electron microscopes work under high-vacuum to avoid electron scattering by gas
molecules. Hence, to analyze hydrated structures such as colloids, a cryo preparation
is generally required to prevent the damage of the native morphology [103]. Polarized
light microscopy (PLM) is instead particularly appropriate for detecting liquid crys-
talline mesophases, which appear as birefringent structures in the microscopy images
[83, 104].
Dynamic viscosity and ultrasound resonator technology (URT) were used for the anal-
ysis of LBF performance at varying dilution ratios. Dynamic viscosity was measured
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with a rotational viscosimeter and provided information about the size and attractive
interactions between microemulsion droplets [94, 95, 105, 106]. Instead, URT was ap-
plied to determine the difference in ultrasound velocity between diluted formulation and
a reference medium, i.e., water. In a homogeneous ideal liquid, the velocity of a sound
wave is known to depend on the density, ρ, and the apparent compressibility, κ, of the
fluid, as described by the Newton-Laplace equation, U = 1/
√
ρκ [107]. Thus, a change
in ultrasound speed was attributable to a change in apparent density or compressibility,
and hence to a structural transition of the formulation. Such analysis was recently per-
formed with surfactant/co-solvent systems. It was demonstrated that these formulation
pass a main structural transformation at a dilution ratio of 1:1 to 1:5 w/w in water,
whereas almost no further change occurred at higher dilution [77].
Advanced light scattering techniques have also found broad application in elucidating
structural changes during LBF dispersion. The scattering behavior of photons is deter-
mined by the relative wavelength of radiation compared to the dimension of the scatter-
ing material. To analyze structures with colloidal dimensions, radiation sources provid-
ing X-rays and neutrons are particularly appropriate (wavelength ∼1 A˚). In this con-
text, small-angle neutron scattering (SANS) and small-angle X-ray scattering (SAXS)
provided essential structural information about the atomic order and the interatomic
distance and angle in colloids [108–113]. Phan et al. recently applied SAXS to inves-
tigate the interplay between lipid-based liquid crystalline structures and drug release
from LBFs [114]. These studies showed that drug release was faster from bicontinuous
cubic structures than from other phases, which indicated that the properties of water
compartments have a pronounced influence on the kinetics of drug release. Thorough
reviews about the application of light scattering techniques with LBFs were provided
by Moulik and Paul [90] and Yaghmur and Rappolt [115].
Nuclear magnetic resonance (NMR) spectroscopy provides information on the molecu-
lar interactions, the structural rearrangement, and the microenvironment of the drug
during formulation dispersion [80, 104, 116]. Larsen et al. applied pulsed field gra-
dient stimulated echo NMR to measure the apparent diffusion coefficient of a model
drug in a self-nanoemulsifying system [80]. These experiments revealed details about
the drug partitioning in LBFs that were dispersed in different pH environments. Simi-
larly, electron paramagnetic resonance (EPR) spectroscopy was applied for studying the
microenvironment of a drug [87, 117–119]. This technique makes use of paramagnetic
molecules (e.g., nitroxides), which are incorporated into the tested system. The inter-
action between electrons and an externally applied magnetic field indicates the polarity
and viscosity of the microenvironment surrounding the probe molecules.
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2.3.2 In vitro dispersion test
The purpose of dispersion testing is to determine how fast and to which extent a drug
is available for absorption after oral administration of a LBF (without considering for-
mulation digestion). The terminology is not consistent in the literature and (dynamic)
dispersion, drug-release, and dissolution are often used as synonyms. The term disso-
lution testing is misleading, because the drug is already dissolved in the formulation
and is not subjected to a real dissolution process during in vitro testing. Dispersion and
drug-release are more appropriate. Indeed, it is assumed that the drug must be dissolved
in either the dispersed formulation or in the bulk aqueous medium to be available for
absorption [14, 120]. As a matter of clarity, only the term dispersion is used in this
chapter.
The underlying principle of dispersion testing is analogous to dissolution testing with
conventional oral dosage forms. Briefly, a dosing unit is immersed in a compendial disso-
lution vessel, containing an aqueous medium, and the concentration of solubilized drug
is measured at intervals. Bulk formulation and precipitated drug are then separated,
e.g., via filtration, to finally measure the concentration of solubilized drug in dispersed
formulation and in the aqueous bulk. In general, the focus of dispersion testing is not
the velocity of formulation dispersion, but the capacity of the formulation to maintain
the drug in the solubilized form. This is a major difference to conventional dissolution
testing.
The composition of dissolution media used for dispersion testing is highly variable in the
literature [69, 81, 84, 85, 121–129]. The medium can notably affect formulation disper-
sion and drug solubilization [128–132], and as a result, cross-comparison of experimental
data is often challenging. For simple experimental setups, such as in routine quality con-
trol, purified water [81, 84] and acidic or basic aqueous solutions [69, 85, 121–124] are
generally adequate. The low drug solubilization capacity can be a limiting factor and
a surfactant such as sodium dodecylsulfate (SDS) or polysorbate 80 may be added to
generate sink conditions [124–126]. This strategy has also been included in the chapter
on dissolution testing of the United States Pharmacopeia (USP) [133]. However, it is
less appropriate for the biopharmaceutical characterization of LBFs, since it would re-
duce the discriminatory power of the test. A more physiological alternative is the use of
biorelevant media, which contain bile salts and phospholipids as solubilizing agents. The
media developed by Dressman et al. are frequently employed in this context, most im-
portantly the fasted state simulated gastric and intestinal media (FaSSGF and FaSSIF,
respectively) and the fed state simulated intestinal medium (FeSSIF) [127–129]. These
media contain bile salts and phospholipids at physiological concentrations. The presence
of surface active compounds is important when testing poorly water-soluble compounds,
as they significantly influence the wettability and drug solubility in GI fluids [134–136].
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Table 2.3: Experimental issues related to sample filtration and centrifugation.
Filtration Centrifugation
Nuclei and small crystals may not be retained
by conventional 0.22µm and 0.45µm filters
Emulsified formulation may separate into an
oil and an aqueous phase
Larger emulsion droplets may be retained by
the filter
Time delay between sampling and analysis
(>15–30 minutes) allows further LBF disper-
sion and/or drug precipitation
Possible drug adsorption on filter material
2.3.2.1 Analytical tools for studying LBF dispersion
The concentration of drug in dispersed LBFs is usually determined using off-line ana-
lytical techniques. Accordingly, an aliquot of acceptor medium is removed at intervals
and the concentration of solubilized drug is measured, e.g., via high-performance liquid
chromatography (HPLC).
In this regard, it is important to select an appropriate technique with the goal to separate
solubilized drug from undispersed formulation and unsolubilized drug. Sample filtration
[29, 37, 128] and sample centrifugation [28, 48, 81] were typically employed, but both
techniques present assets and drawbacks when working with LBFs. Sample centrifu-
gation is effective in separating molecularly dissolved drug from undissolved particles,
but it also implies a critical time lag between sample removal and analysis. This delay
could lead to further formulation dispersion, to drug precipitation, or to a solid-state
transformation of precipitated drug. Hence, the resulting drug concentrations may not
reflect the real formulation dispersion and drug solubilization profile.
Sample filtration is less critical in this respect, since the separation of the solid and the
liquid phase occurs almost immediately. A critical factor is, however, the pore size of
filter material, as it determines the cut-off for retention of solid drug and undispersed
formulation. Sample filtration during in vitro dispersion testing is usually done with a
0.45 µm filter membrane [29, 37, 128]. This pore size is expected to be larger than pre-
cipitated drug particles, and hence, small nuclei and crystals may not be retained; in the
opposite case, when filter pores are too small, emulsion droplets containing solubilized
drug may be erroneously retained by the filter. It was recently shown that filters with a
pore size of less than 100 nm are able to separate molecularly dissolved drug from col-
loidal and undissolved particles [137]. Such filters are therefore particularly appropriate
for detecting drug precipitation, but care is certainly needed when studying LBFs with
droplet size of more than 100 nm in diameter (e.g., LFCS type I and II formulations).
Table 2.3 lists experimental issues related to filtration and centrifugation as separation
techniques.
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In the light of these experimental limitations, on-line techniques appear to be most in-
teresting for detecting drug precipitation. Gao et al. pioneered the use of focused beam
reflectance measurement (FBRM) for studying drug precipitation during LBF dispersion
[75]. FBRM consists of an in-process probe which directs a rotating laser beam into the
process stream (Figure 2.2). Laser light is reflected each time the beam encounters a
particle and, based on this back-scattered light, the chord length distribution of particles
is calculated [138, 139]. Several applications in the field of LBF testing showed that drug
precipitation was clearly detectable despite the high turbidity of dispersed formulation
droplets [29, 75, 77]. The detection limit of FBRM is around 1 µm (chord length).
For quantitative monitoring of drug precipitation, FBRM is often combined with other
in situ techniques, such as Raman or infrared (IR) spectroscopy [140–142]. These meth-
ods have several advantages. They are not only highly specific for chemical compounds,
but can also differentiate between physical states and are suitable for analyses in aque-
ous media. Arnold et al. presented the use of FBRM and Raman spectroscopy for
monitoring drug precipitation in simulated intestinal fluid [142]. Interestingly, despite
the complex medium composition and the presence of excipients, the instruments were
able to clearly differentiate between nucleation and particle growth.
Figure 2.2: FBRM in-process probe (Source: Mettler-Toledo, Switzerland).
2.4 In vitro assessment of LBF digestion
Formulation digestion is the second critical processing step during GI transit of LBFs.
Lipid digestion occurs primarily in the intestine and is catalyzed by the pancreatic lipase
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and co-lipase, the pancreatic lipase related proteins, and the carboxyl ester hydrolase
[143]. Di- and triglycerides are hydrolyzed at the sn-1 and sn-3 ester bonds gener-
ating sn-2 monoglycerides and fatty acids as final lipolysis products. Monoglycerides
and fatty acids form vesicular structures and, in the presence of bile salts, they can be
incorporated into more complex colloidal species [14]. These structures provide a solu-
bilizing compartment for lipophilic molecules and facilitate drug absorption. For oil-rich
formulations, the digestion process is therefore essential for promoting formulation pro-
cessing and drug absorption. However, digestion products are more hydrophilic than the
undigested lipids and this change in polarity may reduce the solubilization capacity of
the formulation. It is therefore possible that formulation digestion results in undesired
intralumenal drug precipitation.
2.4.1 In vitro lipolysis test
The main objective of in vitro lipolysis testing is to assess the drug solubilization ca-
pacity of a LBF in the digestive environment. Very first assays were developed by
Reymond and Sucker [144] and Patton and Carey [145], which provided the basis for
todays commonly used in vitro lipolysis methods. These include the protocols devel-
oped by Sek et al. [146] and by Zangenberg et al. [147, 148], which are also known as
Monash and Copenhagen methods, respectively. Moreover, several additional methods
were described in the literature, which present rather minor differences to those of Sek
et al. and Zangenberg et al. [25, 33, 118, 127, 128, 149–152].
The underlying principle for lipolysis testing is generally the same [30]. In brief, an
aliquot of formulation is dispersed in an aqueous buffer containing bile salts and phos-
pholipids (“lipolysis medium”). After a short equilibration, the pancreatic enzymes are
added to initiate digestion. The hydrolysis reaction generates fatty acids, which lower
the medium pH and, to restore the original value, NaOH is added via an automated
titration unit (Figure 2.3). This titration profile reveals the amount of liberated fatty
acids, and hence, the extent of LBF digestion.
One major difference between the lipolysis method of Sek et al. [146] and of Zangenberg
et al. [147, 148] is the strategy of calcium addition. Calcium ions remove fatty acids
from the surface of oil droplets via precipitation of calcium soaps. This removal mimics
the absorption of fatty acids in vivo, which would otherwise progressively inhibit the
lipolytic enzymes [153, 154]. Sek et al. proposed the direct calcium addition [146], i.e.,
calcium is already present in the lipolysis medium on digestion initiation. In contrast,
with the method of Zangenberg et al., calcium is continuously added during formulation
lipolysis [147, 148]. The advantage of the first method is the proximity to physiological
conditions, where lipolysis products are removed quite rapidly from the surface of oil
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Figure 2.3: In vitro lipolysis model by Sek et al. [146].
droplets in vivo. The purpose of the continuous calcium addition is to directly control
the lipolysis rate by taking advantage of the inhibitory effect of fatty acids on lipoyltic
enzymes. This method allows the analysis of LBF digestion at a higher temporal resolu-
tion, but it may be rather critical for determining lipolysis-triggered drug precipitation.
For such analysis, the physiological lipolysis rate is highly relevant, and thus, direct
calcium addition might be more appropriate.
Other differences in experimental methods concern the composition of the digestion
medium (pH, bile salts, phospholipids), the preparation of lipolytic enzymes, and the
amount of digested formulation (Table 2.4). It is well-known that minor changes in
experimental conditions can notably influence the kinetics of formulation digestion [26].
As a consequence, the cross-comparison of experimental results is often difficult. Much
research effort has been directed to the standardization of testing protocols and this is
also a major aim of the LFCS consortium [155], a collaborative project between indus-
try and academia. Several studies were release by this consortium and a standardized
method for in vitro lipolysis was recently proposed, as detailed in Table 2.4 [26–28].
2.4.2 Analytical tools for measuring lipolysis-triggered drug precipi-
tation
One objective of in vitro lipolysis testing is to assess the drug solubilization capacity of a
LBF during digestion. The drug concentration versus time profile is usually determined
and this analysis is performed on a sampling regime. According to the state of the
art methods of lipolysis testing, an aliquot of digest is removed at intervals and, after
ultracentrifugation, the amount of solubilized and/or precipitated drug is measured by
HPLC [26, 146, 147]. Ultracentrifugation is necessary for separating undigested oil from
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the aqueous bulk.
Such a sampling procedure implies the same experimental drawbacks as discussed for dis-
persion testing (Section 2.3.2.1). There is a considerable delay between sample removal
and analysis, which can lead to further drug precipitation or to a solid-state conversion of
the precipitate. This behavior was observed in recent studies, where ultracentrifugation
was used as a separation technique to determine lipolysis-triggered drug precipitation.
The concentration profiles of solubilized drug were rather biased due to ongoing drug
precipitation, so that they reflected concentrations close to the equilibrium. The true
kinetic concentrations were therefore barely measurable [31]. Nanofiltration was recently
proposed as an alternative method to ultracentrifugation [31]. However, as previously
discussed, care is needed when testing emulsions with comparatively large formulation
droplets.
The LFCS consortium proposed bench-top centrifugation as an alternative separation
technique. The higher sample throughput is a major advantage because it allows faster
sample processing. Moreover, smaller sample volumes are required and the technique
is more convenient in terms of availability and cost. Unfortunately, the separation of
undigested oil was more difficult using bench-top centrifugation, so that the technique
appeared more appropriate for hydrophilic formulations (e.g., type IIIB and IV), which
contain low amount of oil [26].
The use of in situ techniques is highly recommendable for detecting lipolysis-triggered
drug precipitation, since both formulation lipolysis and drug precipitation are dynamic
processes. The first in-line method for detecting drug precipitation during in vitro lipol-
ysis was recently presented by Stillhart et al. [31]. Technical challenges were due to
the complex and varying medium composition, the high turbidity, and the low concen-
tration of analyte. Therefore, selection of appropriate instrumentation appeared to be
essential. Raman spectroscopy was selected as analytical technique, as it provides high
chemical specificity and the capacity to discern between different physical states. A large
spot-size Raman probe was employed to reduce the effects of varying particle size and
turbidity, while chemometrical procedures were applied to remove spectral information
that was uncorrelated with the signal of the analyte. Hence, it was shown that in situ
analysis of lipolysis-triggered drug precipitation is basically possible, but it requires ad-
vanced analytical techniques and chemometrical procedures to increase the accuracy of
the method.
In vitro lipolysis testing has recently been combined with the solid-state characterization
of precipitated drug using X-ray powder diffraction (XRPD) [23, 28, 31, 33, 34]. The
pellet phase obtained from lipolysis of drug-loaded formulation was directly analyzed
after ultracentrifugation. As a reference, the same analysis was performed with the pel-
let phase obtained from lipolysis of drug-free formulation that was spiked with an equal
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amount of pure drug (as used for formulation preparation).
For an amorphous precipitate, the influence of drug precipitation on drug absorption is
expected to be minimal, as it may rapidly re-dissolve in the aqueous fluids. This solu-
bility advantage can be proved via a so-called re-dissolution experiment [33, 34]. To this
end, the pellet phase obtained from drug-loaded formulation is isolated and immersed
in a USP 2 paddle dissolution apparatus containing simulated intestinal medium. The
concentration of solubilized drug is then measured at intervals, analogous to compendial
dissolution testing. As a reference, the experiment is repeated with the pellet phase
obtained from drug-free formulation spiked with crystalline drug.
2.4.3 Analytical tools for monitoring the extent of hydrolysis and
structural changes during formulation digestion
In vitro lipolysis is not only of interest for assessing lipolysis-triggered drug precipitation.
An important aspect is to learn about the susceptibility of LBFs toward digestion and
structural changes occurring on formulation digestion. This knowledge is essential for a
rational development of formulations. This section focuses on the analytical techniques
for quantification of lipolysis products as well as on biophysical tools for the analysis of
colloidal structures evolving during formulation digestion.
During in vitro lipolysis, the extent of formulation digestion is usually assessed via
the direct titration of fatty acids and the so-called back-titration procedure to cor-
rect for the amount of unionized fatty acids [157, 158]. For standard formulation
characterization, this procedure is generally adequate. However, for a differentiated
analysis of lipolysis products, more specific analytical techniques are required. High-
performance thin-layer chromatography (HPTLC) has been frequently used for this
purpose [118, 146, 151, 159, 160]. Due to the lack of chromophoric groups, lipids and
lipolytic products are indeed hardly detectable via traditional analytical methods. A
more simple and accessible method was recently proposed by Lee et al., who used HPLC
with refractive index detection to quantify lipids and lipid digestion products in gastroin-
testinal aspirates [161]. Other quantification techniques for lipolysis products include
flame ionization detection [162] and gas chromatography [163].
The structure of colloidal phases formed with intermediate digestion products has been
intensively explored using microscopy techniques [101, 145, 164–168]. Standard light
microscopy provided very first images of fat digestion and revealed a lamellar liquid
crystalline and a viscous isotropic phase at the surface of oil droplets [145]. Later, the
availability of advanced microscopical techniques significantly improved the quality of
images in terms of contrast and resolution. Rigler et al. used freeze fracture electron
microscopy to identify multilamellar and vesicular lipolytic products in the range of 20
Chapter 2. Theoretical section 23
nm as intermediate phases of fat digestion [164]. More recent studies were performed
using cryogenic transmission electron microscopy (Cryo-TEM) [101, 165–168]. The ad-
vantage of Cryo-TEM is that samples are not fixed on a sample grid, and hence, artifacts
induced by staining are generally avoided. These studies provided key insights into the
transient structures occurring on formulation digestion such as micelles, sperical and
elongated unilamellar vesicles. Atomic force microscopy (AFM) provides information
about the surface topology of lipidic structures. It requires no sample processing and
was most recently applied to characterize colloidal structures in human intestinal fluids
ex vivo [166]. In this study, the combination of Cryo-TEM and AFM demonstrated
the presence of unilamellar vesicles, oil droplets, and facetted vesicles in the aqueous
micellar phase.
Although key structural information was obtained, these microscopical techniques failed
in reproducing the highly dynamic process of formulation digestion with appropriate
temporal resolution. Day et al. pioneered in using multiplex coherent anti-Stokes Raman
scattering (CARS) microscopy to investigate lipid digestion in real-time [169]. CARS
is a non-invasive technique that allows in situ imaging with submicrometer resolution
and millimolar sensitivity. It provided information about the local chemical composi-
tion and the phase behavior inside the oil droplets, without the need to label molecules.
The spatial resolution of CARS is around 0.3 to 1 µm. This resolution was too low for
imaging drug molecules within colloidal structures, but it was shown to be adequate for
monitoring drug partitioning from the excipient into the lipolytic products [169].
Light scattering techniques have also become increasingly important for studying tran-
sient liquid crystalline structures formed during LBF digestion. Fatouros et al. pioneered
the use of small-angle X-ray scattering (SAXS) in the field of pharmaceutical lipid-based
drug carriers [156]. This off-line method was able to detect the nano-scale architecture
of colloids formed during LBF digestion with excellent spatial resolution. However, real-
time structural data were not accessible, and for this reason, Warren et al. presented
the application of synchrotron SAXS [32]. In this study, the time evolution of liquid
crystalline nanostructures during LBF digestion was monitored. This technique is cer-
tainly less convenient in terms of cost and availability, but it provides clear advantages
over benchtop SAXS source. It allowed the analysis of weakly scattering materials due
to the high-intensity light source (∼1000 times more intense than benchtop SAXS [170])
and was shown to be well suited for studying real-time processes in a high-throughput
manner [32, 168].
Recently, another new analytical method has been introduced to study LBFs, i.e., dif-
fusing wave spectroscopy (DWS) [171, 172]. DWS is an optical technique that is derived
from DLS. It provides key information about the viscoelastic properties of supramolec-
ular structures in a continuous phase. These properties are derived from the dynamics
of scattered light, but, while DLS is restricted to systems in which light is scattered
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once, DWS is applied to systems that exhibit multiple light scattering. The technique
is therefore particularly appropriate for the examination of highly turbid systems and
has found application in the field of LBF digestion. Marze et al. recently resolved the
structural transition from a droplet to vesicles and then to micelles during lipid digestion
[172].
Finally, NMR and EPR spectroscopy have also been implemented in the analysis of LBF
digestion. NMR is particularly appropriate for following phase transfer of molecules
[172, 173] and, similarly, EPR spectroscopy provided a deeper understanding of the
interaction between drug and lipids during formulation lipolysis [117, 118].
2.5 Current challenges in in vitro LBF testing
The possibility to perform predictive in vitro tests is a prerequisite for rational devel-
opment of drug delivery systems. For this purpose, several studies analyzed the in
vitro–in vivo correlation of LBF performance. In some cases, it was possible to predict
the rank order of formulations based on in vitro dispersion and digestion testing [19–
23, 29, 52, 174–176]. In other studies, however, no correlation was evident at all [24, 25].
These findings suggested that in vitro conditions should be optimized to better simulate
formulation performance in vivo. Critical parameters of current in vitro dispersion and
lipolysis assays are discussed in the present section.
Conventional dispersion and lipolysis assays are usually one-compartmental tests. This
experimental setup is, however, often problematic when testing formulations with poorly
water-soluble compounds. Drug solubility in the testing medium is generally low and, in
the absence of an absorptive sink, the degrees of supersaturation can be notably higher
than in vivo.
Some advanced strategies for generating an absorptive sink have been described in the
literature. Shi et al. developed a biphasic system for dispersion testing, which consisted
of an aqueous buffer and octanol as organic acceptor phase [50]. The LBF was loaded
into a flow cell (USP 4) and the aqueous medium was circulated between the USP 2
vessel and the flow cell as seen in Figure 2.4. dispersion was measured in the acceptor
compartment, and interestingly, a good correlation was obtained with in vivo pharma-
cokinetic data. Such an approach should certainly be further considered and validated
with more LBFs. It would be advantageous to use biorelevant media instead of a simple
aqueous buffer, to include the influence of bile salts on emulsification and drug solubi-
lization. However, the presence of surface-active compounds may increase the solubility
of the organic phase in the aqueous bulk, which could also be a major drawback for
bi-phasic assays with in vitro lipolysis.
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Figure 2.4: Schematic representation of the biphasic dissolution test developed by
Shi et al. [50]. The aqueous layer was a simple aqueous buffer and the organic layer
consisted of octanol.
Kataoka et al. provided an absorptive sink via an alternative approach. A two-compart-
ment system was established consisting of an apical and a basal chamber separated by
a Caco-2 cell membrane [51]. The LBF was dispersed in the apical chamber (without
lipolytic enzymes) and drug absorption was then measured in the basal compartment.
The use of a biological membrane is highly valuable from a biopharmaceutical perspec-
tive because it provides the most physiological simulation of drug absorption. This is
particularly relevant when studying lipidic excipients, which are known to affect drug
permeability, for example via the inhibition of P-gp transporters [12, 13, 177–180]. Un-
fortunately, this assay revealed only a limited correlation with in vivo drug absorption
data [51]. The low surface-to-volume ratio could be critical in this regard, as the area
for absorption in vitro is much smaller than in vivo. Hence, this method is less suitable
to generate a realistically high absorptive sink.
The establishment of two-compartmental tests with in vitro lipolysis is expected to be
even more challenging, due to cell toxicity caused by lipidic excipients and pancreatic
enzymes [86, 181]. Dahan and Hoffmann proposed in vitro lipolysis with consecutive
drug permeability studies using an intestinal epithelium (ex vivo from rats) [19]. This is
an interesting approach for studying the impact of formulation lipolysis on the intestinal
drug permeability. However, the processes of lipolysis and drug absorption do not occur
simultaneously in this assay, which limits its biopharmaceutical relevance.
A very new approach for biopharmaceutical characterization of LBFs was most recently
presented by Fei et al. [37]. In this study, self-microemulsifying drug delivery systems
were tested using the in vitro dispersion test (without digestive enzymes) and, based
on these data, an in vitro–in silico–in vivo approach was followed to study formulation
performance upon oral administration. The process of drug absorption was, hence, in-
cluded via a computational simulation. This approach provided a remarkably accurate
prediction of drug concentration profiles in human plasma. The combination of in vitro
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data with simulations in silico appears to be a very promising approach for studying
biopharmaceutical processes that can be hardly simulated with in vitro tools only.
Beyond the lack of an absorptive sink, there are other factors, which may limit the pre-
dictability of formulation performance in vivo.
Current in vitro lipolysis assays simulate only intestinal formulation digestion. However,
it was estimated that the human gastric lipase performs ∼25% of GI lipolysis [143, 182].
Although this contribution is comparatively low, it could be relevant for certain formu-
lations, e.g., for LBFs with acidic drugs. An in vitro lipolysis assay simulating both,
gastric and intestinal lipolysis has been proposed by Fernandez et al. [183], but its bio-
pharmaceutical relevance still needs to be confirmed.
Another difference to in vivo performance is the fate of lipolysis products during in
vitro digestion. During GI transit, fatty acids and monoglycerides are solubilized in
the aqueous bulk and form mixed micellar or vesicular structures before being absorbed
[14]. In contrast, during in vitro lipolysis, fatty acids are rapidly removed from solu-
tion via the precipitation of calcium soaps, whereas the concentration of monoglycerides
is progressively increasing due to the absence of an absorptive sink. The kinetic con-
centrations and resulting phase behavior of lipolysis products is therefore considerably
different, which may directly affect the drug solubilization capacity. The formation of
insoluble calcium soaps reduces the ability of fatty acids to solubilize drug in mixed
micellar structures and vesicles [184], while the accumulation of monoglycerides may
increase the drug solubility. Hence, biopharmaceutical assays including an absorptive
sink would also provide the advantage of simulating the removal of lipolysis products.
An accurate prediction of in vivo bioavailability should also include post-absorptive
processes. For example, it has been shown that lymphatic drug transport is lower with
medium-chain lipids than with long-chain lipids. Hence, a drug that is extensively
metabolized in the liver may rather profit from long-chain LBFs, than from medium-
chain lipids [25, 185]. Similarly, saturation or inhibition of intestinal metabolic en-
zymes or transporters by drug or excipients could affect the extent of drug absorption
[12, 13, 23, 177–180].
Finally, particular attention must be directed to the selection of the animal model for
studying in vitro–in vivo correlations. The physiology of the GI tract can be substan-
tially different among animal species [186, 187]. Particularly relevant are differences
in lipolytic activity of digestive enzymes [188] and in the composition of GI fluids. For
example, rats have a continuous bile secretion into the intestine, irrespective of the nutri-
tional state [189]. This difference can notably influence the self-emulsification behavior
of LBFs and the drug solubilization in GI fluids [52].
Chapter 3
Study of drug supersaturation for
rational early formulation
screening of surfactant/co-solvent
drug delivery systems
Summary
The objective of this study was to advance in vitro screening of surfactant/co-solvent
formulations in early development by considering drug supersaturation and the mecha-
nism of solubilization upon aqueous dilution. Two surfactant/co-solvent model systems
were studied at practically relevant aqueous dilution ratios. Precipitation of the model
drug fenofibrate was characterized by focused beam reflectance measurement, X-ray
diffraction, and Raman spectroscopy. We calculated drug supersaturation in diluted
systems and introduced a theoretical model to study the role of excipient interaction
in the process of drug solubilization. Finally, vehicle phase changes upon dilution were
examined using dynamic light scattering and ultrasound analysis.
Phase changes occurred at low dilution levels, while more extensive dilution barely led
to further structural changes. In undiluted formulations, ethanol-surfactant domains
were responsible for fenofibrate solubilization. In dispersed formulations, however, the
co-solvent partitioned out of the surfactant microstructure, leading to drug solubiliza-
tion by independent micellization and co-solvency. This loss of excipient interaction
caused formulation-specific supersaturation, which was indicative for the risk of drug
Stillhart C. et al. Study of drug supersaturation for rational early formulation screening of
surfactant/co-solvent drug delivery systems. Journal of Pharmacy and Pharmacology, 2012, 65, 181–
192.
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precipitation. Experimental protocols of in vitro formulation screening should include
both low and high dilution levels of physiological relevance. The study of excipient
interaction and estimation of supersaturation allows the identification of formulations
that are prone to drug precipitation.
3.1 Introduction
Drug solubilization in the gastrointestinal tract is of pivotal importance for adequate
oral bioavailability. This is a particular challenge for poorly water-soluble drugs that of-
ten exhibit incomplete or variable drug absorption. Lipid-based formulations, such as oil
solutions or self-(micro)-emulsifying drug delivery systems (S(M)EDDS), can overcome
this limiting step by keeping the drug in solubilized form in vivo [9, 190]. Moreover,
these formulations often protect the drug against chemical and enzymatic degradation
in an aqueous environment and may circumvent hepatic first-pass metabolism by en-
hancing lymphatic drug transport [191, 192].
SEDDS are complex mixtures, comprising up to five excipients (triglyceride oils, mixed
glycerides, lipophilic surfactants, hydrophilic surfactants, and water-soluble co-solvents).
The addition of small amounts of water to SEDDS leads to the swelling of inverse mi-
celles. Larger amounts of water cause the formation of water-in-oil emulsions and, if
water and formulation are present in similar amounts, the systems may become bi-
continuous. Finally, at high dilution levels, oil-in-water dispersions are generated [10].
During these phase changes, a compound that is solubilized in the SEDDS will migrate
into oil-rich or water-rich domains, depending on its physicochemical properties (e.g.,
logP). This migration, in turn, presents an enhanced risk of drug precipitation [10].
Drug precipitation in the crystalline form is particularly critical, since re-dissolution of
drug crystals is often rather slow, resulting in incomplete drug absorption in vivo.
It is therefore important to study formulation behavior upon aqueous dilution to an-
ticipate the fate of a lipid-based system in the gastrointestinal lumen. Dilution tests,
comprising one to three dilution ratios in an aqueous medium, are a typical industrial
screening tool for early formulation development. This simple testing procedure gives a
first indication of whether the formulation is able to keep the drug solubilized in aqueous
dispersions. However, profound knowledge of the formulation changes occurring upon
aqueous dilution may minimize this experimental work and rationalize the development
of new lipid-based formulations.
Several approaches have been adopted in recent years to gain a better insight into the
dispersion process of lipid-based formulations. Phase changes in these systems are often
hardly detectable by the naked eye, so that sophisticated physical methods are needed for
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improved structural analysis. Several techniques have been used, such as small-angle X-
ray scattering (SAXS), small-angle neutron scattering (SANS), dynamic laser light scat-
tering (DLS), nuclear magnetic resonance (NMR), time-resolved fluorescence quenching
(TRFQ), conductance, viscosimetry, and ultrasonic velocimetry [90, 94, 95, 193]. Re-
cently, electron paramagnetic resonance (EPR) spectroscopy was successfully adopted to
study microstructural changes of dispersed SMEDDS [87, 117]. Other groups employed
analytical ultrasound techniques to characterize phase changes in SEDDS [194, 195].
Mohsin et al. investigated precipitation of fenofibrate following the dispersion of lipid-
based formulations (Pouton type I–IV systems) in water [48]. The authors reported that
the drug precipitated mostly from formulations with a high content of hydrophilic ex-
cipients. Such systems are particularly interesting for studying structural changes upon
aqueous dilution and the effect on drug solubilization.
This study focuses on Pouton type IV systems, which are typically mixtures of a hy-
drophilic surfactant and co-solvent and do not contain any oil [10]. Such formulations
can lead to high supersaturation upon dilution, which is accompanied by a risk of drug
precipitation [38, 71]. However, there is still a lack of reliable techniques to predict
the risk of drug precipitation for a given lipid-based formulation. An improved under-
standing is needed of how phase changes during dispersion affect drug solubilization and
supersaturation.
The aim of this work was to study how drug supersaturation and precipitation can re-
sult from aqueous dilution of Pouton type IV systems. Specifically, we aimed to gain a
better understanding of the dispersion process to provide a rationale for the selection
of dilution levels in early formulation screening. We studied the features of aqueous
dispersions obtained from two hydrophilic surfactant systems with ethanol as co-solvent
and fenofibrate as the model drug. To describe excipient effects on drug solubiliza-
tion in the undiluted and the diluted state, we employed a theoretical concept termed
non-interacting model, which assumed a drug to be independently solubilized by the
surfactant and the co-solvent. Moreover, theoretical supersaturation as a function of
the dilution level was estimated for both systems.
3.2 Materials and methods
3.2.1 Materials
Polysorbate 80 was purchased from Ha¨nseler AG (Herisau, Switzerland), Cremophor R©
RH 40 from BASF AG (Ludwigshafen, Germany), and ethanol from Baker (Deventer,
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Netherlands). Fenofibrate (2-[4-(4- chlorobenzoyl)phenoxy]-2-methylpropanoic acid iso-
propyl ester; >99%) was obtained from Sigma-Aldrich Chemie GmbH (Buchs, Switzer-
land).
3.2.2 Preparation of formulations
Two different Pouton type IV formulations were used for this study: one was composed
of Cremophor RH 40 and ethanol (1:1 w/w, cremophor system), and the other consisted
of polysorbate 80 and ethanol (1:1 w/w, polysorbate system). Cremophor RH 40 was
melted on a heating plate (40◦C) and, while cooling down to room temperature, ethanol
was added. The polysorbate system was prepared by directly adding ethanol to the sur-
factant. Excipients were mixed on a magnetic stirrer until a homogeneous, clear solution
was obtained.
The poorly water-soluble fenofibrate (logP 5.24 [196]) was selected as model drug. Drug
formulations were prepared by loading the cremophor system and polysorbate system
with fenofibrate at a concentration corresponding to 80% of drug solubility. The formu-
lations were stirred until a clear solution was obtained.
To determine fenofibrate solubility in the formulations, we mixed the systems with an
excess of fenofibrate on a magnetic stirrer (500 rpm) for 24 h in hermetically sealed
glass vials at 37◦C. The suspensions were then filtered through a 0.45-µm polytetrafluo-
roethylene (PTFE) membrane to remove the excessive solid drug, and the concentrations
were determined by UV spectrometry. We used a SpectraMax M2 microplate photome-
ter (Molecular Devices, Sunnyvale, CA, USA) to measure the absorbance at 286 nm.
Solubility measurements were performed in four replicates.
3.2.3 Dilution behavior of fenofibrate formulations and drug-free for-
mulations
Cremophor formulation and polysorbate formulation with and without fenofibrate were
dispersed in demineralized water at six dilution ratios (1:1, 1:2, 1:5, 1:10, 1:20, 1:50,
and 1:100 w/w) at 37◦C. These ratios were expressed as dilution factors and labelled
as 1, 2, 5, 10, 20, 50, and 100, respectively. The low dilutions (i.e., dilution factors
1–20) were included because the main structural changes were expected to occur in this
concentration range. Higher levels of dilution (i.e., dilution factors 50 and 100) were
included in this study because of their physiological relevance.
We first compared the dispersion behavior of systems containing fenofibrate and drug-
free systems visually and then by means of focused beam reflectance measurement
Chapter 3. Supersaturation in surfactant/co-solvent systems 31
(FBRM). When precipitation occurred, we analyzed the solid phase using X-ray powder
diffraction (XRPD) and Raman spectroscopy.
3.2.3.1 Focused beam reflectance measurement
A Lasentec FBRM D600L probe (Lasentec, Redmond, WA, USA) was used to detect
precipitation of drug particles after formulation dispersion (dilution factors 1, 2, 5, 10,
20, 50, and 100). The probe was positioned at an angle of 30◦ in a thermostated glass
vessel (37◦C) and the dispersion was stirred at 500 rpm. Measurements were recorded
every 2 s for 5 min using the iC FBRM software version 4.0 (Mettler-Toledo AutoChem,
Columbia, MD, USA). The formulations were dispersed and measured in triplicate.
3.2.3.2 X-ray diffraction
Dispersions that contained solid structures were filtered after 30 min of dispersion, and
an X-ray diffraction pattern was immediately recorded using a theta-theta X-ray powder
diffractometer (R-XRD Phaser D2; Bruker AXS GmbH, Karlsruhe, Germany) equipped
with a Co and Cu KFL tube (30 kV, 10 mA) as radiation source and a Lynxeye R©
detector. The single sample was scanned in the angular range of 5◦ (2θ) to 40 (2θ) with
a step size of 0.1◦ (2θ) and a count time of 5 s per step. The result was compared with
the reference diffraction pattern of pure fenofibrate.
3.2.3.3 Raman spectroscopy
We prepared the samples for Raman spectroscopy analogously to those for the X-ray
analysis. Thus, following a 30-min dispersion period, the samples containing precipi-
tated drug were filtered and a Raman spectrum of the solid material was recorded. As
a reference, we acquired the spectrum of pure, crystalline fenofibrate as used for the
formulation preparation.
We used a Raman RXN1 analyzer (Kaiser Optical Systems, Inc., Ann Arbor, MI, USA)
in the backscattering mode, equipped with a charge-coupled device (CCD) camera and a
diode laser operating at a wavelength of 785 nm. The spectra were recorded with a laser
power of 400 mW and background Rayleigh scattering was removed by a holographic
filter during spectra acquisition. We used a multi-fibre PhAT probe having a non-contact
sampling device with a laser spot diameter of 6 mm. Scattered radiation was collected
by an array of 50 optical fibers and was transmitted to the CCD detector. The sample
was positioned in a sample holder consisting of a black metal block to shield the samples
from external light. Spectra were collected at a resolution of 4 cm-1 and an acquisition
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time of 500 ms using the iC Raman Instrument software (Version 3.0; Mettler-Toledo
AutoChem Inc., Columbia, MD, USA).
3.2.4 Determination of theoretical supersaturation
The difference in chemical potential ∆µ of a supersaturated solution (µ) and a thermo-
dynamically stable, saturated solution (µeq) is the driving force for drug precipitation.
Assuming that the activity coefficients of a solute in the saturated and supersaturated
state are the same, the relationship between the difference in chemical potential and su-
persaturation can be described by the equation ∆µ = µ−µeq = kT ln(S), where k is the
Boltzmann constant, T the temperature, and S the supersaturation ratio [197]. We cal-
culated S as a measure of the difference in chemical potential, ∆µ, present in the aqueous
dispersions. We determined a theoretical value, Stheor , in the formulations dispersed at
a given ratio according to Stheor = Ctheor /Ceq,meas , where Ctheor is the calculated concen-
tration of fenofibrate resulting after dispersion of the formulation (containing fenofibrate
at 80% of its solubility, i.e., Stheor of 0.8 for the undiluted formulation) and Ceq,meas is
the equilibrium solubility of the drug in a given aqueous dispersion. To measure Ceq,meas ,
the placebo cremophor system and polysorbate system were dispersed in demineralized
water at dilution factors of 1, 2, 5, 10, 20, 50, and 100, and an excess amount of fenofi-
brate was added to the mixtures. Samples were left to stir on a magnetic stirrer at 500
rpm for 24 h in a water bath at 37◦C using hermetically sealed glass vials. The suspen-
sions were then filtered through a 0.45-µm PTFE membrane to separate the excess of
solid drug, and the concentration was determined in the samples by UV spectrometry at
286 nm (n=4, freshly prepared analysis samples per dilution level). To calculate Stheor ,
we used the mean value of Ceq,meas (n=4 at each dilution factor).
3.2.5 Determination of drug solubility in dispersed excipients and data
modeling
We measured fenofibrate solubility in the pure, as well as diluted, excipients (polysor-
bate 80, Cremophor RH 40, and ethanol) corresponding to a dilution factor of 1, 2, 5,
10, 20, 50, and 100. Fenofibrate solubility in the diluted surfactant or co-solvent was
labelled as Ceq,surf or Ceq,co , respectively. Thus, the individual excipients were dispersed
in demineralized water, and an excess amount of fenofibrate was added to the mixtures.
Samples were left to stir on a magnetic stirrer at 500 rpm for 24 h in a water bath at
37◦C using hermetically sealed glass vials. We measured drug solubility at the highest
and lowest excipient concentration after 24, 48, and 72 h of equilibration (analytical
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bracketing). Since after 24 h the equilibrium was reached in these solubility experi-
ments, this time was selected for all other solubility tests. The same procedure was
pursued for solubility measurement in undiluted excipients. The suspensions were then
filtered through a 0.45-µm PTFE membrane to separate the excess of solid drug, and
the concentrations (Ceq,surf and Ceq,co) were determined by UV spectrometry (286 nm).
All solubility values were determined in four replicates.
Fenofibrate solubility was then modeled as a function of the excipient concentration.
The calculations were based on a linear regression for the surfactants (cremophor and
polysorbate), while a log-linear regression was employed for the co-solvent (ethanol). We
used the software Statgraphics Centurion XV Professional (StatPoint Technologies Inc.,
Warrenton, VA, USA) and determined the R2 and p-values for each model fit. The model
p-value demonstrated whether the relationship between the two variables was significant
at a 95.0% confidence level. Based on drug solubility in the pure excipients, Ceq,surf and
Ceq,co , we calculated the theoretically expected fenofibrate solubility, Ceq,model , in the
undiluted and diluted formulations, assuming that the excipients were not interacting.
Finally, the calculated values were compared with the experimental solubility values,
Ceq,meas , measured in the dispersed formulations, as depicted in Figure 3.1.
+ 
Fenofibrate solubility 
in water + surfactant  
(symbol:      )     
Fenofibrate solubility 
in water + co-solvent  
(symbol:        ) 
Expected fenofibrate 
solubility in the 
formulation assuming 
no excipient interaction 
Ceq,co Ceq,model 
Measured values Calculated values 
Measured fenofibrate 
solubility in the 
formulation 
Ceq,meas 
Measured values 
vs. 
Ceq,surf 
Figure 3.1: Illustration of the non-interacting model of drug solubilization.
3.2.6 Physical characterization of placebo dispersions
3.2.6.1 Dynamic laser light scattering
Particle size of dispersed placebo cremophor systems and polysorbate systems was mea-
sured by means of DLS at 37◦C. We dispersed the formulations in demineralized water
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(dilution factors of 1, 2, 5, 10, 20, 50, and 100) and measured particle size using a Zeta-
sizer Nano ZS (Malvern Instruments Ltd, Malvern, UK) equipped with a 4 mW He-Ne
laser operating at a wavelength of 633 nm. The scattering signal was detected at an angle
of 173◦, and each sample was measured for 10 min. The Dispersion Technology Soft-
ware DTS 5.0 (Malvern Instruments Ltd, Malvern, UK) was used to calculate the mean
hydrodynamic particle diameter, expressed as z-average (nm), and the polydispersity
index (PDI). The formulations were dispersed and measured in triplicate.
3.2.6.2 Ultrasonic resonator technology
Ultrasound velocity, U (m/s), was measured using a ResoScan R© system (TF Instruments
Inc., Monmouth Junction, NJ, USA). The instrument was equipped with two identical
parallel resonator cells (sample volume 200 µl) having a path length of 7.0 mm (ground
wave λ = 14 mm) with a fundamental frequency of approximately 10 MHz. Since the
ultrasound velocity is strongly temperature dependent, a thermostat controlled with a
Peltier element ensured a highly stable temperature in the resonator cavities (resolution
1 mK, stability ±5 mK). Ultrasound velocity was measured in the range 1100–1900
m/s.
The relative value of ultrasound speed, U (i.e., Ucell 2 − Ucell 1 ), was considered for
analysis. Thus, we measured the difference of ultrasound velocity, ∆U , between water
(filled in cell 1) and the samples at the defined dilution factors of 1, 2, 5, 10, 20, 50,
and 100 (filled in cell 2) at 37◦C. ∆U was measured every 10 s for 5 min, and the mean
value was determined subsequently. The dispersions were freshly prepared in triplicate
for the analysis.
Finally, we used an Olympus BX 61 polarized light microscope (Olympus Corp., Tokyo,
Japan) to confirm the presence of birefringent structures in the samples at dilution
factor 1.
3.2.6.3 Density measurement
The density of the diluted systems was determined using a DA-110 M density meter
from Mettler-Toledo GmbH (Greifensee, Switzerland), which was equipped with a Peltier
thermostat for temperature control. We measured the density of samples (1 ml) at the
defined dilution factors of 1, 2, 5, 10, 20, 50, and 100 at 37◦C. Three replicates were
measured and the mean value and standard deviation were calculated for each dilution
factor.
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3.2.7 Statistical methods
The effects of dilution on the onset time of precipitation (induction time, tind) were
evaluated using the Friedman’s test. The induction time was arbitrarily defined as the
time when the counts of particles with a chord length below 10 µm exceeded 50, because
this FBRM signal was above the range of instrumental noise. The Kruskal–Wallis test
was performed to analyze the effects of dilution on the PDI and ∆U values, respectively.
A significance level of 95.0% (p<0.05) was selected in all cases. We used the software
Statgraphics Centurion XV Professional for all statistical data treatments. Error bars
in graphical plots represented standard deviations in all cases.
3.3 Results
3.3.1 Macroscopic dilution behavior
We studied the dilution of two Pouton type IV model formulations. One consisted of
equal amounts (w/w) of Cremophor RH 40 and ethanol (cremophor system), while the
other contained polysorbate 80 and ethanol at the same mixing ratio (polysorbate sys-
tem). At 37◦C, fenofibrate solubility was 14.56 ± 1.87 mg/ml and 105.96 ± 0.82 mg/ml
in the cremophor and polysorbate systems, respectively.
The drug-free (placebo) formulations appeared both as homogeneous and transparent
mixtures that remained clear even following dispersion in water (Figure 3.2a and 3.2c).
The undiluted fenofibrate formulations were also clear mixtures, but differences were
observed upon aqueous dispersion. Dilution of the polysorbate system containing fenofi-
brate resulted in considerable turbidity within a few seconds, but this did not occur with
the cremophor system (Figure 3.2b and 3.2d).
3.3.2 Characterization of precipitation
Appearance of particles after aqueous dispersion of the fenofibrate and placebo formula-
tions was monitored by FBRM. This technique consisted of an in-process probe, which
detected the chord length distribution of particles. This laser scanning technique has
been used before to characterize drug precipitation [75] and the general measurement
principle was described by Ruf et al. [138].
No FBRM signal was detected upon dispersion of the cremophor system (fenofibrate
and placebo) and placebo polysorbate system. In contrast, the polysorbate system con-
taining fenofibrate led to increasing particle counts at different levels of dilution. To
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Figure 3.2: Macroscopic dilution behavior of the placebo cremophor system (a),
verum cremophor system (b), placebo polysorbate system (c), and verum polysorbate
system (d) in water. Verum systems contained fenofibrate at 80% of its solubility in the
formulation. All diluted systems were clear except the verum polysorbate formulation
(d), which exhibited pronounced drug precipitation.
follow the number of evolving particles over time, we selected only counts with a chord
length of less than 10 µm, which minimized the noise from those counts resulting from
aggregated particles (Figure 3.3). However, it should be noted that the detection is
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Figure 3.3: Particles counts (chord length < 10µm) upon dilution of the verum
polysorbate system by using FBRM. The level of dilution is referred on the right side
(n = 3 for each level of dilution).
limited to particles with a chord length of more than 1 µm. The lowest dilution ratios
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(1:1 and 1:2 w/w) could not be measured since the large amount of particles hampered
the homogeneous mixing of the sample. The dilutions of 1:5 and 1:10 displayed a sharp
initial increase of counts, while a less pronounced increase was noted for more diluted
samples. From Figure 3.3 we can infer that the initial count rate seemed to be indirectly
proportional to the onset of particle counts. The Friedman’s test proved that the induc-
tion time was significantly different for the more diluted systems (p = 0.027), spanning
a rather narrow range from a few seconds to nearly a minute.
We further studied the solid-state properties of the formed particles. Figure 3.4 dis-
plays the X-ray diffractograms and Raman spectra of the precipitated material and of
crystalline fenofibrate as used in the formulation. From the obtained patterns it could
be clearly observed that the solid-state form of the precipitate corresponded to that of
crystalline fenofibrate.
It was remarkable that only the polysorbate-containing formulation exhibited drug pre-
cipitation when water was added, even though both model systems had the same initial
drug saturation ratio of 0.8 before aqueous dilution.
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Figure 3.4: X-ray diffraction pattern (a) and Raman spectra (b) of the precipitate
and the crystalline fenofibrate as used for formulation preparation.
3.3.3 Calculation of the theoretical supersaturation, Stheor
FBRM indicated that the polysorbate system went through an initial supersaturated
state, which lasted for only a short time. To determine the initial supersaturation in
dispersed systems, we used the value Ctheor calculated based on the amount of fenofibrate
added to the water for each dilution ratio. Figure 3.5 depicts the values of Stheor of the
two systems as a function of the dilution ratio. The dispersed cremophor system reached
a supersaturation of about 2. In contrast, supersaturation in the polysorbate system was
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about 10-fold higher than in the cremophor system, reaching a ratio of more than 20.
Interestingly, the polysorbate system displayed a lower supersaturation level at dilution
factor 1 and reached a peak at dilution factor 2. Supersaturation in the cremophor
system, however, was almost constant over all dilution levels.
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Figure 3.5: Theoretical fenofibrate supersaturation (Stheor ) in the cremophor system
and polysorbate system at different dilution ratios.
3.3.4 Fenofibrate solubilization in excipients and formulations
We analyzed the solubility of fenofibrate in the pure excipients (ethanol, Cremophor
RH 40, and polysorbate 80) to compare these values with fenofibrate solubility in the
cremophor system and polysorbate system.
Figure 3.6 depicts the solubility of fenofibrate in undiluted and diluted co-solvent (ethan-
ol) as a function of ethanol concentration. In line with theoretical expectations [198],
we found a log-linear relationship between fenofibrate solubility in the co-solvent, Ceq,co,
and the co-solvent concentration, Cco (R
2 = 0.978; p<0.0001) according to:
logCeq,co = logCeq,w + σ
′ · Cco (3.1)
where σ′ is the co-solvent solubilization power. We labeled this parameter differently
from Yalkowsky et al. [198], since the constant σ′ was obtained from co-solvent con-
centrations in units of % w/w. The intercept provided a calculated aqueous solubility
(Ceq,w) of 0.011 mM, which agreed well with the experimental value (0.010 ± 0.003 mM).
Subsequently, we determined the surfactant-mediated solubility, Ceq,surf , at different di-
lution levels. The relationship between the surfactant concentration, Csurf , and the
drug solubility, Ceq,surf , was in good agreement with the expected linearity. In theory,
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micelle-mediated solubility is a linear function of the surfactant concentration minus the
critical micelle concentration (CMC) [199]. However, the latter value is often neglected
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Figure 3.6: Fenofibrate solubility in the aqueous dilution of co-solvent, Ceq,co . The
red line represents the regression line and it has to be noted that the solubility is
expressed in the log-scale.
at much higher surfactant concentrations than the CMC [200], leading to the following
equation:
Ceq,surf ∼= Ceq,w + κ′ · Csurf (3.2)
An adequate linear regression was obtained in the case of Cremophor RH 40 (R2 =
0.997; p<0.0001) with a κ′ of 0.30 ± 0.007. Similarly, polysorbate 80 provided a slope of
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Figure 3.7: Fenofibrate solubility in the aqueous dilution of the surfactants, Ceq,surf
(Cremophor RH 40 and polysorbate 80, respectively). The red lines represent the linear
regression lines.
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0.26 ± 0.003 (R2 = 0.999; p<0.0001). Both cases of pure surfactant-dependent fenofi-
brate solubility can be inferred from Figure 3.7 . Only the range of non-gelling dilution
samples was considered.
Based on these results, we combined Eq. 3.1 and Eq. (3.2) to construct the non-
interacting model of drug solubility:
Ceq,model ∼= Ceq,w · (1 + 10σ′·Cco) + κ′ · Csurf (3.3)
The theoretical values (Ceq,model ) were then compared with the experimental fenofibrate
solubility values (Ceq,meas). Figure 3.8 shows a good agreement between Ceq,model and
Ceq,meas , primarily in the diluted state. However, the measured solubility in the undi-
luted cremophor formulation was more than double the theoretical estimate (Ceq,meas
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Figure 3.8: Fenofibrate solubility (mM) in the diluted cremophor system (a) and
polysorbate system (b). Red lines hold for calculated values according to the non-
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40.35 mM versus Ceq,model 16.95 mM). This gap was even more pronounced in the
undiluted polysorbate system, for which the measured solubility was nearly 20 times
the calculated solubility (293.67 mM versus 14.95 mM, respectively) according to the
non-interacting model (Eq. (3.3)).
3.3.5 Structural changes of the vehicle upon aqueous dilution
After characterizing the two formulations in terms of fenofibrate solubilization in the
dispersed state, we further studied the physical changes of the formulation during aque-
ous dilution. Thus, both surfactant/co-solvent systems (drug-free) were analyzed at the
different dilution levels using DLS as well as ultrasound analysis.
3.3.5.1 Dilution analysis by dynamic light scattering
Along with measuring the particle size, we applied DLS primarily to trace the poly-
dispersity of micellar particles arising from the dilution of the two drug-free model
formulations. There was a pronounced variation of PDI depending on the dilution level
(Figure 3.9), which was significant for both systems (p=0.008 and 0.007 for the polysor-
bate and the cremophor system, respectively).
At low dilution, samples were highly polydisperse and an effective mean particle size
was not detectable. On the other hand, rather monodisperse systems (PDI<0.2) were
obtained for more diluted samples so that it was possible to determine the mean diam-
eter of colloidal particles. The abrupt decrease of polydispersity was remarkable. The
cremophor system exhibited a constant particle diameter of 13–14 nm beyond a dilu-
tion factor of 20, while the polysorbate system exhibited a particle diameter of <10 nm
beyond a dilution factor of 5.
3.3.5.2 Dilution analysis by ultrasonic resonator technology
Finally, we studied the structural changes of dispersed Pouton type IV systems by using
ultrasound propagation. The speed of ultrasound waves is known to depend on a sam-
ple’s density and compressibility [107, 201, 202]. Phase changes of a lipid-based system
in water are therefore expected to influence this acoustic response. We measured the
difference in ultrasound velocity, ∆U , between water and the formulations at different
dilution ratios (Figure 3.10).
The qualitative change of the acoustic response was similar for the two systems. ∆U
reached a peak at dilution factor 2 and decreased again at higher dilution ratios. When
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Figure 3.9: Polydispersity index and particle size of diluted (a) cremophor system
and (b) polysorbate system. The particle size is specified only for systems with a PDI
smaller than 0.2.
plotting the acoustic response as a function of the formulation concentration, an approx-
imately linear dependency was revealed between ∆U and the formulation concentration
for most samples. However, the highest concentration (corresponding to dilution fac-
tor 1) was clearly outside this linear range. At this level of dilution we observed optical
birefringence by polarized light microscopy. The Kruskal–Wallis test proved a statisti-
cally significant change in ∆U as a function of the dilution factor (p=0.004 and 0.003
for the polysorbate and the cremophor system, respectively).
The density of the diluted systems followed a nearly linear decay for the different di-
lution levels. However, in contrast to ultrasound values, this trend included even the
samples of dilution factor 1.
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Figure 3.10: Difference of ultrasound velocity, ∆U (©), measured between water
and the diluted cremophor system (a) and polysorbate system (b) as a function of the
dilution factor (large charts) and the formulation concentration (small charts). The
variation of density as a function of dilution is displayed in the insets (4, n = 3).
3.4 Discussion
The analyzed Pouton type IV formulations had a similar composition (i.e., a hydrophilic
surfactant mixed with ethanol 1:1 w/w). Moreover, the two fenofibrate systems had the
same relative drug concentration, corresponding to 80% of drug solubility. However,
once dispersed in water, there was a clear difference regarding their ability to keep the
drug in solution. Considerable drug precipitation resulted with the polysorbate system
but not with the cremophor system.
FBRM measurements showed that precipitation started within several seconds after for-
mulation dispersion. The XRPD pattern confirmed that the precipitate corresponded to
crystalline fenofibrate. Therefore, re-dissolution of this poorly soluble drug is expected
to be critically slow and, as a consequence, such a formulation could lead to erratic drug
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absorption in vivo.
Due to the observed differences in the dilution behavior (presence or absence of drug
precipitation), the cremophor system and polysorbate system were particularly suited
as model formulations, while keeping in mind that capsule compatibility and long-term
stability were not determined in this study. We selected several dilution levels that
were of relevance for industrial dispersion tests. Despite the practical orientation of the
work, the driving force of drug precipitation was of interest to understand differences
in dispersion behavior. The value of estimated supersaturation, Stheor, proved to be
helpful in assessing the risk of drug precipitation. In fact, this parameter was about
10-fold higher in the diluted polysorbate system than in the cremophor system. Due to
rather low supersaturation, the latter formulation was able to keep the drug in solution,
suggesting that the presence of surfactant inhibited drug precipitation. However, there
is a non-linear relationship between drug supersaturation and the risk of precipitation.
At a high level of supersaturation there is a pronounced driving force towards drug pre-
cipitation, which limits the ability of a surfactant to prevent drug precipitation. Thus,
excipient-mediated stabilization of this metastable state is not an absolute effect but
depends on the extent of supersaturation [38].
Similarly, the authors of a recent study observed that the dispersion of a self-emulsifying
formulation containing polysorbate 80 led to high supersaturation and precipitation of
crystalline AMG 517, a poorly water-soluble drug candidate [75]. Interestingly, the
presence of small amounts of hydroxypropylmethylcellulose retarded drug precipitation,
due to drug stabilization in the supersaturated state. Other stabilizing polymers were
investigated and recently reviewed by Warren et al. [71]. In the present case with the
polysorbate formulation, we observed a supersaturation that was obviously too high to
allow stabilization by the surfactant alone. However, the addition of a polymeric precip-
itation inhibitor might have sustained this metastable state and prolonged the induction
time. Further studies are needed to clarify the combined effects of surfactants and poly-
mers on drug precipitation.
From a mechanistic point of view, the newly introduced non-interacting model of drug
solubilization was particularly interesting. This model was able to demonstrate how
solubility was mediated at different levels of aqueous dilution. It was evident from the
formulation composition that drug solubilization in both formulations was facilitated by
either co-solvency, pure surfactant micelles or interaction between co-solvent and mi-
celles. The last situation may exist in different forms, depending on the level of dilution.
In the undiluted formulation, microdomains of surfactant and co-solvent can be present.
In the diluted state, interaction between co-solvent and surfactant may be due again
to two different structures: depending on the dilution level, it is either a bicontinuous
phase including a coherent network of surfactant and co-solvent, or, alternatively swollen
micelles.
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The non-interacting model is a theoretical concept that describes drug solubility in
a system where solubility arises from independent micelle inclusion and co-solvency.
Therefore, good agreement between modeled and measured data indicated that solubil-
ity was independently mediated by ethanol and the surfactant. The ability of the model
to describe the experimental solubility at high dilution was remarkable, keeping in mind
that this equation was a theoretical simulation. Thus, we can deduce that in diluted
samples drug solubilization resulted from co-solvency and micellization independently.
However, at the lowest level of dilution (1:1 w/w), the non-interacting model did not
accurately describe drug solubility. This difference was even more pronounced in the
undiluted formulations, indicating that interaction of the excipients accounted for en-
hanced solubility. In the pure formulations, the ratio of observed to modeled solubility
was around 2 for the cremophor system and almost 20 for the polysorbate system. This
suggests that the solubilization ability of ethanol–polysorbate microdomains was much
higher than ethanol–cremophor structures. Once water was added to the formulations,
ethanol migrated out of the interacting structures and, at dilution factors higher than 5,
excipient interaction was completely lost. Loss of microdomains was particularly criti-
cal for the polysorbate system, leading to a high level of supersaturation upon aqueous
dispersion.
The DLS results showed that the two Pouton type IV systems reached a threshold value
of polydispersity around dilution factor 5. This observation confirmed the extensive
restructuring of the systems at low levels of dilution, which was interpreted as the tran-
sition from a bicontinuous structure to dispersion of discrete micelles. In fact, this is
in good agreement with the transition from a bicontinuous system to discrete micelles
recently observed with SMEDDS [87]. The mean particle sizes at high dilution levels
were comparable to the mean micelle size of diluted, pure polysorbate 80 and Cremophor
RH 40 [91]. This confirmed the assumption that micelles did not swell in the presence
of co-solvent, since ethanol diffused out of micelles.
Ultrasound analysis showed as well a transition of the formulation structure as a func-
tion of dilution level. In a homogeneous ideal liquid, the velocity of a sound wave is
known to depend on the density, ρ, and the compressibility, κ, of the fluid, as described
by the Newton–Laplace equation, U = 1/
√
ρκ . Thus, a change in ultrasound speed
is attributed to a difference in apparent density or compressibility of the medium. In
our systems we observed a concentration-dependent linear variation of ∆U and of the
density between dilution factors 2 and 100. This result was expected for solutions with
solubilized or dispersed particles, where equal microstructures but different particle con-
centrations are present [76]. However, the trend of ∆U was interrupted at the highest
level of dilution, while a similar change was not observed with the density. Based on the
Newton–Laplace equation, we deduced that the medium compressibility and, thus, the
microstructure was changing at dilution factor 1. High ∆U values, such as those present
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at low dilution levels, are typical for elevated stiffness (corresponding to low medium
compressibility), arising from the existence of coherent liquid-crystalline structures [194].
Polarized light microscopy indeed confirmed the presence of optical birefringence in sam-
ples at dilution factor 1. Further dilution led to a pronounced decrease in ∆U indicating
a loss of mechanical stiffness, which was expected for isolated micelles in water. This
was also described by Fanun et al. [94], who analyzed the viscosity of diluted SMEDDS.
These authors observed maximum viscosity around a dilution factor of 1. Interestingly,
the ∆U values obtained from the two formulations were similar. Thus, the structural
properties affecting ultrasound speed were comparable for the two formulations. This
indicates that ultrasound wave propagation was barely influenced by the type of surfac-
tant (Cremophor RH 40 and polysorbate 80).
This study focused on how the drug solubilization capacity of two surfactant/co-solvent
systems changed upon aqueous dispersion. Understanding such changes in drug solubi-
lization and supersaturation is important to predict the fate of a lipid-based system upon
dispersion. However, with respect to the formulation behavior in vivo, further aspects
have to be considered. First, simple in vitro methods, such as the dilution test, do not
have a sink compartment that simulates drug absorption across the intestinal membrane.
If a drug is rapidly absorbed, the resulting supersaturation could be lower and, as a con-
sequence, the risk of precipitation is reduced [76]. Secondly, the gastrointestinal fluid is
a complex matrix consisting of various exogenous and endogenous components, such as
bile salts and phospholipids. The individual composition of the intestinal fluid in vivo
influences the resulting drug solubility. Intestinal fluids also contain digestive enzymes,
which can degrade lipid-based excipients and, thus, change their physicochemical prop-
erties and solubilization capacity [203]. Finally, both the reduction of supersaturation
by drug absorption and the presence of exogenous and endogeneous colloids may affect
the nature of the precipitating material. Amorphous or co-crystallized drug potentially
shows a largely different biopharmaceutical behavior compared with the crystalline form
[61]. Such a precipitate is expected to re-dissolve faster than the crystalline material
[33] and, as a consequence, oral bioavailability might be impaired to a lesser extent than
predicted from in vitro tests.
Despite the known complexity in vivo, simple in vitro models are still needed from a
pharmaceutical development perspective. Especially in the early stages of lipid-based
formulation screening, dilution and dispersion tests have their merits [41]. Using the
non-interacting model provided a better understanding of the in vitro results, which is
needed to rationally select experimental protocols. Moreover, modeling the effects of
excipients on drug solubilization and supersaturation will certainly be important for the
future in silico prediction of drug absorption.
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3.5 Conclusions
Our study of the dilution of two Pouton type IV formulations demonstrated that the
testing of formulation candidates only at a single, high dilution level (e.g., 1:100 w/w)
representing physiological conditions may be insufficient. Structural changes that are
relevant for drug solubilization occur at comparatively low dilution levels. Moreover, a
low dilution results in a high absolute drug concentration, which facilitates the detection
of precipitated material.
Screening of experimental formulations should therefore include at least one rather low
dilution level (i.e., 1:5 w/w or lower). This seems also reasonable with respect to the
in vivo situation. Formulation dispersion in vivo does not immediately reach the final
state but rather passes through a low dilution state, especially when viscous bicoherent
structures are present. Such dynamic effects, lasting seconds to minutes, can reach the
duration of nucleation induction time, and therefore become relevant for drug precipi-
tation.
We introduced a theoretical non-interacting model to investigate the mechanism of drug
solubilization of two model systems at relevant dilution ratios. Our results suggested that
drug solubilization in the undiluted systems was mainly dominated by microdomains
caused by surfactant/co-solvent interaction. In contrast, drug solubilization in the dis-
persed systems was due to independent mechanisms of co-solvency and micellization.
Additional surfactants and co-solvents should be tested to predict how broadly the
concept of non-interacting excipients can be applied. Finally, pharmacokinetic stud-
ies would be of interest to compare the obtained results with in vivo drug precipitation
and absorption.
Chapter 4
Insights into drug precipitation
kinetics during in vitro digestion
of a lipid-based drug delivery
system using in-line Raman
spectroscopy and mathematical
modeling
Summary
The aim was to determine drug precipitation during in vitro lipolysis of a lipid-based
drug delivery system (LBDDS) using Raman spectroscopy as a real-time monitoring
technique. A second aim was to describe the kinetics of lipolysis-triggered drug precip-
itation using a theoretical nucleation and growth model. A model LBDDS containing
different concentration of fenofibrate was digested in vitro and drug precipitation was
determined after ultracentrifugation and nanofiltration (off-line methods), as well as
by Raman spectroscopy (in-line method). Subsequently, a theoretical nucleation and
growth model was fitted to the obtained drug crystallization profiles by considering the
lipolysis-triggered change in drug solubility.
Compared with standard off-line measurements, Raman spectroscopy enabled a more
Stillhart C. et al. Insights into drug precipitation kinetics during in vitro digestion of a lipid-based
drug delivery system using in-line Raman spectroscopy and mathematical modeling. Pharmaceutical
Research, 2013, 30(2), 3114–3130.
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robust and highly time-resolved analysis of lipolysis-triggered drug precipitation. Al-
though the formulation was rapidly digested, fenofibrate remained in a supersaturated
state for several minutes before beginning to crystallize. The in vitro digestion results
were in excellent agreement with the theoretical model. The combination of real-time
Raman spectroscopy and mathematical modeling provided insights into the kinetics of
lipolysis-triggered drug crystallization. This knowledge allows a better biopharmaceuti-
cal understanding and will, ultimately, lead to the improved development of LBDDS.
4.1 Introduction
Contemporary drug discovery screening has generated an increasing number of highly
active but poorly water-soluble drug candidates. Lipid-based drug delivery systems
(LBDDS) are an innovative strategy that significantly enhances the oral bioavailability
of such compounds. Because the formulated drug is already in a dissolved state, the
critical dissolution step is circumvented. This is, however, only one mechanism by which
LBDDS can enhance oral drug absorption. Drug solubilization in the intestinal medium
is generally improved in the presence of lipidic excipients. Furthermore, these excipients
can stabilize a supersaturated drug, may reduce pre-systemic clearance, and can pro-
mote lymphatic absorption [14, 54, 56, 75].
The improvement of oral bioavailability is largely governed by the fate of the LBDDS
in the gut. In addition to formulation dispersion, digestion represents a particularly
critical step, because hydrolyzed glycerides and some surfactants exhibit a change in
polarity [146, 203, 204]. Thus, the capacity of a formulation to solubilize a drug may be
progressively reduced, developing an increased risk of drug precipitation. To predict the
fate of a drug in the gastrointestinal lumen therefore requires adequate in vitro tests.
Although no standard compendial methods have been established so far, first attempts
have been made in this direction [134, 146–148]. Most recently, the Lipid Formulation
Classification System Consortium released a collaborative work, which was aimed at
standardizing in vitro methods to assess the performance of LBDDS, with a particular
focus on lipolysis testing [26, 27].
A lipolysis test should primarily reveal whether a formulation keeps the drug solubilized.
According to the current procedure, samples are removed at given time intervals during
a digestion experiment [26, 30]. After enzyme inhibition, the digests are separated by
ultracentrifugation into a pellet phase (containing precipitated drug), an oil phase, and
an aqueous phase. The drug distribution in these phases is crucial, because the solubi-
lized drug is expected to approximate the dose fraction that is available for absorption
[120].
The influence of lipid digestion on drug solubilization is the result of a complex interplay
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between several factors. Relevant for solubilization are the properties of the drug and
of the lipolysis products in the presence of bile salts and phospholipids. It is assumed
that colloidal structures, which are generated during formulation lipolysis, largely define
drug solubilization. Although these structures have been characterized in several studies
[48, 101, 102, 145, 156, 205, 206], it is difficult to predict the resulting drug solubiliza-
tion. The difficulty arises not only from dynamic changes in the medium but also from
the possibility of drug supersaturation. Indeed, if the period of supersaturation is long
enough to enable drug absorption, then intestinal drug precipitation might be prevented.
Thus, considerable research efforts have focused on drug supersaturation in biorelevant
media, with and without the aid of lipid-based excipients [56, 57, 70]. As well as drug
supersaturation, the solid-state properties of precipitated drug are of biopharmaceutical
relevance. Sassene et al. recently observed the precipitation of amorphous cinnarizine
during digestion of a self-emulsifying system [33]. Drug re-dissolution was measured in
vitro and proved to be faster than from its crystalline form. Such knowledge appears
to be critical to the development of a formulation and indicates that more research is
needed in this pharmaceutical field.
Formulation digestion and drug solubilization are highly dynamic processes, but the
lack of real-time information limits the feasibility of exploring in vitro digestion. War-
ren et al. recently demonstrated the importance of using an in situ method (synchrotron
small-angle X-ray scattering) to gain insight into a rapidly proceeding digestion process
[32]. Significant transformations of the formulation typically occur within a short time
frame and the sampling regime of traditional methods almost precludes the detection of
transient solubility effects.
The use of Raman spectroscopy is an efficient approach to the real-time monitoring
of crystallization processes during chemical production [207–212]. The method allows
rapid spectra collection in a contact-free manner and with high chemical specificity. Re-
cently, Raman spectroscopy has been applied successfully to study drug precipitation in
a biorelevant medium [213] and for process monitoring in complex multiphasic systems
[214]. These are promising features with respect to real-time monitoring of drug crys-
tallization during in vitro digestion. However, the complexity of the medium and the
varying composition during lipolysis are particularly challenging for any spectroscopic
application.
The first aim of the study was to evaluate the potential of Raman spectroscopy for real-
time monitoring of drug precipitation during in vitro lipolysis. Based on this in situ
information, the second aim was to describe the kinetics of drug precipitation using a
theoretical model of nucleation and particle growth, including the lipolysis-triggered
change in drug solubility. Finally, using the combination of real-time spectroscopy
and mathematical modeling, we aimed to gain a better quantitative understanding of
lipolysis-triggered drug precipitation.
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4.2 Materials and methods
4.2.1 Materials
We obtained fenofibrate (≥99%), Trizma R© maleate, calcium chloride dihydrate (≥99%),
pancreatin (from porcine pancreas, 8xUSP specifications), 4-bromophenylboronic acid
(4-BPBA, ≥95.0%), chloroform, and acetonitrile from Sigma-Aldrich Chemie GmbH
(Buchs, Switzerland), and sodium chloride (≥99%) from Carl Roth GmbH (Karlsruhe,
Germany). Lipoid E PC S (phosphatidylcholine from egg yolk) was supplied by Lipoid
GmbH (Ludwigshafen, Germany), sodium taurodeoxycholate by Prodotti Chimici e Al-
imentari S.p.A. (Basaluzzo, Italy), and sodium hydroxide 1 M by Scharlab S.L. (Sent-
menat, Spain). Imwitor R© 988 was purchased from Sasol Germany GmbH (Witten, Ger-
many), Miglyol 812 N from Ha¨nseler AG (Herisau, Switzerland), and Cremophor R© RH
40 from BASF AG (Ludwigshafen, Germany). Imwitor 988 was a blend of medium-chain
mono-, di-, and triglycerides (54.6% monoglyceride [MG], 38.0% diglyceride [DG], and
7.1% triglyceride [TG]) consisting of 98.7% w/w caprylic acid (C8), 1.1% w/w capric
acid (C10), and 0.1% w/w caproic acid (C6), with average molecular weights of 197,
340, and 483 g/mol for MG, DG, and TG, respectively (according to the certificate of
analysis, lot no. 003041, Cremer Oleo GmbH). Miglyol 812 N was a medium-chain TG
consisting of 57.9% w/w caprylic acid (C8), 41.2% w/w capric acid (C10), 0.5% w/w
lauric acid (C12), and 0.1% w/w caproic acid (C6) with an average molecular weight of
517 g/mol (according to the certificate of analysis, lot no. 2008111435, Ha¨nseler AG).
Purified water was prepared with an Arium R© 61215 water-purification system from
Sartorius Stedim Biotech GmbH (Go¨ttingen, Germany). We used Anotop R© 25 Plus
filters (aluminum oxide, 0.1 µm) purchased from Whatman GmbH (Dassel, Germany)
for nanofiltration.
4.2.2 Preparation of the formulation
A self-microemulsifying drug delivery system (SMEDDS) was selected as the model
formulation. The SMEDDS was composed of 40% w/w Miglyol 812, 20% w/w Imwitor
988, and 40% w/w Cremophor RH 40. The components were mixed on a magnetic stirrer
at 40◦C until a clear solution was obtained and then slowly cooled to room temperature.
Fenofibrate (logP 4.6) was used as a poorly water-soluble model drug. The compound
was incorporated into the formulation at levels of 20, 30, 40, 50, 60, 70, and 80 mg/g
(Cform). All formulations were visually assessed for absence of undissolved drug particles.
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4.2.3 In vitro lipolysis test
The in vitro lipolysis test was performed as described in the literature [146]. We prepared
a micellar solution containing 1.25 mM phosphatidylcholine (PC) and 5 mM sodium
taurodeoxycholate (NaTDC) to simulate fasted state intestinal conditions. PC was
dissolved in chloroform and the solvent was evaporated under vacuum (Rotavapor RE
120, Bu¨chi, Switzerland). NaTDC and digestion buffer (50 mM Trizma maleate, 150
mM NaCl, and 5 mM CaCl2·2H2O; pH 7.5) were then added and the mixture was
stirred for 12 h (450 rpm, 5◦C). To prepare the pancreatin extract, we mixed 1 g of
porcine pancreatin powder per 5 ml of digestion buffer (5◦C), stirred for 15 min, and
then centrifuged the suspension (15 min, 1,600xg, 5◦C). Finally, the supernatant was
collected and the pH adjusted to 7.5, which corresponded to the pH of the lipolysis
medium. The pancreatin extract was freshly prepared each day and stored on ice until
use.
The micellar solution (108 ml) was transferred to a thermostated glass vessel (37.0 ±
0.5◦C) and the formulation (2.6 g) was added. The mixture was stirred for 10 min for
complete dispersion, thermal equilibration, and pH adjustment to 7.500 ± 0.001. For
mixing, we used a magnetic stirrer (3 cm in diameter) at a speed of 450 rpm. Digestion
was initiated by the addition of 12 ml pancreatin extract (final nominal lipase activity:
1000 tributyrin units per ml). The free fatty acids (FA) produced during lipolysis were
titrated using 1 M NaOH to maintain pH 7.500 using a pH-stat apparatus (842 Titrando
and 800 Dosino, Metrohm AG, Switzerland), which was operated using the Tiamo R© 1.2
software package (Metrohm AG, Switzerland). Lipolysis was allowed to proceed for 30
min.
To determine the NaOH consumption caused by digestion of the blank digestion medium,
we performed the lipolysis test with pure digestion medium without formulation (n=3).
Fenofibrate formulations with varying drug loads (20, 30, 40, 50, 60, 70, and 80 mg/g)
were digested in triplicate and the amount of precipitated and/or solubilized drug was
assayed using three different procedures, i.e., ultracentrifugation, nanofiltration, and
Raman spectroscopy.
4.2.3.1 ”Back-titration” and calculation of free fatty acids liberated during
digestion
It was previously shown that the titrated NaOH volume represents only an approxi-
mation of the free fatty acids (FA) liberated during lipolysis. Some FA exist in their
unionized state, according to the pKa value, leading to an underestimation of the to-
tal FA liberation. This must be corrected by a procedure that was previously termed
“back-titration” [157, 158]. We performed the back-titration experiment as described
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in the literature, with minor changes. At the end of the 30 min digestion period, the
pH was rapidly increased to 9 by addition of 1M NaOH for complete FA ionization
(deprotonation). The experiment was also done with blank digestion buffer including
pancreatin extract (without formulation, PC, and NaTDC) to determine the NaOH vol-
ume needed to increase the pH in the absence of lipolysis products. The latter volume
was subtracted from the total back-titration volume obtained in the presence of lipol-
ysis products to obtain the value of FAtitr(back-titration). The correction factor was
calculated according to the formula:
Correction factor =
FAtitr(direct titration) + FAtitr(back-titration)
FAtitr(direct titration)
(4.1)
where FAtitr(direct titration) is the amount of FA titrated after the 30 min digestion
period.
A correction factor was calculated for both the lipolysis of formulations and the lipolysis
of pure digestion medium (without formulation). Finally, the amount of FA liberated
from the pure digestion medium was subtracted from the total amount of FA titrated
in presence of the formulation.
4.2.4 Determination of drug precipitation
4.2.4.1 Ultracentrifugation method
During formulation lipolysis, aliquots (2.7 ml) were taken from the digestion media af-
ter a 1, 2.5, 5, 7.5, 10, 12.5, 15, 20, 25, and 30 min digestion period. We immediately
added 20 µl of a 4-BPBA solution (1 M in methanol) to inhibit further lipolysis [215]
and ultracentrifuged the samples (80,000xg, 37◦C, 90 min) in a Centrikon T-1180 ul-
tracentrifuge equipped with a TFT-80.4 fixed-angle rotor (Kontron Instruments, Milan,
Italy). The aqueous phase was then diluted with acetonitrile and centrifuged (16,000xg,
15 min). The pellet was suspended in purified water, diluted in acetonitrile, and cen-
trifuged (16,000xg, 15 min). Finally, all samples were analyzed using high-performance
liquid chromatography (HPLC).
4.2.4.2 Nanofiltration method
A 2 ml sample was withdrawn from the lipolysis medium after 1, 2.5, 5, 7.5, 10, 12.5,
15, 20, 25, and 30 min. The samples were directly passed through an Anotop 25 Plus
syringe filter (pore size 0.1 µm, aluminum oxide filter membrane) [137] and the filtrate
was immediately diluted in acetonitrile to stop further lipolysis. The samples were then
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centrifuged (16,000xg, 30 min) and analyzed by HPLC. We verified experimentally that
no loss of dissolved substance occurred through adsorption onto the filter material.
The Mann–Whitney test was performed to compare the concentration of solubilized
drug after 0 and 1 min of lipolysis. For statistical treatments we used the software
Statgraphics R© Centurion XV Professional (Statpoint Technologies Inc. Warrenton, USA)
and selected a significance level of 95.0% (p<0.05).
4.2.4.3 In-line determination of drug precipitation using Raman spectros-
copy
A multi-fiber Raman PhAT probe was used to determine the course of fenofibrate precip-
itation in situ. The titration vessel was covered with a custom-built vessel lid (Metrohm
AG, Zofingen, Switzerland) with an extra cavity for the PhAT probe, which was posi-
tioned 1 cm above the initial level of the lipolysis medium (Fig. 4.1). A comparatively
large titration vessel, and thus a relatively high volume of digestion medium, were re-
quired because of the PhAT probe size (outer diameter: 32 mm). The entire lipolysis
vessel was wrapped in aluminum foil and the laboratory was darkened to avoid the in-
fluence of external light on the Raman signal.
We used a Raman RXN1 analyzer (Kaiser Optical Systems, Inc., Ann Arbor, MI, USA)
equipped with a charge-coupled device (CCD) camera and a diode laser operating at
a wavelength of 785 nm. The spectra were acquired with a laser power of 400 mW
 
Figure 4.1: Experimental setup of the in vitro lipolysis test combined with Raman
spectroscopy. The PhAT probe consisted of a non-contact optic device and provided a
large laser spot area (6 mm in diameter).
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and background Rayleigh scattering was removed by a holographic filter during spec-
tra acquisition. A single spectrum was acquired every 20 s (acquisition time 18.5 s)
with a resolution of 4 cm−1 using the iC Raman R© Instrument software (Version 3.0,
Mettler-Toledo AutoChem Inc., Columbia, MD, USA). The Raman PhAT probe was a
multi-fiber probe with a non-contact sampling optic device having a laser spot diameter
of 6 mm. The scattered radiation was collected by an array of 50 optical fibers and
delivered to the CCD camera.
To remove sources of non-linearity and spectral information that was uncorrelated with
the concentration of the analyte, the spectra were subjected to several preprocessing
algorithms, i.e., the multiplicative scatter correction (MSC) [216], the standard normal
variate (SNV) transformation [217], and the Savitzky–Golay (SG) polynomial deriva-
tive filter [218]. All data were mean-centered and, finally, a calibration model was built
by partial least-squares (PLS) regression [219]. The optimal number of PLS factors
was defined where the root-mean-square error of cross-validation (RMSECV) reached a
minimum (<1% of spectral variation). Cross-validation was performed with the leave-
one-out method. We evaluated different spectral ranges to include in the PLS regression
model, i.e., the entire spectrum (500–1800 cm−1), the fingerprint range of fenofibrate
(1000–1800 cm−1), and specific fenofibrate peaks (1132–1164 cm−1, 1550–1615 cm−1,
and 1635–1663 cm−1). Spectral preprocessing and PLS regression analysis were calcu-
lated using Matlab R© (MathWorks, Naticks, MA, USA). The calibration models were
evaluated in terms of the correlation coefficient R2, the cross-validation coefficient Q2,
the root-mean-square error of calibration (RMSEC), and the RMSECV.
4.2.5 Drug solubilization upon dispersion without lipolysis
Drug solubilization under non-digesting conditions was determined to assess whether
fenofibrate precipitated spontaneously upon aqueous dispersion of the formulation (with-
out lipolysis). Thus, 2.6 g of formulation with 80 mg/g fenofibrate were dispersed in
108 ml of digestion buffer (containing NaTDC and PC) in a glass vessel at 37◦C and
stirred at 450 rpm. After equilibrating the system for 10 min, 12 ml of pure digestion
buffer (without pancreatin extract) were added and the medium was stirred for 30 min.
Subsequently, three 2 ml aliquots were centrifuged for 30 min (16,000xg, 37◦C) and the
concentration of solubilized and precipitated fenofibrate was measured by HPLC. The
experiment was carried out in triplicate.
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4.2.6 Determination of drug solubility
Drug solubility was determined in the undiluted formulation (C∗form). Excess solid drug
was added to a 2 ml aliquot of blank formulation and stored in hermetically sealed glass
vials during equilibration (37◦C, 450 rpm). After 24 h, 48 h, and 72 h the samples were
centrifuged (37◦C, 16,000xg, 30 min) and the supernatant was analyzed by HPLC. Equi-
librium was assumed when two consecutive solubility samples varied by <5% (w/w).
Furthermore, we determined the drug solubility (C∗m,t) in the lipolysis medium contain-
ing drug-free formulation after a 1, 2.5, 5, 7.5, 10, 12.5, 15, 20, 25, and 30 min digestion
period. The enzyme inhibitor (4-BPBA, 1M in methanol, 9 µl per ml of digest) was
added to the medium at the aforementioned time points to stop further digestion. Excess
solid drug was transferred to a 10 ml aliquot of the lipolysis medium and was hermetically
sealed in glass vials. After equilibration (450 rpm, 37◦C), the samples were ultracen-
trifuged (80,000xg, 37◦C, 90 min). The liquid phase was then diluted in acetonitrile,
centrifuged (16,000xg, 15 min), and finally analyzed by HPLC. Because the solubili-
ties were found to decrease at equilibration times longer than 24 h, we considered the
value obtained at 24 h of equilibration as the relevant solubility. The observed decrease
in solubility was attributed to kinetic instability of the colloidal structures in digested
medium [27, 56]. Whenever a lipid phase was obtained upon ultracentrifugation, the
lipid and the aqueous phase were re-emulsified, to measure the overall concentration of
solubilized drug. The drug solubility experiments were carried out in triplicate.
4.2.7 High-performance liquid chromatography (HPLC)
For HPLC analysis (Agilent Technologies 1200 Series) we used an autosampler (G1329A),
an isocratic pump (G1310A), and a variable wavelength detector (G1310A). All mea-
surements were done on a LiChrospher R© 60, RP select B 125-4 (5 µm) column (Merck,
Darmstadt, Germany), using a flow rate of 1 ml/min, a UV detection wavelength of
287 nm, and an injection volume of 20 µl. The mobile phase consisted of acetonitrile
and ammonium acetate buffer (pH 3.5; 25 mM) at a ratio of 65:35 v/v [220]. All sample
measurements were in the linear range of calibration.
4.2.8 Dynamic light scattering (DLS)
We measured the particle size of the dispersed formulation before lipolysis initiation by
DLS using a Zeta Sizer Nano ZS (Malvern Instruments, Malvern, UK), equipped with
a 4 mW He-Ne Laser operating at a wavelength of 633 nm. The scattering signal was
detected at an angle of 173◦ and each sample was measured in triplicate for 10 min. The
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result was expressed as intensity averaged particle diameter (nm) and as polydispersity
index (PDI).
4.2.9 X-ray powder diffraction (XRPD)
The pellet phase that was obtained upon digestion and ultracentrifugation of the drug-
containing formulation was analyzed by XRPD. The formulation with 80 mg/g fenofi-
brate was digested for 30 min in the in vitro lipolysis test and, after enzyme inhibition,
an aliquot was ultracentrifuged (80,000xg, 37◦C, 90 min). The pellet phase was im-
mediately isolated and an X-ray diffractogram was recorded. The same procedure was
followed with the pellet phase obtained from a 30 min lipolysis experiment with drug-
free formulation, which was spiked with an equal amount of pure fenofibrate (as used for
formulation preparation). Moreover, we recorded the X-ray diffractogram of crystalline
fenofibrate as a reference.
We used a theta-theta X-ray powder diffractometer (R-XRD Phaser D2, Bruker AXS
GmbH, Karlsruhe, Germany) equipped with a Co and Cu KFL tube (30 kV, 10 mA)
as radiation source and a Lynxeye R© detector. The samples were scanned in the angular
range of 5◦ (2θ) to 40◦ (2θ) with a step size of 0.1◦ (2θ) and a count time of 5s per step.
4.2.10 Modeling the kinetics of lipolysis-triggered drug precipitation
The increased chemical potential of a supersaturated solution, in which the actual con-
centration of solubilized drug exceeds its solubility, is the driving force for drug precipi-
tation. Precipitation can be described by two consecutive processes, i.e., nucleation and
particle growth. The relationship between precipitation and supersaturation is reflected
in the expressions describing the kinetics of these processes. According to the classical
nucleation theory, the nucleation rate, J (m−3s−1), is given by [64]:
J =
dC
′
pr
dt
= A′Se−
B
ln2 S (4.2)
where C
′
pr is the number of nuclei formed per unit volume and S is the degree of super-
saturation given by S = C/C∗, with C being the actual drug concentration and C* its
solubility in the medium. Parameter A
′
(m−3s−1) holds for the kinetic component of
nucleation and is proportional to the number of nucleation-active centers. Its value dif-
fers between volume-diffusion-controlled and interface-controlled nucleation and is many
orders of magnitude smaller for heterogeneous nucleation than for homogeneous nucle-
ation [197]. B stands for the thermodynamic component of the process and is given by:
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B = 16piν20γ
3/3(kT )3 (4.3)
where ν0 is the molecular volume of the crystalline phase, γ is the interfacial energy per
unit area of the crystal, k is the Boltzmann constant, and T is the temperature. In the
case of heterogeneous nucleation, the work of nucleation is reduced because of the lower
interfacial energy, leading to smaller values of B.
The particle growth rate G (m·s−1) is often expressed heuristically as a power-law [63]:
G = k
′
g(C − C∗)g (4.4)
where k
′
g is the particle growth coefficient, and g is the order of particle growth.
To apply Eqs. 4.2 and 4.4 for modeling the kinetics of lipolysis-triggered drug precipita-
tion, the changes in C* and S as a function of time had to be considered. Fenofibrate
solubility depends on the concentration of lipids in the medium and is therefore affected
by the lipolysis, which changes the lipid composition over time. Hence, solubility was
expressed as a function of time by a heuristic equation, which considered the contribu-
tion of different lipid species to solubility.
Considering the lipolysis kinetics on the one hand, and the specificity/activity of diges-
tive enzymes (i.e., pancreatic lipase, co-lipase, and carboxyl ester hydrolase [146, 157–
159]) on the other, we subdivided the lipolysis of the formulation (containing TG, DG,
and MG) into two kinetic stages. TG and DG were assumed to be digested rapidly
by the pancreatic lipase and co-lipase (first stage), while MG were digested slowly by
the carboxyl ester hydrolase (second stage). The time point of transition between the
first and second stages, tx, was obtained graphically from the experimental FA titration
curve. Based on the titration data and the stoichiometry of glyceride lipolysis, we calcu-
lated the moles of TG and DG (M1(t)) digested into MG during the first stage and the
moles of MG (M2(t)) digested during the second stage. The course of drug solubility in
both stages was modeled using Eqs. 4.5 and 4.6:
C∗m,t(stage 1) = C
∗
m,0 ·
(
1− M1(t)
M0
)
+ C∗m,tx ·
(
M1(t)
M0
)
(4.5)
C∗m,t(stage 2) = (C
∗
m,tx − C∗m,30 ) ·
(
1− M2(t)
Mtx
)
+ C∗m,30 (4.6)
where C∗m,0 , C∗m,tx , and C∗m,30 are the experimental drug solubility values in the lipolysis
medium at times 0, tx, and 30 min, respectively. M0 is the molar quantity of TG and
DG at 0 min, and Mtx is the molar quantity of MG in the medium at tx. M1(t) and
M2(t) were proportional to the logarithm of time.
The kinetics of lipolysis-triggered drug precipitation was modeled by adapting Eqs. 4.2
and 4.4, and combining them with Eqs. 4.5 and 4.6. Three time intervals were defined
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that were delimited by t0 (beginning of the experiment), tn (beginning of nucleation),
tg (beginning of particle growth), and t30 (end of the experiment). Thus, the model
comprised the following system of ordinary differential equations:
t0 < t < tn :
dCpr
dt
= 0 (4.7)
tn < t < tg and t < tx :
dCpr
dt
= ASe−
B
ln2 S with S =
C
C∗m,t(stage 1)
(4.8)
tn < t < tg and t > tx :
dCpr
dt
= ASe−
B
ln2 S with S =
C
C∗m,t(stage 2)
(4.9)
tg < t < t30 and t < tx :
dCpr
dt
= kg · (C − C∗)g with S = C∗m,t(stage 1) (4.10)
tg < t < t30 and t > tx :
dCpr
dt
= kg · (C − C∗)g with S = C∗m,t(stage 2) (4.11)
Cpr refers to the mass concentration of precipitated drug. During the induction time
(between t0 and tn), no precipitation takes place (Eq. 4.7). During nucleation, the de-
gree of supersaturation S may be given by Eqs. 4.8 and 4.9 depending on the position of
tx relative to tn and tg. Analogously, during particle growth, the expression of solubility
C* may depend on the position of tx with respect to tn and tg (Eqs. 4.10 and 4.11).
The values of parameters A, B, kg, g, tn, and tg, were estimated by regressing this sys-
tem of differential equations to the concentration data obtained by Raman spectroscopy.
Mean Cpr values of each drug load between 40 and 80 mg/g (n=3) were used.
Calculations were carried out using Matlab. For parameter estimation we used the Mat-
lab optimization algorithm fminsearch, which is based on the simplex procedure. The
ordinary differential equations were numerically solved using the Matlab ode45 solver
and the model quality was assessed based on the R2 value and the root-mean-square
error (RMSE).
4.3 Results
4.3.1 Formulation characteristics
The lipid-based system emulsified spontaneously within 10 s, resulting in a fine emulsion
with a droplet diameter of 39.5 ± 0.3 nm and a PDI of 0.047 ± 0.018 (mean ± standard
deviation (SD), n=3). No drug precipitation was measured 30 min after dispersion un-
der non-digesting conditions. Fenofibrate solubility in the undigested lipolysis medium
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was 2.60 ± 0.44 mg/ml. However, upon addition of pancreatin extract, the solubility
dropped rapidly to a value of 0.403 ± 0.006 mg/ml within the first minute of diges-
tion. By the end of the lipolysis experiment (t=30 min), solubility further decreased
to 0.129 ± 0.005 mg/ml. On the other hand, fenofibrate solubility in the undispersed
formulation,C∗form , was 139.6 ± 0.7 mg/g.
Before lipolysis initiation, fenofibrate was below saturation, even at the highest drug
load. As a consequence of the rapid decrease in drug solubility with formulation lipol-
ysis, fenofibrate became supersaturated within the first minute of digestion. At the
highest drug load (80 mg/g) the supersaturation ratio reached a value of 4.19 ± 0.03
(1 min of digestion), whereas at a drug load of 20 mg/g, the corresponding supersatu-
ration ratio was 1.04 ± 0.02.
Figure 4.2 shows the NaOH titration profile obtained from formulation lipolysis. Imme-
diately after initiation of digestion, the hydrolysis was fast, while after approximately
1 min the rate had clearly decreased. No clear differences were observed between the
lipolysis profiles of formulations with different drug loads.
Because not all FA were expected to be ionized at the pH of the assay, we employed the
“back-titration” procedure. We obtained a back-titration factor of 1.09 for the formu-
lation lipolysis, implying that 9% of the free FA were protonated at pH 7.5 and, thus,
not determined by direct titration. The lipolysis and back-titration of pure digestion
medium (without SMEDDS) resulted in a correction factor of 1.77.
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Figure 4.2: Free FA originating from formulation digestion as a function of time.
Values (means ± SD, n = 3) were corrected for background lipolysis (pure lipolysis
medium) and include additional FA detected by back-titration.
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4.3.2 Detection of drug precipitation during lipolysis
4.3.2.1 Ultracentrifugation method
To determine the amount of precipitated drug, we first applied ultracentrifugation for
sample preparation, which appeared to be the most widespread method in this field of
in vitro testing. Following ultracentrifugation, only two phases were obtained, i.e., an
aqueous and a pellet phase. No oil phase was visually detectable with the given samples.
This was, as expected, different from the samples that were not digested (t=0), in which
an oil phase was additionally observed.
Figure 4.4a displays the fenofibrate precipitation profiles of formulations with varying
drug loads, as obtained using ultracentrifugation. Drug precipitation started rapidly
upon initiation of digestion and leveled off after approximately 2.5 min for formulations
with drug loads of 40 to 80 mg/g. Formulations with a lower drug load displayed some
drug precipitation as well but the rates and extents were moderate.
Drug concentration in the aqueous phases decreased over time, in parallel to the increase
in precipitation. After a 2.5 min digestion period, the concentrations of solubilized drug
approached the equilibrium values, C∗m,t, for all formulations with a drug load of 40–
80 mg/g.
We recorded the XRPD pattern of pure fenofibrate, of the pellet containing precipitated
fenofibrate, and of a reference pellet. This reference was the pellet obtained after lipol-
ysis of drug-free formulation, which was spiked with crystalline fenofibrate. As seen in
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Figure 4.3: XRPD pattern of the pellet phase obtained upon ultracentrifugation
and resulting from (a) the formulation with 80 mg/g fenofibrate, (b) the pellet phase
of drug-free formulation spiked with crystalline fenofibrate, and (c) pure crystalline
fenofibrate.
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Fig. 4.3, the angular range of peaks of the pellet containing precipitated drug corre-
sponded to that of the reference pellet. Therefore, apparently, fenofibrate precipitated
in the crystalline form during lipolysis.
4.3.2.2 Nanofiltration method
The nanofiltration method allowed the determination of solubilized fenofibrate in the
filtrate. Therefore, the concentration of precipitate was calculated as the difference
between the total drug concentration and the amount of solubilized drug (Fig. 4.4b).
Similar to the ultracentrifugation method, we observed significant drug precipitation
within 30 min of lipolysis with all formulations having a drug load of 40 mg/g and
more. However, the time course was different, as there was an initial lag phase without
precipitation before the drug finally started to precipitate out. Thus, for the SMEDDS
with the highest drug load, precipitation started after approximately 2.5 min, while for
the formulation with a drug load of 30 mg/g, drug precipitated after about 15 min. The
concentration of solubilized drug did not significantly change within the first minute of
digestion for each drug load (p>0.05). Finally, only minimal precipitation was observed
in the formulation with a 20 mg/g drug load.
4.3.2.3 Raman spectroscopy
The Raman spectra of fenofibrate in the crystalline and solubilized forms displayed a
characteristic pattern, as seen in Fig. 4.5a. Unprocessed spectra are depicted, which were
recorded during the lipolysis experiment at different time points (drug load: 70 mg/g).
Moreover, the Raman spectra of crystalline fenofibrate and of the drug-free lipolysis
medium are shown. The spectra recorded after 40 s, 5 min, and 30 min of lipolysis
displayed noticeable variations in the range of 1132–1164 cm−1 and 1550–1663 cm−1.
A PLS model was built for the concentration of crystallized fenofibrate based on a set
of 42 spectra, as detailed in Table 4.1.
Table 4.1: Calibration set as used for quantitative application of Raman spectroscopy.
Cpr (mg/g) Time span of
acquisition (s)
Cpr (mg/ml) Total number of
calibration spectra
20, 30, 40, 50, 60, 70 20–40 0 18
50, 60, 70, 80 1480–1500 Cpr
a 12
50, 60, 70, 80 1780–1800 Cpr
a 12
a Results obtained using the ultracentrifugation method.
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Figure 4.4: Time course of fenofibrate precipitation during formulation lipolysis as
detected (a) upon ultracentrifugation, (b) upon nanofiltration and (c) with Raman
spectroscopy. Each color represents a single drug loading, Cform . Values are expressed
as means ± SD (n=3).
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Figure 4.5: Part (a) depicts the unprocessed Raman spectra of drug-free lipolysis
medium (I), lipolysis medium with fenofibrate after 40 s (II), 5 min (III), and 30 min
(IV) digestion periods, and pure fenofibrate (V). Plots of the weights of the first PLS
factor (b) and scores over time of all three PLS factors used in the PLS model (c). The
numbers in (c) represent the variance captured in the corresponding PLS factor. All
plots are offset for clarity.
Chapter 4. Kinetics of lipolysis-triggered drug precipitation 65
The reference values were mostly selected from concentrations and time points that
demonstrated consistent results in both off-line methods (i.e., ultracentrifugation and
nanofiltration). The concentrations in samples with a drug load of 50–80 mg/g, assayed
at 25 and 30 min of digestion, were consistent between the two methods and were there-
fore used for model calibration of the corresponding spectra. To further include spectra
of digests without precipitate, we relied on the data from the nanofiltration method. Ac-
cording to these results, the concentration of solubilized drug after 1 min of lipolysis was
not significantly different from the concentration before initiation of lipolysis (p>0.05
in all cases). This observation indicates that no precipitation occurred during the first
minute of digestion. Therefore, for model calibration we selected the earliest spectrum
(i.e., the spectrum that was acquired 40 s after lipolysis initiation) of each formulation
with a drug load of 20–70 mg/g and set Cpr equal to zero. The 80 mg/g drug load was
excluded from this part of the calibration.
We evaluated different methods for data preprocessing. Two scatter-correction methods
(MSC, SNV) and a derivative method (SG) were compared [216–218]. Moreover, three
different spectral ranges were considered for model calibration. Table 4.2 compares the
performance of calibration models that were obtained using the different pre-processing
methods and spectral ranges. The best calibration model was attained with the SG
algorithm (1st derivative) and a spectral range between 1000 and 1800 cm−1. Three
PLS factors described 99.4% of the spectral variation, with an R2 value of 0.994, while
the first, second, and third factors accounted for 96.6%, 1.4%, and 1.3% of the variation,
respectively. Only the first PLS factor is shown in Fig. 4.5b, as it accounted for most of
the variation. Herein, three ranges with a high PLS weight were identified, which cor-
responded to the peaks of the crystalline fenofibrate. The second and the third factors
contributed to the model variation to a lower extent. However, they may account for
residual non-linearity in the data set as seen in Fig. 4.5c. The cross-validation proce-
dure yielded a Q2 value of 0.972 and an RMSECV of 0.111 mg/ml, indicating a robust
calibration model.
Finally, we applied this calibration model to all other Raman spectra to determine the
precipitation profiles over a 30 min digestion period. Figure 4.4c shows that fenofibrate
precipitated after an initial lag time in all formulations with drug loads of more than
30 mg/g. Minimal drug precipitation was observed for the formulation with a drug load
of 20 mg/g.
In summary, the comparison of fenofibrate precipitation profiles (Fig. 4.4a, 4.4b, and
4.4c) demonstrated an excellent agreement between the nanofiltration and the spectro-
scopic methods. Both methods suggested that drug precipitated only after an initial
lag phase. This was in contrast to the ultracentrifugation method, which indicated
precipitation almost immediately after digestion started.
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Table 4.2: PLS analysis result of Raman spectroscopy
Pre-
processing
method
Spectral
rangeb
PLS
factors
R2 Q2 RMSEC
(mg/ml)
RMSECV
(mg/ml)
None A 5 0.985 0.969 0.0142 0.113
B 4 0.985 0.959 0.0104 0.129
C 3 0.979 0.960 0.0501 0.112
SNV A 3 0.984 0.907 0.0298 0.194
B 3 0.988 0.962 0.0199 0.152
C 4 0.953 0.962 0.0108 0.124
MSC A 4 0.985 0.958 0.0129 0.132
B 3 0.978 0.958 0.0133 0.132
C 3 0.982 0.966 0.0158 0.117
SGa A 3 0.993 0.971 0.0083 0.117
B 3 0.994 0.972 0.0079 0.111
C 3 0.990 0.969 0.0099 0.111
a Parameters used in the SG algorithm: window size 10 points, 1st derivative, 2nd polynomial.
b Spectral ranges: A=500–1800 cm−1; B=1000–1800 cm−1; C=1132–1164, 1550–1615, 1635–
1663 cm−1.
4.3.3 Modeling the kinetics of lipolysis-triggered drug precipitation
The high temporal resolution of in-line Raman spectroscopy encouraged a more detailed
analysis of drug precipitation kinetics. The theories of nucleation and growth (Eqs. 4.2
and 4.4) were applied to model the course of lipolysis-triggered drug precipitation. Be-
fore lipolysis initiation, drug concentration in the lipolysis medium was below satura-
tion. Enzymatic digestion of lipids resulted in a diminished drug solubilization, which
in turn induced supersaturation and led to drug precipitation. Because the drug solu-
bility changed continuously through ongoing lipolysis, an expression for time-dependent
solubility was introduced.
The progress of lipolysis is reflected by the amount of FA titrated as a function of time
(Fig. 4.2). These data show that lipolysis occurred rapidly at first and then slowed
down considerably. By drawing two straight lines through the data points between 0
and 40 s, and between 16.6 and 30 min, we found the intersection point, tx, at 82.1 s.
This time point was used to define the transition of the initial rapid lipolysis stage to
the second, slow lipolysis stage. Based on the titration data and the stoichiometry of
hydrolysis, we calculated the amount of glycerides that were apparently hydrolyzed in
these two stages (Fig. 4.6a), and compared it with the amount of formulation lipids.
The good agreement between experimental data (Fig. 4.6a), and the formulation com-
position (Table 4.3) supports the view that the first stage corresponded primarily to the
hydrolysis of TG and DG, whereas the second stage was attributable to the hydrolysis of
MG. The latter value included MG, those present in the formulation (Imwitor 988) and
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Figure 4.6: TG and DG digestion (white square) and sn-1 MG digestion (white circle)
over time, as calculated based on titrated FA and the stoichiometry of glyceride hydrol-
ysis according to the literature (a). The red lines represent logarithmic functions of the
time fitted to these time courses (M1(t) = 0.57 ln(t)+2.37 andM2(t) = 1.12 ln(t)−0.419,
respectively). (b) Fenofibrate solubility in the lipolysis medium as determined exper-
imentally at different lipolysis times (circles) and as calculated from Eqs. 4.5 and 4.6
(red line).
those generated from the lipolysis of sn-1,3 DG. In contrast, sn-2 MG resulting from the
digestion of TG were assumed not to be further hydrolyzed [159]. With respect to the
different enzyme activities, we expected rapid digestion of DG and TG by the pancreatic
lipase and co-lipase, whereas the activity of the carboxyl ester hydrolase is known to be
comparatively low [157, 158]. This difference in lipolysis rates was in good agreement
with our observations, as DG and TG were digested considerably faster than MG. The
amount of digested TG and DG (M1(t)) and of digested MG (M2(t)) was found to be
well described by a logarithmic function of time (R2 > 0.99), as shown by the fitted
lines in Fig. 4.6a.
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Table 4.3: Estimation of the amount of FA liberated from 2.6 g SMEDDS according to
assumptions inferred from the literature [157–159] and maximal amount of hydrolysable
ester bonds in 2.6 g SMEDDS.
Excipient Composition
in SMEDDS
(% w/w)
Excipient
composition
(% w/w)
Excipient in
2.6 g formu-
lationb
(mmol)
FA liberation
according to
the litera-
turea (mmol)
Max. avail-
able FA
(mmol)
Miglyol 812 40 100 (TG) 2.01 4.03† 6.04
Imwitor 988 20 54.6 (TG) 1.45‡ 1.45 1.45
38.0 (TG) 0.58 0.58† and
0.58‡
1.16
7.1 (TG) 0.077 0.15† 0.23
Cremophor
RH 40
40 100 (TG) 0.39‡ 0.09 1.16
a TG in Miglyol 812 and Imtiwor 988 are digested to sn-2 MG and 2 FA; sn-1,3 DG in Imwitor
988 are digested to sn-1 MG and 1 FA, and then to glycerol and 1 FA; sn-1 MG in Imwitor 988
are digested to glycerol and FA; Cremophor RH 40 was assumed to be hydrolyzed by 7.5% (w/w)
according to Cuine et al. [203]. Digestion of TG to sn-1,2 DG and sn-2 MG and of sn-1,3 DG to
sn-1 MG was assumed to occur rapidly (†, first stage), while the digestion of Cremophor RH 40
and of sn-1 MG to glycerol and FA was supposed to occur slowly (‡, second stage).
b Average molecular weights (g/mol) used for calculation: 516.8 (Miglyol 812), 196.2 (MG in Imwitor
988), 339.4 (DG in Imwitor 988), 482.6 (TG in Imwitor 988), 2699 (Cremophor RH 40 [203]).
These findings of lipolysis kinetics were used to propose a mathematical expression for
solubility as a function of time. It was assumed that two phases contributed to overall
solubility. An oil phase consisted of TG and DG, whereas a colloidal phase consisted
primarily of MG. Both contributions to the total solubility were considered additively.
Therefore, drug solubility in the first and second stages of lipolysis was given by Eqs. 4.5
and 4.6, respectively. Figure 4.6b demonstrates that the curve, which was calculated
(not fitted) using these equations, accurately reflected the experimental solubility values.
The drug solubility at 82.1 s was found by interpolation and corresponded to a value of
0.39 mg/ml. It must be mentioned that no single mathematical expression was able to
describe adequately the change in drug solubility over the entire time course of lipolysis.
Eqs. 4.2 and 4.4 were combined with Eqs. 4.5 and 4.6 to give the system of differen-
tial equations (Eqs. 4.7–4.11), which was fitted to the concentration data obtained by
Raman spectroscopy. The model was found to excellently describe the experimental
concentrations of precipitated drug (R2 > 0.975) at all drug loads (Fig. 4.7). Table 4.4
details the values of A, B, kg, g, tn, and tg that were estimated from this optimization.
The nucleation parameters A and B had comparable values for all studied drug loads,
while the nucleation induction time, tn, increased with decreasing drug load. The growth
parameters exhibited values within a similar range for each drug load. No fitting was
carried out for the smallest drug loads of 20 and 30 mg/g because of the large scatter
in Raman data.
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Figure 4.7: Concentration profile of precipitated fenofibrate as measured with Raman
spectrocopy (circles) and as obtained from mathematical modeling (red lines). Each
plot represents the result of a single drug loading and the circles are mean values of
three experiments.
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Table 4.4: Results of parameter estimation of drug precipitation kinetics.
Cform
(mg/g)
A
(µg·ml/s)
B tn (s) tg (s) kg
(10−3/s)
g R2 RMSE
(mg/ml)
80 2.0 6.1 149.0 291.0 9.0 0.8 0.990 0.052
70 2.9 4.8 210.5 395.2 7.3 0.9 0.987 0.052
60 2.0 6.6 300.2 478.7 9.0 1.4 0.992 0.041
50 2.8 6.3 335.9 671.7 8.4 1.2 0.978 0.051
40 1.6 6.2 362.0 824.8 8.2 1.3 0.976 0.040
4.4 Discussion
4.4.1 Detection of drug precipitation during in vitro lipolysis
The fate of a LBDDS in the gastrointestinal tract is decisive for drug absorption and,
therefore, for the performance of the formulation. Poorly water-soluble drugs often
precipitate from lipid-based systems already upon dispersion in aqueous fluids. Such
potentially inferior systems can be identified early in formulation screening using simple
in vitro dilution and dispersion tests [41]. Other formulations exhibit drug precipitation
in the course of formulation digestion. The analysis of such lipolysis-triggered drug pre-
cipitation was the main focus of the present work.
Traditionally, drug solubilization during in vitro lipolysis is analyzed using methods
that rely on a sampling regime. Accordingly, aliquots of the digest are drawn from
the lipolysis medium at defined time points and the concentration of solubilized and/or
precipitated drug is usually measured following ultracentrifugation. This approach has
so far provided fundamental knowledge on the lipolysis of lipid-based systems as well
as the in vitro fate of poorly water-soluble drugs. However, real-time monitoring seems
to be essential to further analyze the dynamic changes of the formulation and to study
effects of drug supersaturation.
The first aim of this study was to evaluate Raman spectroscopy for real-time moni-
toring of drug precipitation during in vitro lipolysis. A model SMEDDS containing
fenofibrate was digested using a common lipolysis test [146]. The application of Raman
spectroscopy to in vitro lipolysis represented a particularly challenging case for moni-
toring of crystallization. While classical crystallization monitoring in chemical processes
usually involves high drug concentrations and a constant medium, the present applica-
tion of Raman spectroscopy had to cope with low analyte concentrations in a changing
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digestion medium. The hydrolysis products interfered with the drug-related Raman sig-
nal and had to be considered in the interpretation of spectra. Moreover, the two off-line
methods (ultracentrifugation and nanofiltration) revealed some conflicting results, which
led to an even more challenging development of a robust calibration model. Hence, an
accurate selection of instrumental parameters, chemometric procedures, and reference
measurements was required.
The time courses of drug precipitation obtained from the two off-line sample preparation
methods were dissimilar, particularly in the initial stage of precipitation. This difference
was likely due to additional drug precipitation occurring during sample ultracentrifuga-
tion. Even though ultracentrifugation was proven to separate the solid, aqueous, and
oil phases efficiently [26], the influence of sample preparation on drug precipitation can
barely be avoided. First, there was an unavoidable time delay of up to 30 min be-
tween sample removal and ultracentrifugation. Second, we allowed ultracentrifugation
to proceed for 90 min. This step usually takes a shorter time (30 min [26]), but we
deliberately selected an extreme condition (90 min [25]) to simulate a worst-case sample
preparation. These steps introduced time delays during which the drug could further
precipitate. Therefore, the results of the ultracentrifugation method might not provide
the actual kinetic concentration but rather an advanced stage of drug precipitation. This
assumption was supported by the observation that drug concentrations in the aqueous
phase, as measured upon ultracentrifugation, were almost equal to the corresponding
solubilities. In contrast, the nanofiltration method allowed a more rapid separation of
the liquid phase. This method has proven to effectively separate undissolved drug from
colloidal drug solutions in biorelevant release tests [137].
The selection of calibration spectra and reference measurements relied on these previous
findings. According to the nanofiltration results, the concentration of solubilized drug
did not significantly change within the first minute of lipolysis. This observation proved
that fenofibrate did not precipitate instantaneously when lipolysis was started, but only
after an initial lag phase. It was therefore justified to include the earliest spectra and the
corresponding nanofiltration result within the calibration set. Between 25 and 30 min of
digestion, the nanofiltration and ultracentrifugation methods yielded consistent results
and thus the corresponding spectra and reference values were included in the calibration
set. Finally, between 40 s and 25 min there was a lack of reliable reference measure-
ments, hence those spectra were excluded from the set of calibration spectra.
The generation of lipolysis products led to a notable increase in medium turbidity. This
light scattering originated mostly from FA precipitation in the presence of calcium and
from precipitated drug. To reduce particle-size effects, we selected adequate sampling
optics consisting of a large spot-size Raman probe [221]. Furthermore, we evaluated dif-
ferent pre-processing algorithms for the entire set of Raman spectra prior to PLS regres-
sion analysis. This was necessary to correct for light scattering and residual particle-size
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effects [219]. We found that an SG smoothing and differentiation filter (1st derivative)
was best for reducing this systematic variation. Residual sources of non-linearity were
finally corrected by a three-component PLS regression model, while cross-validation
demonstrated good robustness.
After spectra pre-processing and calibration, we applied the resultant quantification
model to the entire data set. The real-time data demonstrated that drug started to pre-
cipitate after a lag phase of three to six min, while this period decreased with increasing
drug load. Interestingly, there was excellent agreement between the course of drug pre-
cipitation obtained from Raman spectroscopy and from the nanofiltration method, even
though only spectra from the initial and final time points were included in the calibra-
tion set.
Raman spectroscopy demonstrated clear advantages compared with the traditional ul-
tracentrifugation method. The main issue in the latter method was the time delay
caused by sample preparation. The application of benchtop centrifugation instead of
ultracentrifugation, as proposed in a recent publication [26], could reduce this time de-
lay. However, temporal resolution is still better using an in situ method such as Raman
spectroscopy.
In contrast to ultracentrifugation, conventional Raman spectroscopy may be barely able
to determine drug solubilization in the aqueous and the oil phases separately. However,
the authors of a recent study suggested that the concentration of solubilized drug in the
entire medium (and not only in the aqueous phase) may be the relevant measure for
predicting intestinal permeation of a drug [120]. In this respect, Raman spectroscopy
can provide the relevant data for estimating the absorbable dose fraction. Even though
Raman spectroscopy was applied to the quantification of crystalline drug in the present
case, the technique would also be able to quantify amorphous drug precipitation. This
is certainly an advantage over, for example, in situ XRPD. However, the combination
of XRPD and Raman spectroscopy is certainly of interest for studying transient poly-
morphic changes [222].
4.4.2 Kinetics of lipolysis-triggered drug precipitation
The second aim of the study was to determine the kinetics of drug precipitation dur-
ing formulation lipolysis. Modeling precipitation kinetics may offer advantages in the
biopharmaceutical characterization of lipid-based systems. Indeed, the amount of drug
available for absorption does not only depend on whether or not the drug precipitates in
the gastrointestinal lumen. Besides improving drug solubility, lipid-based formulations
can increase bioavailability by the temporary stabilization of a drug in the supersatu-
rated state. Although it is in a metastable condition, this induction time is particularly
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relevant for compounds with good permeability. Indeed, supersaturation generates an
increased flux across the intestinal membrane and precipitation in vivo may be reduced
or even be absent. This awareness is crucial for formulation development. Drug su-
persaturation and the solid-state properties of a precipitate are often neglected during
industrial screening tests of lipid-based formulations. Such candidate systems generally
drop out of screening programs and, consequently, there is a risk of excluding candidate
formulations that may still exhibit sufficient oral availability in vivo. Physiologically
based pharmacokinetic (PBPK) models are valuable tools for predicting the formula-
tion behavior in vivo on the basis of characteristics that are measured in vitro [41].
These models consider drug release and absorption as a dynamic interplay to predict
the bioavailability of a drug. However, to obtain a precise estimation, PBPK modeling
requires accurate prediction of supersaturation and potential drug precipitation during
formulation dispersion and/or lipolysis.
4.4.2.1 Nucleation and growth model
We presented a nucleation and growth model that considered the dynamic changes in
drug solubility during formulation digestion. The new model successfully described the
data of lipolysis-triggered fenofibrate precipitation and yielded reasonable parameter
values. The kinetic and thermodynamic pre-factors of the nucleation rate, A and B,
respectively, were consistent for different drug loads and are in good agreement with
the literature [197]. For such comparison, it has to be noted that the pre-factor A is
here expressed as a mass concentration per unit time. The growth constant kg and the
exponent g were also in accordance with previously reported values [63].
When comparing the kinetics of drug precipitation with the kinetics of formulation lipol-
ysis, we observed a non-linear correlation between the two variables (Fig. 4.8). This was
interesting in relation to the findings of Sassene et al., who observed linearity between
precipitated cinnarizine and titrated FA using a self-microemulsifying formulation [33].
In this previous study, continuous calcium addition and the different sample prepara-
tion method (ultracentrifugation) may have influenced the observed kinetics. To clarify
such effects, more studies that compare the different lipolysis tests using the same drug
formulation are certainly needed.
Our study indicates that the nucleation time tn decreased with increasing drug load,
i.e., with higher levels of supersaturation, in good agreement with expectation, as the
degree of supersaturation generally decreases the induction period [63]. This dependence
is highly relevant for selecting the adequate dose strength. Accordingly, the administra-
tion of a single lipid-based capsule with high dose strength might result in a different
pharmacokinetic profile compared with the administration of multiple units at lower
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Figure 4.8: Fenofibrate precipitation as a function of titrated FA. Each color repre-
sents a single drug loading and is the mean value of three experiments.
dose strength. These considerations are in good agreement with a recent attempt to
study the effects of drug loading on the lipolysis of lipid-based formulations [34].
Several studies used the in vitro digestion model to predict formulation performance in
vivo. However, limited correlation between in vitro solubilization and in vivo exposure
was often apparent. For instance, in an attempt to prove supersaturation stabilization
in SEDDS with polymers, Anby et al. showed a clearly beneficial effect of polymer
addition upon in vitro digestion, but no correlation was found with in vivo data [56].
Other studies showed an agreement between in vitro and in vivo data, but primarily as
a rank-order correlation [19–21, 25, 223]. An improved characterization of drug super-
saturation, precipitation, and re-dissolution might be the key to better understand the
pharmacokinetic processes in vivo. To this end, real-time Raman spectroscopy, together
with mathematical modeling of lipolysis-triggered drug precipitation, could play an im-
portant role. These techniques may become part of future drug absorption modeling
and improve the predictivity of in vitro–in vivo correlations.
4.4.2.2 Drug solubility as a function of time
An important part of the presented nucleation and growth model was to consider the
change in drug solubility as a function of time. The proposed heuristic function was in
line with previous studies that proved a direct correlation between drug solubility and
the concentration of formulation components and digestion products [102, 224, 225].
However, some discussion is needed to explain why the present heuristic approach was
proposed. The pancreatin extract consisted of a mixture of digestive enzymes and co-
enzymes, most importantly pancreatic lipase and co-lipase, as well as carboxyl ester
hydrolase [226, 227]. These enzymes exhibit different lipolytic activities and substrate
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specificities, as described previously [143, 157–159]. These properties of lipolytic enzymes
and the composition of the model formulation suggested that lipolysis occurred in two
stages. Pancreatic lipase and co-lipase are known to rapidly hydrolyze TG and DG at
the sn-1,3 position, yielding sn-2 MG and FA as digestion products. It is assumed that
this substrate specificity is due to the high affinity of the pancreatic lipase and co-lipase
to insoluble lipids [157, 158]. In contrast, the second stage was likely characterized by the
digestion of MG, which is catalyzed mostly by carboxyl ester hydrolase. This enzyme has
high affinity to lamellar structures and micelles containing MG and its lipolytic activity is
lower than that of pancreatic lipase [157, 158]. Although the regioselectivity of carboxyl
ester hydrolase is still a debated topic, it is assumed to cleave MG preferentially at
the sn-1 position [143, 228]. Sek et al. quantified the digestion products of medium-
chain and long-chain glycerides upon in vitro digestion, using the same experimental
conditions as in the present study [159]. Interestingly, sn-2 MG were weakly digested
by porcine digestive enzymes, whereas sn-1 MG were hydrolyzed to a large extent. For
this reason, we assumed that primarily sn-1 MG were digested in the second stage of
lipolysis.
The amounts of DG and TG hydrolyzed during the first stage of lipolysis (as obtained
from the titration data) were in good agreement with the nominal amount of lipids that
was present in the formulation. For the second stage of lipolysis, we expected sn-1 MG
and a small fraction of Cremophor RH 40 to be hydrolyzed (Table 4.3, FA liberation
according to the literature). Interestingly, considering these assumptions, the amount of
titrated FA exceeded the expected FA liberation. This observation could originate from
higher Cremophor RH 40 hydrolysis than the reported fraction of 7.5% [203]. This value
was obtained from the in vitro lipolysis of pure excipient and it might not be the same
for Cremophor RH 40 digestion in a lipid mixture. Care is needed when assuming that a
single excipient is digested equally to when it is present in combination with an oil phase
in a formulation. The situation is particularly complex for surfactants, as they are known
to act as substrates and as inhibitors of lipolytic enzymes [203]. A further explanation
for the observed lipolysis degree is that some sn-2 MG were further digested. Mattson
and Volpenhein observed that a small fraction of sn-2 MG exhibited a non-enzymatic
isomerization to sn-1 MG [229]. In line with their observation, it seems possible that a
small amount of sn-2 MG exhibited isomerization and was further digested.
As a result, the proposed equation for fenofibrate solubility as a function of time was
in very good agreement with the experimental solubility values. DG and TG were the
most lipophilic glycerides present in the formulation. Therefore, the removal of these
compounds was correlated with a pronounced decrease in fenofibrate solubilization. In
contrast, we measured a less pronounced decrease during the second stage of lipolysis
because of the smaller contribution of MG to solubilization.
Chapter 4. Kinetics of lipolysis-triggered drug precipitation 76
4.5 Conclusions
Real-time analytics is fundamental to gain an improved understanding of the highly
dynamic processes of formulation digestion. In this study we evaluated the quantitative
application of Raman spectroscopy for real-time monitoring of drug precipitation during
in vitro lipolysis. The method was compared with two off-line procedures, which were
based on a sampling regime. Raman spectroscopy measured fenofibrate precipitation
with a high temporal resolution and minimal experimental bias. In contrast, care is
needed when determining the kinetics of drug precipitation by methods that require
sample preparation. Indeed, the lag time between sample removal and analysis could
lead to further drug precipitation.
The precipitation profiles obtained by Raman spectroscopy were used to model the ki-
netics of lipolysis-triggered drug precipitation. We introduced a mathematical model,
which was based on theoretical equations of nucleation and growth by considering sol-
ubility changes over time. This model provided an excellent prediction of fenofibrate
crystallization during lipolysis. The drug began to precipitate after an initial lag phase
of supersaturation. The temporary supersaturation is not only of theoretical interest.
This metastable state is particularly important for poorly water-soluble compounds with
high permeability, i.e., when the process of drug precipitation occurs in a similar time
span as drug absorption.
The proposed model for lipolysis-triggered drug precipitation may be part of more com-
plex pharmacokinetic models. Physiologically based drug absorption models are par-
ticularly interesting in this aspect. More refined mechanistic modeling of this type will
ultimately help to better predict the fate of a LBDDS in vivo.
Chapter 5
Biopharmaceutical modeling of
drug supersaturation during
lipid-based formulation digestion
considering an absorption sink
Summary
In vitro lipolysis is widely utilized for predicting in vivo performance of oral lipid-based
formulations (LBFs). However, evaluation of LBFs in the absence of an absorption sink
may have limited in vivo relevance. This study aimed at employing biopharmaceutical
modeling to simulate LBF digestion and drug supersaturation in a continuous absorp-
tive environment. Three fenofibrate-loaded LBFs were characterized in vitro (dispersion
and lipolysis) and drug precipitation was monitored using in-line Raman spectroscopy.
In vitro data were combined with pharmacokinetic data derived from an in vivo study
in pigs to simulate intestinal LBF transit. This biopharmaceutical model allowed cal-
culation of lipolysis-triggered drug supersaturation while drug and lipolysis products
are absorbed from the intestine. The biopharmaceutical model predicted that, in a
continuous absorption environment, fenofibrate supersaturation was considerably lower
compared to in vitro lipolysis (non-sink). Hence, the extensive drug precipitation ob-
served in vitro was predicted to be unlikely in vivo. The absorption of lipolysis products
increased drug supersaturation, but drug precipitation was unlikely for highly permeable
Stillhart C. et al. Biopharmaceutical modeling of drug supersaturation during lipid-based formula-
tion digestion considering an absorption sink, Pharmaceutical Research, 2014, in press.
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drugs. Biopharmaceutical modeling is a valuable approach for predicting LBFs perfor-
mance in vivo.
5.1 Introduction
Low aqueous solubility and poor dissolution in the gastrointestinal (GI) fluids are major
reasons for limited oral absorption of poorly water-soluble compounds. Such drug candi-
dates may therefore exhibit low and variable oral bioavailability, which hinders effective
drug development. Lipid-based formulations (LBFs) are gaining increasing interest as
a drug delivery strategy for poorly water-soluble compounds. The improvement in oral
bioavailability is obtained via several mechanisms. The critical dissolution step is cir-
cumvented and the apparent drug solubility in GI fluids is generally increased in presence
of lipidic excipients. Additionally, lipid excipients may increase drug permeability across
the intestinal membrane and promote drug uptake via the intestinal lymphatics [190].
The improvement of oral absorption from LBFs is also significantly influenced by the
fate of the LBF in the GI tract. Digestion of lipidic excipients by endogenous lipases is
particularly critical due to the formation of more polar lipolysis products (i.e., mono-
glycerides (MGs) and fatty acids (FAs)) and the potential of drug precipitation. Such
drug precipitation in vivo is undesirable, as subsequent re-dissolution is likely to delay
and/or reduce the overall extent of drug absorption. The solid-state properties of the
precipitate that forms in vivo therefore become critical. While it has been shown for
some drugs that the formation of an amorphous precipitate may be favorable in terms
of higher apparent solubility and facilitated re-dissolution, this is not the case in all
drug types [33, 34]. There is growing evidence that the kinetics of precipitation is also a
significant determinant of LBF performance in vivo [38, 56]. From a biopharmaceutical
perspective, the initial induction period of drug nucleation is highly relevant, as during
this stage the actual drug concentration exceeds equilibrium solubility, i.e., the drug
is supersaturated. Although being thermodynamically unstable, this supersaturated
state promotes absorptive flux across the intestinal membrane, and hence, the longer
the induction period, the more drug can be absorbed [38]. To maximize the biophar-
maceutical benefit, supersaturation should be high enough to enhance drug uptake, but
without inducing nucleation of drug particles in a physiologically relevant time span.
An in vitro lipolysis assay is commonly employed to study the impact of digestion on the
drug solubilization capacity of LBFs [146, 147]. Formulation digestion is performed using
simulated intestinal medium and pancreatic enzymes, and the digestion is monitored by
direct titration of the liberated FAs. Several reports categorized LBFs in terms of their
propensity for lipolysis-triggered precipitation in vitro, but the in vivo performance was
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successfully predicted only in few studies and mainly rank-order correlations have been
observed [230]. Strategies are therefore necessary to improve accuracy of in vitro–in vivo
correlation (IVIVC) for LBFs. It is hypothesized that a major limitation of the current
in vitro lipolysis test is the absence of an absorptive sink compartment. Given that the
current test is a closed system (i.e., no absorption sink), the drug concentrations may
differ from those observed in vivo, especially for highly permeable compounds, which
are continuously removed via absorption.
In an attempt to improve the relevance to the in vivo situation, Shi et al. developed a
biphasic system, comprising an aqueous buffer and an organic solvent as acceptor phase
[50]. Although a good IVIVC was obtained, this approach was only suitable for simulat-
ing LBF dispersion in the absence of biorelevant media. Alternative approaches using
artificial or biological membranes [51] have also been applied, but in addition to the in-
creased model complexity, critical parameters, such as the appropriate filter membrane
selection (regarding molecular cut-off) as well as the small surface area for absorption
require careful consideration.
Computational methods are a promising alternative for simulating complex biophar-
maceutical processes. Most recently, Fei et al. presented such an in silico approach
for modeling the GI performance of self-emulsifying formulations [37]. Thus, in vitro
dissolution data (without digestive enzymes) were incorporated in a biopharmaceuti-
cal model to simulate simultaneous formulation dispersion and drug absorption. The
resulting in silico model suitably predicted oral bioavailability in humans. The LBFs
comprised mostly surfactants (SFs) with comparatively low amounts of digestible lipids,
and hence, LBF dispersion was considered the most critical step with respect to drug
precipitation. However, in presence of larger amounts of digestible lipids, formulation
digestion may become increasingly critical. For such formulations, the possibility to
model formulation lipolysis and lipolysis-triggered drug precipitation is highly desirable.
Recently we introduced a mathematical nucleation and growth model that described
drug precipitation during formulation lipolysis [31]. This model was based on in vitro
lipolysis data that were acquired under standard conditions, i.e., without an absorption
sink.
The purpose of the present study was to develop a computational approach to predict
the impact of formulation digestion in an absorption environment. To this end, using
both in vitro and in vivo data, we developed an in silico biopharmaceutical model of
LBF digestion and simultaneous drug absorption. Intestinal drug concentration pro-
files were derived from an in vivo study (in pigs) following oral administration of three
fenofibrate-loaded LBFs [29]. A mathematical model simulating the time evolution of
drug solubility in the intestine was developed based on in vitro solubility and in vitro
lipolysis data. The biopharmaceutical model was then used to calculate intralumenal
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drug supersaturation to predict the likelihood of lipolysis-triggered drug precipitation
in vivo.
5.2 Materials and methods
5.2.1 Materials
Fenofibrate (2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropionic acid 1-methylethyl ester,
≥99%), olive oil Ph. Eur., Tween R© 85, Trizma R© maleate, calcium chloride dihydrate
(≥99%), pancreatin (from porcine pancreas, 8xUSP specifications), chloroform, and ace-
tonitrile were obtained from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland), and
sodium chloride (≥99%) from Carl Roth GmbH (Karlsruhe, Germany). Lipoid R© E PC S
(phosphatidylcholine from egg yolk) was supplied by Lipoid GmbH (Ludwigshafen, Ger-
many), sodium taurodeoxycholate by Prodotti Chimici e Alimentari S.p.A. (Basaluzzo,
Italy), sodium hydroxide 1 M by Scharlab S.L. (Sentmenat, Spain), and 4-bromophenyl-
boronic acid (4-BPBA, ≥95.0%) by AK Scientific (Union City, CA, USA). Miglyol R©
812 N was purchased from Ha¨nseler AG (Herisau, Switzerland), and Cremophor R© RH
40 from BASF AG (Ludwigshafen, Germany). Purified water was prepared using an
Arium R© 61215 water-purification system from Sartorius Stedim Biotech GmbH (Go¨ttin-
gen, Germany). We used Anotop R© 25 Plus filters (aluminum oxide, 0.1 µm) purchased
from Whatman GmbH (Dassel, Germany) for nanofiltration.
Miglyol 812 N was a medium-chain triglyceride (TG) consisting of 57.9% w/w caprylic
acid (C8), 41.2% w/w capric acid (C10), 0.5% w/w lauric acid (C12), and 0.1% w/w
caproic acid (C6) with an average molecular weight of 517 g/mol (according to the cer-
tificate of analysis, Ha¨nseler AG, Switzerland). Olive oil Ph. Eur. is a natural TG
principally composed of oleic acid (C18, 80%) and linoleic acid (C18, ∼20%). Tween
85 is a polyoxyethylene sorbitan trioleate surfactant (HLB 11) and Cremophor RH 40
is polyoxyl 40 hydrogenated castor oil (HLB 15).
5.2.2 Preparation of formulations
The compositions of the three LBFs used in this study are summarized in Table 5.1.
The model LBFs comprised two SFs (Cremophor RH 40 and Tween 85) at a fixed ratio
of 1:2 w/w. Formulation IIIB/IV was a surfactant-only system, whereas IIIA LC and
IIIA MC additionally comprised an oil component of 40% w/w olive oil (long-chain TG)
and 40% w/w Miglyol 812 (medium-chain TG), respectively.
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The excipients were weighted and mixed until a clear solution was obtained. Fenofi-
brate was then incorporated into the formulations at 80 mg/g, which corresponded to a
saturation level of 56%, 83%, and 77% in formulation IIIA LC, IIIA MC, and IIIB/IV,
respectively [29]. The blends were stirred at 50◦C for 30 min and stored overnight at
37◦C to ensure complete dissolution of the drug. All formulations were visually assessed
for absence of undissolved drug particles prior to use.
Table 5.1: Composition of the formulations IIIA LC, IIIA MC, and IIIB/IV.
Component IIIA LC IIIA MC IIIB/IV
Olive oil 40 % w/w - -
Miglyol 812 - 40 % w/w -
Cremophor RH 40 20 % w/w 20 % w/w 33 % w/w
Tween 85 40 % w/w 40 % w/w 67 % w/w
Fenofibrate 80 mg/g 80 mg/g 80 mg/g
5.2.3 In vitro lipolysis
The in vitro lipolysis test was performed as described in the literature [146]. Briefly, 108
ml of a micellar solution (50 mM Trizma maleate, 150 mM NaCl, and 5 mM CaCl2·2H2O;
pH 7.5) were heated in a thermostated glass vessel (37.0 ± 0.5◦C) and the formulation
(3 g) was added. The mixture was stirred (450 rpm, 10 min) for complete dispersion,
thermal equilibration, and pH adjustment to 7.5. Digestion was initiated with the
addition of 12 ml pancreatin extract (final nominal lipase activity: 1000 tributyrin units
per ml) obtained from porcine pancreatin powder [146].
The free FAs produced during lipolysis were titrated using 1 M NaOH to maintain pH 7.5
using a pH-stat apparatus (842 Titrando and 800 Dosino, Metrohm AG, Switzerland),
with the Tiamo 1.2 software package (Metrohm AG, Switzerland). Lipolysis was allowed
to proceed for 60 min. To determine the NaOH consumption caused by digestion of the
blank digestion medium, lipolysis experiments were run with pure digestion medium
without formulation. In vitro lipolysis was assayed in triplicate with each formulation.
To determine the total amount of FAs released during formulation digestion a so-called
“back-titration” was conducted as previously described [31]. This was necessary because
some FAs exist in their unionized state, according to the pKa value, leading to an
underestimation of the amount of total FAs liberated.
The extent of formulation digestion was calculated according to:
Extent of digestion =
FAtottitr
Theor. amount of digestible FAs in LBF
(5.1)
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where FAtottitr was the total amount of ionized and unionized FAs liberated by 60 min of
digestion. The theoretical amount of digestible FAs in LBFs was calculated assuming
that each TG and SF molecule liberated two FAs.
5.2.4 Quantification of drug precipitation using Raman spectroscopy
Raman spectroscopy was used to quantify fenofibrate precipitation during in vitro lipol-
ysis as previously described [31]. A multi-fiber Raman PhAT probe and a Raman RXN1
analyzer (Kaiser Optical Systems, Inc., Ann Arbor, MI, USA) equipped with a diode
laser (wavelength of 785 nm, laser power of 400 mW) were used. A single spectrum
was collected every 20 s (acquisition time 18.5 s) with a resolution of 4 cm−1 using the
iC Raman Instrument software (Version 3.0, Mettler-Toledo AutoChem Inc., Columbia,
MD, USA).
To remove sources of non-linearity and spectral information that was uncorrelated with
the concentration of the analyte, the spectra were subjected to the Savitzky–Golay
polynomial derivative filter [31]. The spectral range corresponding to the fingerprint
range of fenofibrate (1000–1800 cm−1) was used for drug quantification. All data were
mean-centered and, finally, a calibration model was built by partial least-squares (PLS)
regression [219]. The optimal number of PLS factors was defined for which the root-
mean-square error of cross-validation reached a minimum (<1% of spectral variation).
Cross-validation was determined with the leave-one-out method; spectral preprocessing
and PLS regression were calculated using Matlab R© (MathWorks, Naticks, MA, USA).
The calibration models were evaluated in terms of the correlation coefficient, R2, the
cross-validation coefficient, Q2, the root-mean-square error of calibration (RMSEC), and
of cross-validation (RMSECV).
The concentration of solubilized drug in the digests was determined using an off-line
method as reference for the calibration of Raman spectra [31]. A 2 ml sample was re-
moved from the lipolysis medium prior to and after 5, 10, 15, 20, 25, 30, 40, 50, 60
min of lipolysis. The samples were directly passed through an Anotop 25 Plus syringe
filter (pore size 0.1 µm, aluminum oxide filter membrane) and the filtrate was imme-
diately diluted in acetonitrile to halt further lipolysis. Control experiments were also
performed that verified that no loss of dissolved drug occurred via potential filter adsorp-
tion. The samples were then centrifuged (16,000xg, 30 min) and analyzed by HPLC [31].
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5.2.5 X-ray powder diffraction
X-ray powder diffraction (XRPD) was used to determine the solid-state properties of
fenofibrate precipitating during in vitro lipolysis. LBFs containing fenofibrate were di-
gested for 60 min and, after enzyme inhibition, an aliquot was ultracentrifuged (80,000xg,
37◦C, 90 min) in a Centrikon T-1180 ultracentrifuge equipped with a TFT-80.4 fixed-
angle rotor (Kontron Instruments, Milan, Italy). The pellet phase was immediately
isolated and an X-ray diffractogram was recorded. The same procedure was followed
with the pellet phase obtained from a 60 min lipolysis experiment with drug-free for-
mulation, which was spiked with an equal amount of pure fenofibrate (as used for LBF
preparation). Moreover, the X-ray diffractogram of crystalline fenofibrate was recorded
as reference. We used a theta-theta X-ray powder diffractometer (R-XRD Phaser D2,
Bruker AXS GmbH, Karlsruhe, Germany) equipped with a Co and Cu KFL tube (30 kV,
10 mA) as radiation source and a Lynxeye R© detector. The samples were scanned in the
angular range of 5◦ (2θ) to 40◦ (2θ) with a step size of 0.1◦ (2θ) and a count time of 5 s
per step.
5.2.6 Measurement of fenofibrate solubility in lipolysis medium at dif-
ferent lipolysis times
The solubility of fenofibrate in lipolysis medium containing LBF was determined at dif-
ferent lipolysis times (C∗m,t). In vitro lipolysis with drug-free formulation was performed
as described and enzyme inhibitor (4-bromophenylboronic acid, 1M in methanol, 9 µl
per ml of digest) was added to the medium at defined time points to stop further di-
gestion. An aliquot was transferred to hermetically sealed glass vials and excess solid
fenofibrate was added. The samples were equilibrated (450 rpm, 37◦C), and an aliquot
was centrifuged after 4 h, 8 h, and 24 h (16,000xg, 37◦C, 30 min). The solubilities were
found to decrease after 24 h of equilibration, which was attributed to kinetic instability
of the colloidal structures in digested medium [27, 31, 56]. The liquid phase was diluted
in acetonitrile, centrifuged (16,000xg, 15 min), and finally analyzed by HPLC. When-
ever a distinct lipid phase was obtained upon centrifugation, the lipid and the aqueous
phase were re-emulsified to measure the overall concentration of solubilized drug. Drug
solubility experiments were carried out in triplicate with each formulation.
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5.2.7 Determination of the in vivo bioavailability of fenofibrate-loaded
LBFs
The pharmacokinetic (PK) profiles of fenofibric acid after peroral (p.o.) administration
of formulation IIIA LC, IIIA MC, and IIIB/IV and after intravenous (i.v.) administra-
tion of a fenofibrate solution were obtained from the literature [29]. Briefly, six male
landrace pigs (15–20 kg, mean 17.5 kg) were fasted for 16 h prior to experiments. On
day 1, an indwelling i.v. catheter was inserted into the jugular vein under general anaes-
thesia. On day 3, following an overnight fast, the oral formulations were administered in
gelatine capsules with the aid of a dosing gun, after which the pigs received ∼50 ml of tap
water via a syringe. The animals had continuous access to water during the study and
were fed 8 h after LBF administration. Blood samples (4 ml) were collected pre-dosing
and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 h post-dosing. The study was conducted as a three
way cross-over, with a 7 day washout period. For the i.v. dosing, a separate group of
four pigs were administered 25 mg fenofibrate dissolved in ethanol-based solution. The
solution was administered by slow infusion (over 2 min) of 3 ml of a solution containing
8.33 mg/ml fenofibrate in 80% w/w ethanol (96% w/v) and 20% saline into an ear vein.
Blood sampling was performed as outlined above, with an additional three blood sam-
ples taken at 0.0833, 0.25, 0.75 h post-dose. The concentration of the active metabolite
fenofibric acid was then determined in blood samples, since fenofibrate is rapidly and
completely transformed to fenofibric acid by tissue and plasma esterases [231].
5.3 Theoretical section
A mathematical model that simulates the time course of drug supersaturation in the
intestine after oral administration of LBFs was developed. This profile was then used to
estimate the likelihood of lipolysis-triggered drug precipitation in an absorption environ-
ment. In order to model intestinal drug supersaturation, the concentration of solubilized
drug and drug solubility in intestinal fluids was required. The intralumenal concentra-
tions of solubilized drug were derived from in vivo plasma concentration versus time
data. The time evolution of drug solubility in the intestinal fluids was calculated by
combining in vitro solubility and lipolysis data with the pharmacokinetic parameters
derived from the in vivo studies.
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5.3.1 Modeling the drug concentration profile in the intestine
To model the profile of solubilized fenofibrate in the intestinal lumen, Cid(t), we fitted
a physiologically based pharmacokinetic model to the in vivo PK data obtained from
pig studies. The plasma profile of fenofibric acid obtained after i.v. administration was
used to estimate the rate constants of drug disposition (kpt, ktp) and elimination (kel),
as well as the volume of distribution in the plasma compartment (Vd) by fitting a two-
compartment model to the experimental data according to the equations:
dDp(t)
dt
= −kel ·Dp(t)− kpt ·Dp(t) + ktp ·Dt(t) (5.2)
dDt(t)
dt
= kpt ·Dp(t)− ktp ·Dt(t) (5.3)
Cp(t) =
Dp(t)
Vd
(5.4)
where Dp and Cp are the drug mass and concentration in the plasma, respectively;
Dt is the drug mass in the peripheral tissue; kpt and ktp are the rate constants for
drug disposition from plasma to peripheral tissue and from peripheral tissue to plasma,
respectively.
The PK profiles obtained after oral administration of LBFs were then described using
Eqs. 5.5–5.11 (Figure 5.1):
dDgu(t)
dt
= −kgd ·Dgu(t)− kge ·Dgu(t) (5.5)
dDgd(t)
dt
= kgd ·Dgu(t)− kge ·Dgd(t) (5.6)
dDiu(t)
dt
= kge ·Dgu(t)− kid ·Diu(t) (5.7)
dDid(t)
dt
= kge ·Dgd(t) + kid ·Diu(t)− Peff,FF · 2
r
· f ·Did(t) · 3600 (5.8)
dDp(t)
dt
= Peff,FF · 2
r
· f ·Did(t) · 3600− kel ·Dp(t)− kpt ·Dp(t) + ktp ·Dt(t) (5.9)
Cp(t) =
Dp(t)
Vd
· Fa (5.10)
Cid(t) =
Did(t)
Vi
(5.11)
Chapter 5. Modeling formulation lipolysis considering an absorption sink 86
Dgu and Dgd are the drug mass in undispersed and dispersed LBF in the stomach, re-
spectively; Diu and Did are the drug mass in undispersed and dispersed LBF in the
intestine, respectively. We assumed an effective permeability coefficient for fenofibrate,
Peff,FF , of 2.66·10−5 cm/s [37], an intestinal radius, r, of 1.5 cm [186], and an effec-
tive surface expansion factor, f, of 30 [232]. A volume of intestinal fluids, Vi, of 50 ml
was assumed, which corresponded to the volume of co-administered water. The gastric
emptying constant, kge, and the fraction absorbed, Fa, were estimated by regressing
Eqs. 5.5–5.11 to the plasma concentration profiles obtained after p.o. administration of
formulations IIIA LC, IIIA MC, and IIIB/IV.
 
Figure 5.1: Scheme of model parameters describing drug transit after oral adminis-
tration of LBFs.
The dispersion rate constants in gastric fluid, kgd, and in intestinal fluid, kid, were ob-
tained from the results of in vitro dissolution/dispersion testing reported by Griffin et
al. [29]. This test was performed using a mini-vessel dissolution apparatus containing
fasted-state simulated gastric fluid (FaSSGF) and fasted-state simulated intestinal fluid
(FaSSIF-v2). The constants kgd and kid were obtained by fitting a first-order kinetic
equation to the dispersion profiles measured in FaSSGF and FaSSIF-v2, respectively
(Table 5.2).
Table 5.2: Dispersion rate constants (value ± 95% CI) in FaSSGF and FaSSIF-v2,
as obtained from the fitting of data described in the literature [29]. The distinction
between dispersed an undispersed formulation was given by the experimental mini-
vessel test. The dispersion rates were described excellently by a first order kinetic
equation (R2 > 0.93).
Formulation kgd (h
−1) kid (h−1)
IIIA LC 10.9 ± 1.3 15.2 ± 1.5
IIIA MC 7.4 ± 3.1 7.2 ± 1.9
IIIB/IV 9.0 ± 1.8 6.4 ± 0.6
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It should be noted that this biopharmaceutical model assumed no drug precipitation in
the GI lumen. Moreover, the model assumptions included that drug absorption occurred
only in the intestine and only from dispersed formulation (i.e., no absorption occurred
in the stomach and from undispersed formulation). Modeling was performed using
Matlab. The differential equations were numerically solved using the ode45 solver, and
optimization procedures were carried out with the fminsearch algorithm.
To evaluate the goodness of fit (modeled versus experimental plasma data), the similarity
factor, f2, was calculated as follows:
f2 = 50 · log
√√√√1 + 1
n
·
n∑
i=1
(Mi − Ti)2 · 100
 (5.12)
where n is the number of sampling time points, Mi is the ratio between the plasma
concentration at time point i and the maximum plasma concentration in the modeled
profile, and Ti is the ratio between the plasma concentration at time point i and the
maximum value in the experimental plasma concentration profile [233].
5.3.2 Modeling the time evolution of drug solubility during LBF di-
gestion
A mathematical approach to model drug solubility during formulation lipolysis in the
intestinal environment was developed. Initially, a general model of drug solubility during
in vitro formulation lipolysis was developed. Subsequently, this model was applied to
simulate drug solubility in the intestinal environment (i.e., under continuous absorptive
conditions). This solubility profile is finally used to calculate the time course of drug
supersaturation and, hence, to estimate the likelihood of precipitation from LBFs under
physiological conditions.
5.3.2.1 Theoretical concept
Previously, we have reported a heuristic approach to model the time evolution of drug
solubility during in vitro lipolysis [31]. This approach assumed that different lipidic
species contributed additively to the overall drug solubility. Therefore, drug solubility
was proportional to the concentration of lipids and of lipolysis products (LPs). A sim-
ilar assumption was applied to the current study to model the time evolution of drug
solubility during LBF digestion. However, the model was intended to simulate drug sol-
ubility not only during in vitro lipolysis (closed system), but also during the intestinal
transit of LBFs (open system). Some adaptations of the previous mathematical model
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were therefore necessary.
The theoretical concept of solubility modeling is represented graphically in Figure 5.2.
The amount of TGs and SFs decreases during formulation digestion. As it can be as-
sumed that there is linearity between the concentration of lipids and drug solubility
[199, 234], the drug solubilization caused by these excipients reduces accordingly (C∗TG,t
and C∗SF,t, respectively). At the same time, the hydrolysis of TGs and SFs liberates LPs,
which can contribute to drug solubilization. This increasing solubility is represented by
C∗LP1,t and C
∗
LP2,t, where LP1 are lipolysis products liberated from TGs and LP2 are
lipolysis products liberated from SFs. Fenofibrate solubility in pure lipolysis medium
(without LBF) was comparatively small and was hence considered negligible for solubil-
ity modeling.
 
LP1 
LP2 
𝐶𝐿𝑃1,𝑡
∗  
𝐶𝐿𝑃2,𝑡
∗  
Figure 5.2: Time evolution of (a) lipidic species and (b) drug solubilities in the
lipolysis medium during LBF digestion (assuming no LPs absorption). Colored lines
represent the amounts and solubility contributions of the single lipidic species and the
black line represents the resulting overall drug solubility.
In summary, the overall drug solubility in the lipolysis medium, C∗m,t, was calculated by
considering the contribution of each lipidic species additively:
C∗m,t = C
∗
TG,t + C
∗
SF,t + C
∗
LP1,t + C
∗
LP2,t (5.13)
To determine these contributions, a relative drug solubility value was introduced, which
was the amount of drug that is solubilized by 1 mmol of excipient per ml of lipolysis
medium at equilibrium (mg·ml−1·mmol−1). Thus, the product of the relative fenofi-
brate solubility and the corresponding amount of excipient as a function of time (mmol)
determined the time course of each partial contribution to drug solubility:
C∗m,t(t) = Cˆ
∗
TG · TG(t) + Cˆ∗SF · SF (t) + Cˆ∗LP1 · LP1(t) + Cˆ∗LP2 · LP2(t) (5.14)
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where Cˆ∗TG, Cˆ
∗
SF , Cˆ
∗
LP1, and Cˆ
∗
LP2 are the relative fenofibrate solubilities in TGs, SFs,
LP1, and LP2, respectively, and TG(t), SF(t), LP1(t), and LP2(t) are the molar amounts
of excipient at time t.
Formulation IIIB/IV contained only SF and, thus, the overall drug solubility was calcu-
lated according to:
C∗m(t) = Cˆ
∗
SF · SF (t) + Cˆ∗LP2 · LP2(t) (5.15)
The values of Cˆ∗TG, Cˆ
∗
SF , Cˆ
∗
LP1, and Cˆ
∗
LP2 were derived from experimental solubility
data as described in the next section. Modeling and simulation of solubility profiles was
performed using Matlab.
5.3.2.2 Calculation of relative drug solubilities
The relative drug solubilities Cˆ∗TG, Cˆ
∗
SF , Cˆ
∗
LP1, and Cˆ
∗
LP2 were obtained from experi-
mental solubility values with undigested (for Cˆ∗TG and Cˆ
∗
SF ) and digested (for Cˆ
∗
LP1 and
Cˆ∗LP2) formulations.
Formulation IIIB/IV was composed of SFs only and, hence, the drug solubilities mea-
sured in undigested and digested formulation IIIB/IV were used to calculate Cˆ∗SF and
Cˆ∗LP2, respectively. Cˆ
∗
SF corresponded to the solubility C
∗
m,0 (i.e., drug solubility in
100% undigested SF) divided by the molar amount of SF in dispersion at t=0, SFtot
(Eq. 5.16). Cˆ∗LP2 was the relative drug solubility in completely digested formulation
IIIB/IV (i.e., only LP2). An experimental value was not available, because formulation
IIIB/IV was only partially digested by 60 min of in vitro lipolysis. However, it is known
from literature that there is a linear relationship between the concentration of a SF and
drug solubility [199]. Thus, we determined Cˆ∗LP2 via linear extrapolation based on the
measured drug solubility C∗m,60 and the extent of digestion by 60 min of lipolysis; the
resulting value was then divided by the molar amount of LP2 at the end of digestion,
LP2tot (Eq. 5.17). It has to be noted that formulation IIIA LC and IIIA MC also con-
tained Cremophor RH 40 and Tween 85 at a ratio of 1:2. Thus, the calculated values of
Cˆ∗SF and Cˆ
∗
LP2 were the same for each formulation.
The relative solubility Cˆ∗TG was calculated for the oil-containing formulations IIIA LC
and IIIA MC only. Prior to lipolysis, fenofibrate was solubilized by undigested SF and
TG. Thus, the contribution of TGs to drug solubility was the difference between the
overall drug solubility, C∗m,0, and the contribution of SFs, C∗SF . C
∗
SF was the product
of the relative solubility Cˆ∗SF and the molar amount of undigested SF prior to lipolysis,
(SF0). This difference was then divided by the molar amount of TGs in dispersion at
t = 0, TGtot (Eq. 5.18).
Finally, Cˆ∗LP1 was obtained by regressing Eq. 5.14 to the experimental solubility values,
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C∗m,t for formulations IIIA LC and IIIA MC.
Cˆ∗SF = C
∗
m,0/SFtot (5.16)
Cˆ∗LP2 =
(
C∗m,0 −
C∗m,0 − C∗m,60
Extent of digestion
)
/LP2tot (5.17)
Cˆ∗TG =
(
C∗m,0 − Cˆ∗SF · SF0
)
/TGtot (5.18)
5.3.2.3 Determination of the kinetics of TG and SF digestion
The kinetics of formulation digestion was determined using in vitro lipolysis data. First,
the course of TG and SF digestion was determined from the FA titration profiles by
considering the stoichiometry of hydrolysis. It was assumed that TGs were digested
rapidly on lipolysis initiation, whereas SFs were digested more slowly in a second stage
of lipolysis. This two-step lipolysis kinetics arises from the different hydrolysis rates
of lipolytic enzymes present in the pancreatic extract. The pancreatic lipase and co-
lipase preferentially bind insoluble lipids and, therefore, they hydrolyze primarily TGs
and DGs. In contrast, the carboxyl ester hydrolase shows higher affinity to lamellar
and micellar structures containing SFs [157, 158]. Moreover, the lipolytic activity of
the pancreatic lipase and co-lipase is higher compared to that of the cholesterol ester
hydrolase [157, 158]. For formulation IIIA LC and IIIA MC, two time profiles were
anticipated: one for the digested TGs (first stage) and one for the digested SFs (second
stage). Instead, only one stage of lipolysis was assumed for the surfactant-only formu-
lation IIIB/IV. Based on the resulting profiles of undigested glycerides (mmol) versus
time, we defined a general power-law describing the digestion rate as a function of the
amount of available substrate:
dTG(t)
dt
= −kdig,TG · (TG)nTG (5.19)
dSF(t)
dt
= −kdig,SF · (SF)nSF (5.20)
where kdig,TG and kdig,SF are the digestion rate constants, and nTG and nSF are the
order of kinetics for TG and SF digestion, respectively. These constants were estimated
by regressing Eqs. 5.19 and 5.20 to the experimental values.
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5.3.2.4 General model of formulation digestion used for solubility modeling
To describe the kinetics of LBF digestion with a time-independent transition from the
first to the second stage of hydrolysis, formulation digestion was modeled using Eqs. 5.21
and 5.22–5.24. According to the two-step kinetics, SFs were expected to be digested after
forming micelles. The kinetics of micelles formation was assumed to correspond to the
kinetics of TG digestion. Hence, Eq. 5.22 and 5.23 describe the time evolution of SFs
in oil droplets and in micelles, respectively. The total amount of undigested SFs, which
is ultimately used for solubility modeling, is described by Eq. 5.24. The generation of
LP1 (Eq. 5.25) and LP2 (Eq. 5.26) corresponded to the kinetics of TG and SF digestion,
respectively, according to the stoichiometry of lipolysis.
dTG(t)
dt
= −kdig,TG · (TG(t))nTG (5.21)
dSFoil(t)
dt
= −kdig,TG · (TG(t))nTG · NSF
NTG
(5.22)
dSFmic(t)
dt
= kdig,TG · (TG(t))nTG · NSF
NTG
− kdig,SF · (SFmic(t))nSF (5.23)
dSF(t)
dt
= −kdig,SF · (SFmic(t))nSF (5.24)
dLP1(t)
dt
= kdig,TG · (TG(t))nTG (5.25)
dLP2(t)
dt
= kdig,SF · (SFmic(t))nSF (5.26)
NSF /NTG is the ratio of molar amounts of SFs and TGs in undigested formulation.
To model the lipolysis-triggered change in drug solubility during in vitro lipolysis (closed
system), we inserted the numerical solutions of Eqs. 5.21, 5.24, 5.25, and 5.26 into
Eqs. 5.14 and 5.15.
5.3.2.5 Modeling intestinal formulation digestion and drug solubility
Intestinal formulation lipolysis and drug solubility were simulated using the general
model of formulation digestion (Eqs. 5.21 and 5.22–5.24) and the physiological param-
eters describing the GI transit of LBFs. As a first approximation, we assumed that (i)
there is no lipolysis in the stomach; (ii) TGs and DGs are not absorbed from the GI
tract; (iii) LPs are absorbed only in the intestine.
The kinetics of undigested lipid-based excipients in the GI tract can be described as
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follows:
dXgu(t)
dt
= −kgd ·Xgu(t)− kge ·Xgu(t) (5.27)
dXgd(t)
dt
= kgd ·Xgu(t)− kge ·Xgd(t) (5.28)
dXiu(t)
dt
= kge ·Xgu(t)− kid ·Xiu(t) (5.29)
where X holds for amount of TGs or SFs; Xgu and Xgd are the amounts of excipient
in the stomach in undispersed and dispersed formulation, respectively, and Xiu is the
amount of undispersed excipients in the intestine. The time evolution of dispersed TGs
and SFs in the intestine depends on the lipolysis rate of the specific glyceride and was
described by the following equations:
dTGid(t)
dt
= kge · TGgd(t) + kid · TGiu(t)− kdig,TG · (TGid(t))nTG (5.30)
dSFid,oil(t)
dt
= kge · SFgd(t) + kid · SFiu(t)− kdig,TG · (TG(t))nTG · NSF
NTG
(5.31)
dSFid,mic(t)
dt
= kdig,TG · (TG(t))nTG · NSF
NTG
− kdig,SF · (SFid,mic(t))nSF (5.32)
dSFid(t)
dt
= kge · SFgd(t) + kid · SFiu(t)− kdig,SF · (SFid,mic(t))nSF (5.33)
dLP1(t)
dt
= kdig,TG · (TGid(t))nTG − Peff,LP · 2
r
· f · LP1(t) · 3600 (5.34)
dLP2(t)
dt
= kdig,SF · (SFid,mic(t))nSF − Peff,LP · 2
r
· f · LP2(t) · 3600 (5.35)
Eq. 5.30 denotes the time course of undigested TGs and Eqs. 5.31 and 5.32 describe
the time evolution of undigested SFs in oil droplets and in micelles, respectively. The
time evolution of LP1 is determined by the lipolysis kinetics of TGs and the absorption
rate of LP (Eq. 5.34), and that of LP2 is given by the lipolysis kinetics of SFs and the
absorption rate of LP (Eq. 5.35). Peff,LP is the effective permeability of LPs and the
same value was assumed for LP1 and LP2.
Drug solubility in the intestine was finally modeled by inserting the numerical solutions
of Eqs. 5.30, 5.33, 5.34, and 5.35 into Eqs. 5.14 and 5.15. We simulated only intestinal
drug solubility, because this compartment is the primary site of formulation lipolysis.
The GI transit of excipients after p.o. administration of the LBFs is visualized in Fig-
ure 5.3.
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Figure 5.3: Scheme of model parameters describing the GI transit of excipients after
oral administration. The distinction between dispersed and undispersed formulation
was given by the experimental mini-vessel test in [29].
5.3.3 Calculation of the saturation ratio during LBF digestion
The drug saturation ratio, SR, during formulation lipolysis was calculated according to:
SR(t) =
Csol(t)
C∗(t)
(5.36)
where Csol(t) is the actual concentration of solubilized drug and C
∗(t) the drug solubility.
SR(t) during in vitro lipolysis was calculated using the Csol(t) obtained from Raman
spectroscopy, whereas SR(t) in the in vivo situation was calculated using the Csol(t)
values obtained from Eq. 5.11.
For in vitro lipolysis, the recently proposed maximum supersaturation ratio, SRM , was
calculated according to [26]:
SRM =
Csol,max
C∗m,60
(5.37)
where Csol,max is the maximum attainable concentration of fenofibrate in solution as-
suming no precipitation and C∗m,60 is the lowest fenofibrate solubility in the lipolysis
medium during digestion (t=60 min).
5.3.4 Parameter sensitivity analysis
The impact of the LP absorption rate on intralumenal drug solubility and supersatu-
ration was studied. Thus, a Peff,LP of 0, 10
−7, 10−5, and 10−3 cm/s was inserted in
Eqs. 5.34 and 5.35 to simulate no absorption as well as slow, moderate, and fast LP
absorption, respectively. The resulting drug solubility and supersaturation profiles were
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analyzed.
Moreover, the intestinal drug supersaturation profiles were simulated for different drug
permeability values, Peff , and lipolysis rates. Peff was varied in the range of 0.1 to 10
times the nominal value of 2.66·10−5 cm/s and the lipolysis rate was varied in the range
of 0.01 to 100 times the lipolysis rates obtained from in vitro experiments. The result
was depicted as a 3D surface plot showing the peak saturation ratio as a function of Peff
and lipolysis rate.
5.4 Results
5.4.1 Rate and extent of LBF digestion
The digestion of three LBFs was studied employing a commonly used in vitro lipolysis
method [31]. The amount of unionized FAs was measured via back-titration and the
resulting correction factors were 1.61, 1.10, and 1.30 for formulation IIIA LC, IIIA MC,
and IIIB/IV, respectively. Hence, the largest fraction of unionized FAs was measured
with long-chain FAs (61% in formulation IIIA LC and 30% in formulation IIIB/IV). This
result was a consequence of the higher pKa of long-chain FAs compared to medium-chain
FAs and was in agreement with previously reported values [26].
Different rates and extents of digestion were observed among the three formulations
(Figure 5.4). A two-stage profile resulted from the digestion of IIIA LC and IIIA MC,
consisting of an initial stage of rapid lipolysis followed by a second stage of slower lipol-
ysis. These two formulations were completely hydrolized within 60 minutes resulting in
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Figure 5.4: Digestion profiles of the three model LBFs containing 80 mg/g fenofibrate
(in vitro lipolysis according to Sek et al. [146]). The NaOH volume obtained from direct
titration was adjusted for the amount of protonated FAs at pH 7.5 (via back-titration)
and the NaOH consumption caused by the digestion phospholipids was subtracted from
the total volume (mean ± 1 SD, n=3).
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an extent of digestion of 109.4 ± 5.9% and 103.3 ± 0.03% (mean ± 1 SD, n=3), respec-
tively. Lipolysis of formulation IIIB/IV was comparatively slow and only 56.0 ± 2.0%
of excipients were digested. The two-stage lipolysis profile of formulations IIIA LC and
IIIA MC agreed with our assumption of fast TG and slow SF digestion. Analogously,
only one stage of lipolysis was observed with formulation IIIB/IV, due to the presence
of only SFs and the absence of an oil phase.
The amount of digested glycerides was calculated based on the titration profiles in Fig-
ure 5.4 and the stoichiometry of lipolysis. The rate of TG and SF lipolysis was then
determined according to Eqs. 5.19 and 5.20, and the resulting kinetic constants kdig,TG,
kdig,SF , nTG, and nSF are detailed in Table 5.3. The power-laws described the profiles
of glyceride digestion accurately, resulting in R2 > 0.92.
Table 5.3: Kinetic constants (value ± 95% CI) for glyceride digestion.
LBF
TG digestion SF digestion
kdig,TG nTG R
2 kdig,SF nSF R
2
IIIA LC 587.7 ± 95.9 1.35 ± 0.18 0.9628 25.93 ± 0.55 2.17 ± 0.04 0.9937
IIIA MC 276.5 ± 13.6 2.30 ± 0.15 0.9768 18.08 ± 0.36 1.29 ± 0.03 0.9851
IIIB/IV n/a n/a n/a 1.18 ± 0.03 5.32 ± 0.06 0.9216
5.4.2 Determination of lipolysis-triggered drug precipitation (in vitro)
The three formulations containing 80 mg/g fenofibrate were digested in vitro and the
course of drug precipitation was monitored using in-line Raman spectroscopy. A specific
calibration model was built for each formulation based on a set of 30 reference spectra
spanning the entire concentration range of precipitated drug. Accurate calibration mod-
els were obtained with R2 values of 0.9862 to 0.9974 and a RMSEC between 0.0124 and
0.0046 mg/ml. The cross-validation procedure yielded Q2 values of 0.9244 to 0.9561 and
RMSECV smaller than 0.16 mg/ml, indicating robust calibrations.
These PLS models were then applied to all Raman spectra of the corresponding LBF to
determine the drug solubilization profiles over the 60 min digestion period. As a result,
each LBF demonstrated extensive drug precipitation as seen in Figure 5.5, showing the
kinetics of solubilized drug. With formulations IIIA LC and IIIB/IV, fenofibrate started
to precipitate after an initial lag phase of 10 to 15 min. In contrast, with formulation
IIIA MC, drug precipitation started rapidly after lipolysis initiation and reached equi-
librium after ∼10 min.
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Figure 5.5: Drug solubilization profiles measured with in-line Raman spectroscopy
during in vitro lipolysis of LBF IIIA LC, IIIA MC, and IIIB/IV. Decreasing concen-
trations of solubilized drug indicated precipitation. The black line represent the con-
centration profiles determined via Raman spectroscopy and green circles are reference
values measured upon nanofiltration (mean ± 1 SD, n=3).
Interestingly, Griffin et al. [29] reported notably different precipitation profiles. Only
formulation IIIB/IV resulted in comparable extent drug precipitation (∼70%), whereas
less than 10% of the drug precipitated with IIIA LC and IIIA MC. These differences in
the extent of precipitation between the two studies were most likely due to the different
drug contents in the lipolysis assay (80 mg versus 240 mg), different amounts of formu-
lation lipid (1 g versus 3 g), and a minor difference in digestion media (i.e., type of bile
salts).
To study the solid-state of precipitated drug, a pellet was isolated after ultracentrifu-
gation at the end of the in vitro lipolysis experiment and then analyzed by XRPD.
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Figure 5.6 depicts the resulting XRPD spectra of the pellet phases obtained by ultra-
centrifugation, of pure crystalline fenofibrate, and of a reference pellet. This reference
was the pellet obtained after lipolysis of drug-free formulation, which was spiked with
crystalline fenofibrate. The angular range of peaks of the pellets containing precipitated
drug corresponded to that of the reference pellet. Therefore, XRD analyses suggested
the precipitation of fenofibrate in a crystalline state during lipolysis with each formu-
lation. This observation was in good agreement with Raman spectroscopy data, which
showed a clear shift of fenofibrate peaks toward the position of crystalline reference ma-
terial.
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Figure 5.6: XRPD pattern of the pellet phase obtained upon lipolysis of LBF IIIA
LC, IIIA MC, and IIIB/IV. The reference was the pellet phase obtained from lipolysis
of drug-free formulation, which was spiked with crystalline fenofibrate. The XRPD
pattern of reference pellets were almost equal for formulation IIIA LC, IIIA MC, and
IIIB/IV, and hence, only the pattern obtained from formulation IIIA MC is depicted.
5.4.3 Drug solubility during in vitro lipolysis
Fenofibrate solubility in lipolysis medium, C∗m,t, was determined at different digestion
times. The highest initial solubility, C∗m,0, was obtained with formulation IIIA MC
(2.19 ± 0.01 mg/ml), followed by IIIA LC (1.41 ± 0.03 mg/ml) and IIIB/IV (0.93 ±
0.01 mg/ml). On lipolysis initiation, the solubilities decreased in each case due to the
generation of comparatively hydrophilic lipolysis products. This decrease in drug solu-
bility was most extensive with IIIA MC, where 80% lower solubility was measured at
5 min of digestion (C∗m,5: 0.44 ± 0.01 mg/ml), and less pronounced with IIIA LC and
IIIB/IV, which resulted in a C∗m,5 of 0.81 ± 0.03 and 0.67 ± 0.07 mg/ml, respectively.
By 60 min of digestion, the total loss of solubilization capacity was 72.3%, 87.6%, and
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50.0% for formulation IIIA LC, IIIA MC, and IIIB/IV, respectively.
The relative fenofibrate solubilities Cˆ∗TG, Cˆ
∗
SF , Cˆ
∗
LP1, and Cˆ
∗
LP2 were calculated based
on measured drug solubility values and the molar amounts of excipients in the LBFs.
As seen in Table 5.4, the relative fenofibrate solubility in long-chain TGs was lower
than in medium-chain TGs (0.631 versus 0.701 mg·ml−1·mmol−1). In contrast, drug
solubility in long-chain LPs was higher than in medium-chain LPs (0.369 versus 0.093
mg·ml−1·mmol−1). To calculate Cˆ∗SF and Cˆ∗LP2 no differentiation was done between
Cremophor RH 40 and Tween 85.
Table 5.4: Relative fenofibrate solubility in dispersed TG, SF, LP1, and LP2
(mg·ml−1·mmol−1). Cˆ∗LP1 was estimated via parameter fitting (value ± 95% CI).
LBF Cˆ∗TG Cˆ
∗
SF Cˆ
∗
LP1 Cˆ
∗
LP2
IIIA LC 0.631 0.640 0.369 ± 0.001 0.069
IIIA MC 0.701 0.640 0.093 ± 0.011 0.069
IIIB/IV n/a 0.640 n/a 0.069
5.4.3.1 Modeling drug solubility and supersaturation during in vitro lipol-
ysis
The drug solubility as a function of time during in vitro lipolysis (without absorption
sink) was modeled initially, given that these experimentally determined solubility values
were available for model validation. Figure 5.7 displays the experimental (circles) and
modeled (continuous lines) drug solubility profiles. There were excellent correlations
between experimental and modeled profiles (R2 >0.89).
The SRs during in vitro lipolysis were calculated according to Eq. 5.36 based on the
concentrations of solubilized drug obtained from Raman spectroscopy and the modeled
drug solubility profiles. Prior to lipolysis, dispersed formulations IIIA LC and IIIB/IV
were slightly supersaturated (SR of 1.36 and 1.94, respectively). In contrast, IIIA MC
was initially below saturation (SR of 0.83) but rapidly became supersaturated on lipoly-
sis initiation. The SRs of all three formulations increased following initiation of lipolysis
reaching a peak SR value of 2.62, 3.34, and 2.31 with formulations IIIA LC, IIIA MC,
and IIIB/IV, respectively.
For comparison, the SRM values were also calculated, which is the ratio of the highest
drug concentration in solution to the lowest drug solubility (i.e., C∗m,60). This theoret-
ical value has been previously defined to indicate the maximum SR obtainable during
in vitro lipolysis [28]. The values were generally higher than the SR and the rank order
was slightly different, i.e., IIIA MC (6.81)>III B (3.70)>IIIA LC (3.17).
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Figure 5.7: Fenofibrate solubility during in vitro lipolysis of formulation IIIA LC, IIIA
MC, and IIIB/IV. There was a very good agreement between experimental solubility
data (circles) and the mathematical model of drug solubility (red lines), resulting in a
R2 of 0.9952, 0.9941, and 0.8930 for IIIA LC, IIIA MC, and IIIB/IV, respectively.
5.4.4 Modeling lipolysis-triggered drug supersaturation in the intesti-
nal lumen
5.4.4.1 In vivo LBF performance and estimation of PK parameters
Griffin et al. [29] previously reported absolute oral bioavailabilities of 65.6%, 70.7%, and
71.7% for formulation IIIA LC, IIIA MC, IIIB/IV, respectively. These relatively high
and similar oral bioavailabilities suggested that intralumenal fenofibrate precipitation
was either absent or only minimal and similar for the three formulations. The in vivo
data were used to estimate the PK parameters as well as the intralumenal drug concen-
tration profiles of fenofibrate.
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The plasma concentrations obtained after i.v. administration of fenofibrate allowed an
estimation of Vd, kel, kpt, and ktp and the resulting parameter values were 6.4 ± 0.2 L,
0.187 ± 0.008 h−1, 0.093 ± 0.046 h−1, and 0.179 ± 0.025 h−1 (estimated value ± 95%
CI), respectively (R2=0.9963, Figure 5.8). The similarity factor f2 of 61.1 indicated that
the difference between modeled and experimental plasma concentration profiles was less
than 10%.
The plasma concentrations obtained after p.o. administration of fenofibrate were then
modeled using Eqs. 5.5–5.11. This model assumed that the entire oral dose was avail-
able for absorption, i.e., that no precipitation occurred in the GI lumen. As seen in
Figure 5.8, the plasma profiles of fenofibric acid were described accurately by the math-
ematical model.
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Figure 5.8: Experimental (circles) and modeled (red lines) plasma concentration
profiles obtained after administration of fenofibrate.
The similarity factor f2 was higher than 36 with each formulation, indicating that the
average difference between experimental and modeled plasma concentration profiles was
less than 20%. The largest deviation was observed at peak plasma concentrations, where
the physiologically-based model slightly underestimated the real plasma concentrations.
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The values of kge and Fa obtained by regressing Eqs. 5.5–5.11 to the plasma concentra-
tion profiles are detailed in Table 5.5.
Table 5.5: Pharmacokinetic parameters (value ± 95% CI) estimated from plasma
data after p.o. administration of the three LBFs (96 mg fenofibrate).
LBF kge (h
−1) Fa (%) f2 R2
IIIA LC 0.555 ± 0.327 68.3 ± 16.7 37.9 0.8777
IIIA MC 0.681 ± 0.347 78.1 ± 15.3 41.8 0.9119
IIIB/IV 0.377 ± 0.178 75.7 ± 17.1 42.9 0.8995
5.4.4.2 Simulating formulation digestion and drug solubility in the intesti-
nal lumen
Using this model, the fenofibrate concentration profile in the intestinal lumen after
p.o. administration of the three formulations. Figure 5.9a shows that maximum drug
concentrations were reached ∼1 h after administration and that the drug was almost
completely absorbed within 6 h. To simulate the amount of excipients in the intestinal
lumen, the PK parameters obtained from in vivo data and the digestion rate of formu-
lation lipids (calculated from in vitro lipolysis experiments) were utilized. The resulting
time evolution of formulation lipids is depicted in Figure 5.9 c–f.
Low amounts of undigested TGs were available in the intestine, indicating that TGs
were rapidly digested (Figure 5.9c). In contrast, the amount of intralumenal SFs was
notably higher, especially with formulation IIIB/IV (Figure 5.9d). Figures 5.9 e and f
show the time course of LP1 and LP2 assuming no LPs absorption (continuous lines)
and rapid LPs absorption (Peff,LP of 10
−4 cm/s, dotted lines). Because LPs absorption
was much faster than formulation digestion, the LPs concentrations in the absorption
environment were very low.
The time evolution of drug solubility in the intestinal lumen was then calculated based
on the profiles of TGs, SFs, LP1, and LP2, and the relative fenofibrate solubilities listed
in Table 5.4. Figure 5.9b shows the solubility profiles of the three LBFs assuming no LPs
absorption (continuous lines) and rapid LPs absorption (dotted lines). During the first
hour of intestinal transit, the drug solubility was similar for the three formulations (as-
suming no LP absorption). At later time points, the solubility with formulation IIIB/IV
was higher, followed by IIIA LC and IIIA MC. The impact of LPs absorption on drug
solubility was particularly pronounced with formulation IIIA LC and IIIA MC, with
substantially lower concentrations in the intestinal lumen under rapid LP absorptive
conditions. In contrast for the Type IIIB/IV formulations the impact of LPs absorption
was negligible.
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Figure 5.9: Time evolution of (a) fenofibrate concentration and (b) fenofibrate sol-
ubility, and of the amounts of (c) TG, (d) SF, (e) LP1, and (f) LP2 in the intestinal
lumen upon p.o. administration of formulation IIIA LC (blue), IIIA MC (green), and
IIIB/IV (red). Simulations were performed assuming no LPs absorption (continuous
lines) and rapid LPs absorption (dotted lines). Only the first 6 h of GI transit are
depicted in the plots, which corresponds to the estimated gastric and small intestinal
emptying time [235, 236].
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5.4.4.3 Drug supersaturation in intestinal fluids
The intralumenal drug concentration and solubility profiles were then used to calculate
the SR in the intestinal fluids according to Eq. 5.36. This SR profiles provided the basis
for evaluating the risk of lipolysis-triggered drug precipitation in an absorptive environ-
ment.
Figure 5.10a shows the profile of drug supersaturation assuming the nominal fenofibrate
permeability (Peff,FF of 2.66·10−5 cm/s) and rapid LPs absorption (Peff,LP of 10−4 cm/s).
We focused on the initial 6 h of intestinal transit as this was the estimated residence
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Figure 5.10: Time evolution of the SR in intestinal fluids assuming (a) sink condi-
tions (Peff,FF 2.66·10−5 cm/s andPeff,LP 10−4 cm/s) and (b) non-sink conditions for
formulation IIIA LC (blue), IIIA MC (green), and IIIB/IV (red). Only the first 6 h
of GI transit are depicted in the plots, which corresponds to the estimated gastric and
small intestinal emptying time in the fasted state [235, 236].
time of drug formulation in the gut [235, 236]. With the Type IIIB/IV and IIIA LC
formulations, the highest SRs reached a value of ∼4, but then rapidly decreased and fell
below saturation after 1.5 and 3 h, respectively. With formulation IIIA MC, the peak
SR value was slightly lower (∼3), but the drug remained supersaturated for the longest
period of time (>4 h).
In vitro lipolysis simulates conditions without an absorptive environment, and for com-
parison, it was interesting to calculate the time evolution of supersaturation in the
intestinal lumen assuming no fenofibrate and LPs absorption. As seen in Figure 5.10b,
each formulation became highly supersaturated. The rank-order of formulations ob-
tained was similar to that observed with the in vitro lipolysis test, with highest SRs for
formulation IIIA MC, followed by IIIA LC, and IIIB/IV. The SRs were particularly high
with formulation IIIA MC where, after 6 h of digestion, values of ∼16 were obtained.
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5.4.4.4 Impact of LPs absorption on drug solubility and supersaturation
In the previous simulation, we assumed rapid LPs absorption to simulate the worst case
in terms of drug solubility. To better understand the influence of LPs absorption, we
examined the intralumenal SR assuming a range of different Peff,LP values. The result of
this simulation is depicted in Figure 5.11 for the absence of LPs absorption (Peff,LP = 0
cm/s), as well as for slow (Peff,LP = 10
−7 cm/s), moderate (Peff,LP = 10−5 cm/s), and
fast (Peff,LP = 10
−3 cm/s) LPs absorption.
With formulations IIIA LC and IIIA MC, the intralumenal drug solubility was sub-
stantially lower when assuming high Peff,LP values (> 10
−5 cm/s). This effect was
particularly pronounced with formulation IIIA LC (Fig. 5.11a), which was not only
extensively digested, but also resulted in LPs with relatively high drug solubilization
(Cˆ∗LP1: 0.369 mg/ml). In contrast, the solubilization capacity of medium-chain LPs was
rather low (Cˆ∗LP1: 0.093 mg/ml) and, thus, the influence of LPs absorption on drug
solubility was less pronounced (Fig. 5.11c). With formulation IIIB/IV, drug absorption
was much faster than formulation digestion and, as a consequence, LPs absorption had
a negligible influence on drug solubility and supersaturation (Fig. 5.11e).
The SR in intestinal lumen as a function of time are shown in Figure 5.11b, d, and
f. A notable increase in SR was observed when Peff,LP exceeded Peff,FF , as seen with
formulation IIIA LC and IIIA MC (red profiles in Fig. 5.11b and d). In contrast, when
drug absorption was much faster than formulation lipolysis and/or LPs absorption, the
SR was minimally affected by LPs absorption (Fig. 5.11f).
5.4.4.5 Impact of drug permeability and lipolysis rate on drug supersatu-
ration
The influence of drug permeability and lipolysis rate on the extent of intralumenal su-
persaturation was subsequently evaluated. The supersaturation profile was determined
assuming drug permeabilities, Peff , in the range of 0.1 to 10 times the nominal value for
fenofibrate (2.66·10−5 cm/s) and assuming digestion rates in the range of 0.01 to 100
times the experimental lipolysis rate. The peak SRs occurring during intestinal transit
were then mapped as a function of Peff and the relative lipolysis rate (Figure 5.12).
The resulting surface plots for the formulations IIIA LC and IIIA MC were significantly
different from that of formulation IIIB/IV. With formulation IIIA LC and IIIA MC, the
peak SRs were highly dependent on the drug absorption and formulation lipolysis rates.
The SRs became critically high (i.e., exceeding a value of ∼3 [6]) under low permeabil-
ity conditions (i.e., Peff < 10
−5 cm/s) and/or for relative lipolysis rates higher than 1.
In contrast, for high permeability and/or slow formulation lipolysis, the intestinal SRs
remained at a constant low level of less than 4. With formulation IIIB/IV, the impact of
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Figure 5.11: Influence of LPs absorption on intralumenal drug solubility (C∗) and SR
for formulations IIIA LC, IIIA MC, and IIIB/IV. Different Peff,LP values were assumed,
which resulted in different LP absorption rates, i.e., 0 (black), 10−7 (green), 10−5
(orange), and 10−3 (red) cm/s. The gray line shows the time evolution of intralumenal
fenofibrate concentration assuming a Peff,FF of 2.66·10−5 cm/s. Only the first 6 h of
GI transit are depicted in the plots and the horizontal dotted lines correspond to a SR
of 1.
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drug absorption and lipolysis rate on the intralumenal SR was negligible and the highest
SR was much less pronounced.
Figure 5.12: 3D surface plot showing the impact of drug permeability and lipolysis
rate on the intralumenal SR for formulation (a) IIIA LC, (b) IIIA MC, and (c) IIIB/IV.
The SR values corresponding to a Peff of 2.66·10−5 cm/s and and to the experimental
lipolysis rate are shown by the black lines. The 3D surface plots were truncated for SR
values higher than 10.
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5.5 Discussion
In the present study, we analyzed three fenofibrate-loaded LBFs that showed a poor cor-
relation between formulation performance in vitro and in vivo. Using in vitro lipolysis
testing without an absorption sink, all formulations resulted in extensive drug precipita-
tion of crystalline material. This result suggested a notable loss in absorbable drug dose
in the intestinal lumen. However, the PK profile obtained after p.o. administration of
the LBFs to pigs showed that ∼70% of the administered drug dose was absorbed and no
substantial difference in oral bioavailability was observed among the three formulations
[29].Thus, it would appear that the extensive precipitation observed in vitro did not
adversely impact drug absorption in vivo. Such poor correlations have been previously
reported [230] and there is a clear need for more predictive in vitro assays for LBFs.
The aim of this study was to examine LBF lipolysis in an absorptive environment by
introducing a predictive biopharmaceutical model of formulation digestion and drug ab-
sorption. This model revealed the drug supersaturation profile in the intestinal lumen,
which provided a basis for estimating the risk of drug precipitation in vivo. It should
be noted that this simulation was based on conservative assumptions, which resulted in
worst-case prediction of in vivo LBF performance.
5.5.1 Biopharmaceutical model of drug supersaturation during LBF
digestion
The novel biopharmaceutical model enabled analysis of drug supersaturation, and hence,
of the risk of drug precipitation in the intestinal environment. A key aspect of supersat-
uration modeling was the simulation of drug solubility during intestinal transit of LBFs.
To this end, we used a mathematical approach that was previously developed for mod-
eling drug solubility in closed systems [31]. However, drug solubilization in the GI tract
is more dynamic and some adaptations were therefore necessary. The basic assumption
was that each lipidic species (i.e., TGs, SFs, and LPs) contributed additively to drug
solubilization at equilibrium and that there was a linear relationship between drug solu-
bility and the concentration of excipients [31, 199, 234]. The resulting solubility model
was validated using experimental data obtained during in vitro lipolysis and resulted in
an excellent correlation.
This strong correlation was a key requirement to simulate, in a second step, the time
evolution of drug supersaturation in vivo. As a first evaluation, we simulated intestinal
lipolysis with simultaneous drug and LPs absorption assuming the nominal fenofibrate
permeability (Peff,FF: 2.66·10−5 cm/s) and rapid LP absorption (Peff,LP: 10−4 cm/s).
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This Peff,LP value was deliberately sselected to simulate worst-case in terms of drug sol-
ubilization capacity in the intestinal lumen. For comparison, we calculated the intralu-
menal supersaturation profile assuming no absorptive environment, which corresponded
with the conditions used during routine in vitro lipolysis.
This comparison showed that the extent of fenofibrate supersaturation was dramatically
lower assuming sink conditions than for non-sink conditions (Figure 5.10a and b). For
example, with formulation IIIA MC the peak SR in a non-sink environment was around
15, which indicated a highly unstable system and a substantial risk of drug precipitation.
In contrast, assuming an absorption sink, the SRs were below 3. Similarly, the other
formulations resulted in peak SRs in the range of 2.5 to 6.
These smaller degrees of supersaturation certainly involved a much reduced risk of drug
precipitation compared to non-sink conditions. However, since the concentration of
solubilized drug still exceeded the saturation level, the drug remained at risk for pre-
cipitation. It is important to consider that the model assumptions were simulating a
worst-case situation. Some physiological parameters were associated with a relatively
high degree of uncertainty and for these parameters conservative assumptions were em-
ployed (e.g., the surface expansion actor, f, and the volume of intestinal fluids, Vi). The
volume of intestinal fluid in which the drug dose was diluted prior to absorption is partic-
ularly relevant in this regard. To our knowledge, no reference volume of intestinal fluids
is available for pigs, and hence, we assumed a volume of 50 ml. This was the amount of
water administered to the animals on formulation dosing and did not include intestinal
secretions and the continuous access to water. A sensitivity analysis is straightforward in
this case and demonstrates that the SR is highly dependent from Vi. If for example the
Vi is doubled (i.e., 100 ml), which may reflect a more physiologically relevant scenario,
the extent of supersaturation is divided in half resulting in SRs in the range of 1.25 to
3. Such values certainly suggest a substantially lower risk of drug precipitation.
A second aspect to consider is the definition of critical supersaturation. From a thermo-
dynamic perspective, any saturation ratio >1 will lead to drug precipitation if sufficient
time is given. The induction period for precipitation can be in the range of months
to years for very low degrees of supersaturation, but becomes very short (seconds to
minutes) when a critical range of supersaturation is exceeded [63]. The critical super-
saturation ratio is therefore very important from a biopharmaceutical perspective.
Williams et al. recently addressed the importance of this parameter for drug precipi-
tation during in vitro lipolysis [28]. They proposed the SRM value as a measure for
evaluating the risk of drug precipitation and found a critical threshold in the range of
2.5 to 3. Accordingly, drug precipitation was very likely to occur if the SRM exceeded
this critical range during LBF lipolysis. Consistent results were found for several drugs
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(danazol, fenofibrate, and tolfenamic acid) and different types of LBFs (LFCS type II–
IV) [28, 56].
Care is certainly needed when applying a critical supersaturation ratio obtained from
in vitro experiments to formulation lipolysis in vivo. The critical supersaturation ratio
is, indeed, not the only determinant for drug precipitation in an absorptive environ-
ment. Important additional factors are the drug absorption rate and the duration of
the induction period prior to precipitation. When the SR exceeds a critical level, drug
precipitation becomes highly probable, but the induction period still provides the op-
portunity for the drug to be absorbed. In case of a long induction period and/or fast
drug absorption, the SR can rapidly fall below the critical value and drug precipitation
may ultimately be prevented. It is therefore likely that the driving force (i.e., the su-
persaturation ratio) must be higher for inducing drug precipitation in vivo than during
in vitro lipolysis.
The biopharmaceutical model assumed that the drug was directly available for intestinal
absorption once the formulation was dispersed. In this regard, we did not differentiate
between drug that was solubilized in oil droplets, mixed micelles, and free drug in the
aqueous bulk. Such a partitioning step is likely to have limited relevance on the overall
drug absorption rate, as was recently suggested by Vertzoni et al. [120]. However, there
were other cases where only the free drug was directly available for absorption [68]. This
influence might be drug and formulation specific, and more studies are required to eluci-
date the mechanism of drug absorption.An additional drug partitioning step is expected
to decelerate drug absorption. Neglecting this drug partitioning would therefore lead
to an overestimation of the absorption rate. Such an overestimation was, however, not
confirmed by the modeled data. On the contrary, the model described in vivo data very
accurately with the exception of maximum plasma concentrations, which were slightly
underestimated. However, due to this uncertainty, we also performed a parameter sen-
sitivity analysis assuming a range of drug permeabilities, as will be discussed later in
this section.
5.5.2 Influence of LPs absorption, drug permeability, and lipolysis rate
on intralumenal drug supersaturation
The biopharmaceutical model of drug supersaturation provided the unique possibility
to estimate the impact of LPs absorption on the solubilization capacity of LBFs during
digestion, and hence, to assess the risk of lipolysis-induced precipitation under continu-
ous absorptive conditions.
We analyzed the impact of LPs absorption as a parameter sensitivity analysis while as-
suming a range of different Peff,LP values. Precise estimates of the effective permeability
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of LPs are difficult to obtain. One major reason is the fact that LPs are converted
back into TGs in the enterocytes. Hence, conventional methods for permeability mea-
surement cannot be applied in this particular case. Moreover, the flux of LPs across
biological membranes might be influenced by the composition of the formulation (e.g.,
via the interaction with membrane transporters or the temporary residence of LPs at
the oil-to-water interface).
We observed that the influence of LPs absorption on fenofibrate solubility varied sub-
stantially among the formulations. The most pronounced decrease in solubility was
observed with formulation IIIA LC and IIIA MC. Formulation IIIA LC was rapidly
digested and the long-chain LPs liberated from olive oil exhibited relatively high solu-
bilization capacity. Hence, the removal of long-chain LPs had a pronounced influence
on intestinal solubility. In contrast, the solubilization capacity of LPs liberated from
Miglyol and from SFs was comparatively low and, although formulation IIIA MC was
rapidly digested, there resulted a moderate influence of LPs removal on the overall drug
solubility. The effect of LPs absorption on the SR was largely determined by the relative
rates of drug and LPs absorption. Indeed, the SR was only affected when the absorption
of LPs was faster than the absorption of fenofibrate. This observation indicated that,
although the impact of LPs on the intestinal SR was minimal for fenofibrate, it might
be critical in case of poorly permeable drug compounds, especially when LPs provide
substantial drug solubilization.
A comparatively different behavior was observed with formulation IIIB/IV. This formu-
lation was digested slowly and the resulting LPs had low drug solubilization capacity.
As a result, LPs absorption had almost no influence on intralumenal supersaturation.
It should also be noted that the relative solubilities Cˆ∗LP1 and Cˆ
∗
LP2 were obtained from
drug solubility studies using digests from in vitro lipolysis. These values theoretically
included the contribution of monoglycerides, monosorbitanesters, and FAs to drug sol-
ubilization. However, in the in vitro lipolysis model, the FAs are largely removed from
solution via precipitation of calcium soaps and micellization with bile salts. The solu-
bilization capacity of these precipitated FAs is expected to be lower than that of the
solubilized products [184]. Hence, these experimental solubilities may slightly underes-
timate the real solubilization capacity of digested formulations in vivo.
Finally, we examined the intralumenal SR for different lipolysis and drug absorption
rates (Figure 5.12). This analysis was motivated by potential differences between the
formulation lipolysis rates in vitro and in vivo. Similarly, the drug absorption rate could
be influenced by the presence of lipid-based colloids, and thus, deviate from the nominal
value of 2.66 · 10−5, as previously discussed. To examine how drug supersaturation is
affected by these parameters, we mapped the peak saturation ratio occurring during
intestinal transit as a function of both lipolysis rate and effective permeability.
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The results were significantly different among the three formulations. With formula-
tion IIIB/IV the peak saturation ratio was not affected by the lipolysis and/or drug
absorption rate (Figure 5.12c). This result was due to the fact that formulation IIIB/IV
became supersaturated upon simple dispersion (peak SR=5.7 assuming a Vi of 50 ml)
and, since formulation lipolysis was always slower than drug absorption, this SR was
never exceeded. Such a behavior might be typical for surfactant-only systems, for which
formulation dispersion is generally more critical than formulation digestion [48].
IIn contrast, with the extensively digested formulations IIIA LC and IIIA MC, the re-
sulting SRs were largely influenced by the rates of lipolysis and drug absorption (Figures
5.12a and 5.12b, respectively). Assuming fast drug absorption (i.e., Peff >10
−5 cm/s),
the peak SRs remained below ∼4 even for very fast digestion rates. In contrast, for
slower absorption rates, the intralumenal supersaturation rapidly increased, particu-
larly for relative lipolysis rates higher than one.
These results suggested that, for highly permeable drugs, intestinal lipolysis is less crit-
ical regarding drug precipitation, even if the formulation is extensively digested. This
situation is clearly different for drugs with low permeability characteristics. These com-
pounds are at higher risk for lipolysis-triggered supersaturation and may result in rele-
vant drug precipitation prior to absorption. With surfactant-only formulations, lipolysis
generally plays a minor role, but drug precipitation can be induced by simple formula-
tion dispersion, especially at higher drug loads. For this type of LBF, the in vitro–in
silico–in vivo approach presented by Fei et al. might be appropriate to simulate formu-
lation behavior in vivo, although it did not include formulation digestion [37].
5.6 Conclusions
This study introduced the first biopharmaceutical model of lipolysis-triggered drug su-
persaturation during intestinal LBF digestion. We analyzed three fenofibrate-loaded
LBFs that resulted in extensive drug precipitation during in vitro lipolysis, but led to
good oral bioavailability in vivo. The biopharmaceutical model showed that, for these
formulations, the extent of supersaturation was considerably lower when lipolysis oc-
curred in a continuous absorptive environment. This novel approach provided strong
evidence of the importance of an absorption sink to estimate drug supersaturation, and
hence, the risk of precipitation. Current in vitro assays simulate the worst-case with
respect to drug precipitation, due to the absence of an absorption sink. Drug supersat-
uration is considerably higher than in the intestinal lumen and, as a consequence, drug
precipitation is more likely to be observed in vitro.
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Biopharmaceutical modeling was useful for gaining a deeper understanding of LBF per-
formance in the GI tract. For highly permeable compounds, drug absorption is rather
fast compared to formulation digestion and critical degrees of supersaturation may there-
fore be avoided. Thus, the digestion of LBFs containing highly permeable drug com-
pounds is less critical than previously assumed. This realization is highly encouraging
with respect to the use of LBFs for oral administration of poorly water-soluble, but
highly permeable drugs.
In the absence of in vitro tools simulating an absorption sink, such biopharmaceutical
modeling should be further considered in LBF research and development. This strategy
offers several opportunities for improving the prediction of LBF performance in vivo. A
drug precipitation step could be included in the simulation and, to this end, the complex
interplay between formulation digestion, drug supersaturation, and precipitation must
be further investigated. Future biopharmaceutical modeling may also include biolog-
ical effects of drug and excipients on oral absorption, such as the influence on efflux
transporters or on the lymphatic drug transport.
Chapter 6
Toward an improved
understanding of the precipitation
behavior of weakly basic drugs
from oral lipid-based formulations
Summary
The aim of this study was to analyze the impact of lipid-based formulation (LBF) dis-
persion and digestion on the precipitation behavior of weakly basic drugs. Loratadine
and carvedilol were formulated in a range of LBFs and drug solubilization was analyzed
under simulated dispersive and digestive conditions (fasted state). The extent of super-
saturation and drug precipitation as well as the solid-state properties and re-dissolution
behavior of precipitated drugs were assessed.
Carvedilol precipitated in a crystalline form upon dispersion, but interestingly, this drug
gave an amorphous precipitate during lipolysis. In contrast, loratadine precipitated as
crystalline material during both formulation dispersion and digestion. No influence of
the formulation composition on the type of precipitation was observed. These results
suggested that in vitro conditions (dispersive vs. digestive) largely determined the solid-
state properties of precipitating weak bases. Solid-state characterization of precipitated
drugs under different experimental conditions should be routinely performed in formu-
lation screening to better understand the biopharmaceutical behavior of LBFs. Hence,
these findings are of high practical importance for the pharmaceutical development and
in vitro assessment of LBFs using weakly basic drugs.
Stillhart C. et al. Toward an improved understanding of the precipitation behavior of weakly basic
drugs from oral lipid-based formulations Journal of Pharmaceutical Sciences, 2014, 103(4):1194-203.
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6.1 Introduction
Poorly water-soluble drug candidates often show reduced and variable systemic bioavail-
ability upon oral administration. The solubility issue is particularly complex in the case
of ionizable drugs such as poorly water-soluble weak bases. These compounds are influ-
enced by the pH gradient experienced during transition from the gastric in the intestinal
environment. The gastric pH favors ionization of a basic drug, depending on pKa, which
generally results in adequate solubilization in the stomach. However, following transfer
into the intestinal fluid, deprotonation to the free base can occur, leading to compar-
atively lower aqueous solubility. Depending on the administered dose, this decrease in
drug solubility may cause drug supersaturation, with a risk of precipitation.
Drug precipitation is generally undesirable, because re-dissolution is typically incom-
plete for poorly soluble compounds within the time span of intestinal transit. For this
reason, the fraction of precipitated drug is frequently assumed not to be available for
absorption. However, there is increasing evidence that the impact of drug precipitation
on oral bioavailability does not only depend on the extent of precipitation. A significant
determinant is the physical state of precipitated drug. Indeed, high-energy solids such
as amorphous materials have higher apparent solubilities and might therefore re-dissolve
faster compared with their crystalline counterparts [60, 79]. The drug may have suffi-
cient time to re-dissolve during intestinal transit and to become available for absorption.
It is also important to consider the stability and extent of drug supersaturation, which
is the driving force for drug precipitation. Although it is a metastable state, drug su-
persaturation defines the time span during which the drug is solubilized and becomes
available for absorption [38, 56].
It has recently been shown that the stability toward intestinal precipitation of a weakly
basic drug can be increased by a LBF [237]. This is, however, only one mechanism by
which LBFs possibly enhance oral drug bioavailability. The drug is already in a dissolved
state when it is administered and thus the critical dissolution step is circumvented. Li-
pidic excipients also often increase the apparent solubility of the drug in intestinal fluids,
may reduce pre-systemic clearance, and can enhance drug permeation across the intesti-
nal membrane [6, 14]. Although LBFs offer a great potential for the oral administration
of poorly water-soluble compounds, the improvement in oral bioavailability is ultimately
governed by the fate of the formulation in the gut. Formulation dispersion and excipient
digestion represent particularly critical steps because they change the micro-environment
of a drug. Therefore, the capacity of a formulation to keep the drug in solution may be
progressively reduced, developing an increased risk of drug precipitation.
There is considerable research interest in the factors that determine the precipitation
of weakly basic compounds upon oral administration. Few studies have analyzed the
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features of intestinal drug precipitation in vivo by aspirating intestinal content [61, 238].
However, as the in vivo evaluation of intraluminal content is inherently difficult, drug
precipitation has generally been studied using in vitro assays. One- or two-compartment
experimental setups were developed and simulated gastrointestinal media were usually
employed to simulate the transfer from the stomach into the small intestine [213, 239–
242]. These assays simulate dispersive conditions without digestive enzymes and can
provide valuable information about the intrinsic pH-induced precipitation behavior of
weakly basic compounds (in the presence of bile salts and phospholipids).
Other studies used digestive conditions to analyze the precipitation behavior of lipophilic
weak bases in LBFs [23, 33, 34] and particular attention has been paid to the solid-state
of precipitated drugs. The results of Sassene et al. [33], reporting the formation of an
amorphous precipitate in the course of formulation digestion of the drug cinnarizine,
are particularly interesting. Also important were the findings of the Lipid Formulation
Classification System (LFCS) consortium, which studied fenofibrate and tolfenamic acid
in different LBFs [28]. While the precipitates of fenofibrate appeared to be of the same
crystalline form as the reference drug, tolfenamic acid crystallized, at least partially, in
a different polymorphic form. The latter work underlined the necessity to study the
formulation behavior upon lipolysis, with a special emphasis on the solid-state charac-
terization of potential precipitate.
Despite the importance of this research field, little information is currently available
regarding the impact of specific formulation processing, i.e., dispersion versus digestion,
on the precipitation behavior of weak bases. Moreover, there is a lack of understand-
ing about the influence of formulation composition on the solid-state properties of a
precipitate. Such understanding is fundamental for more rational development of phar-
maceutical LBFs and for selecting appropriate in vitro assays for formulation screening.
The present study focused on the precipitation behavior of lipophilic, weakly basic drugs
from LBFs. A major aim was to investigate the influence of dispersion and digestion on
the precipitation behavior of model bases. Therefore, the effect of pure dispersion was
analyzed separately from the dispersion in a digestive environment. Particular atten-
tion was directed to the extent of drug supersaturation and precipitation, as well as to
the solid-state properties and re-dissolution behavior of evolving precipitates. A further
aim was to evaluate the influence of the LBF composition on dispersion- and lipolysis-
triggered drug precipitation. The present study offers an improved understanding of the
fate of LBFs with poorly soluble weak bases in the intestinal lumen.
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6.2 Methods
6.2.1 Materials
We obtained loratadine, carvedilol, and 4-bromophenylboronic acid (4-BPBA, ≥95.0%)
from AK Scientific (Union City, CA, USA). Trizma R© maleate, calcium chloride dihy-
drate (≥99%), pancreatin (from porcine pancreas, 8xUSP specifications), sodium chlo-
ride (≥99%), ammonium acetate (≥99%), chloroform, and acetonitrile were from Sigma-
Aldrich Chemie GmbH (Buchs, Switzerland). Lipoid E PC S (phosphatidylcholine from
egg yolk) was supplied by Lipoid GmbH (Ludwigshafen, Germany), sodium taurodeoxy-
cholate by Prodotti Chimici e Alimentari S.p.A. (Basaluzzo, Italy), and sodium hy-
droxide 1 M by Scharlab S.L. (Sentmenat, Spain). Imwitor R© 988 was purchased from
Sasol Germany GmbH (Witten, Germany), Miglyol R© 812 N from Ha¨nseler AG (Herisau,
Switzerland), and Cremophor R© EL from BASF AG (Ludwigshafen, Germany). Ethanol
was obtained from Baker (Deventer, Netherlands). Transcutol R© HP and Capryol R© 90
were kindly donated by Gattefosse (Saint-Priest, France). Purified water was prepared
with an Arium R© 61215 water-purification system from Sartorius Stedim Biotech GmbH
(Go¨ttingen, Germany).
Imwitor 988 was a blend of medium-chain glycerides (54.6% monoglycerides, 38.0%
diglycerides, and 7.1% triglycerides) with average molecular weights of 197, 340, and
483 g/mol, respectively (according to the certificate of analysis, Cremer Oleo GmbH).
Miglyol 812 N was a medium-chain triglyceride consisting of 57.9% w/w caprylic acid
(C8), 41.2% w/w capric acid (C10), 0.5% w/w lauric acid (C12), and 0.1% w/w caproic
acid (C6) with an average molecular weight of 517 g/mol (according to the certificate of
analysis, Ha¨nseler AG). Capryol 90 was composed from propylene glycol monocaprylate
(99.9% caprylic acid (C8), certificate of analysis, Gattefosse AG) and the surfactant
Cremophor EL consisted of polyoxyl 35 castor oil.
Figure 6.1: Chemical structures of the model drugs (a) loratadine (pKa 5.3 [243],
logP 3.9) and (b) carvedilol (pKa 7.8 [243], logP 4.1).
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6.2.2 Preparation of formulations
Three LBF were selected as model formulations and the compositions are detailed in
Table 6.1. The lipidic components were mixed on a magnetic stirrer at 40◦C until a
clear solution was obtained. The mixtures were then slowly cooled to room temperature
and finally the co-solvent (ethanol or Transcutol HP) was added.
We selected loratadine and carvedilol as lipophilic, weakly basic model compounds
(Fig. 6.1). The formulations were loaded with the free bases at 80% of their satura-
tion solubility in the corresponding formulation. All formulations were visually assessed
for absence of undissolved drug particles prior to use.
Table 6.1: Composition of drug-free lipid-based formulations.
Excipient Formulation F1
(% w/w)
Formulation F2
(% w/w)
Formulation F3
(% w/w)
Migliol 812 30.0 12.5 -
Imwitor 988 30.0 12.5 -
Cremophor EL 30.0 65.0 44.6
Ethanol 10.0 10.0 -
Capryol 90 - - 33.0
Transcutol HP - - 22.4
6.2.3 Preparation of simulated intestinal medium and pancreatic ex-
tract
The simulated intestinal medium was composed of an aqueous buffer, 1.25 mM phos-
phatidylcholine (PC), and 5 mM sodium taurodeoxycholate (NaTDC) at concentrations
simulating fasted state intestinal conditions. PC was dissolved in chloroform, and the
solvent was evaporated under vacuum (Rotavapor RE 120, Bu¨chi, Switzerland). NaTDC
and digestion buffer (50 mM Trizma maleate, 150 mM NaCl, and 5 mM CaCl2·2H2O;
pH 7.5) were then added and the mixture was stirred for 12 h (450 rpm, 5◦C).
To prepare the pancreatin extract, we mixed 1 g of porcine pancreatin powder per 5
ml of digestion buffer (5◦C), stirred for 15 min, and then centrifuged the suspension
(15 min, 1600xg, 5◦C). Finally, the supernatant was collected and the pH adjusted to
7.5, which corresponded to the pH of the lipolysis medium. The pancreatin extract was
freshly prepared each day and stored on ice until use.
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6.2.4 Drug solubilization upon dispersion without lipolysis
We assessed the amount of precipitated loratadine and carvedilol during simple disper-
sion in the simulated intestinal medium (without digestive enzymes). Drug-containing
formulation (3.0 g) was dispersed in 108 ml of digestion buffer (containing NaTDC and
PC) in a glass vessel at 37◦C and stirred at 450 rpm. After equilibrating the system for
10 min, 12 ml of pure digestion buffer (without pancreatic extract) were added and the
medium was stirred for 1 h. A 2 ml aliquot was removed prior to and after 10, 30, and
60 min of dispersion. The samples were immediately filtered through a 0.1 µm poly-
tetrafluoroethylene (PTFE) syringe filter [31] and diluted with acetonitrile (loratadine)
and methanol (carvedilol). After centrifugation (16,000xg, 25◦C, 30 min), the concen-
tration of solubilized drug was measured by HPLC. The experiments were carried out
in triplicate. We verified experimentally that no loss of dissolved substance occurred
through adsorption onto the filter material.
6.2.5 In vitro lipolysis test
The in vitro lipolysis test was performed as described in the literature [146]. Simulated
intestinal medium (108 ml) was transferred to a thermostated glass vessel (37.0 ± 0.5◦C),
and the formulation (3.0 g) was added. The mixture was stirred during 10 min for
complete dispersion, thermal equilibration, and pH adjustment to 7.500 ± 0.001. For
mixing, we used a magnetic stirrer (3 cm in diameter) at a speed of 450 rpm. Digestion
was initiated by the addition of 12 ml pancreatin extract (final nominal lipase activity:
1000 tributyrin units per ml). The free fatty acids (FA) produced during lipolysis were
titrated using 1 M NaOH to maintain pH 7.500 using a pH-stat apparatus (842 Titrando
and 800 Dosino, Metrohm AG, Switzerland), which was operated using the Tiamo R© 1.2
software package (Metrohm AG). Lipolysis was allowed to proceed for 30 min, and each
experiment was carried out in triplicate.
6.2.5.1 “Back-titration” and determination of the extent of formulation di-
gestion
It was previously shown that the titrated NaOH volume represents only an approxima-
tion of the free FA liberated during lipolysis. Some FA persist in the unionized state,
according to the pKa value, leading to an underestimation of the total FA liberation.
To account for these unionized molecules, the so-called back-titration procedure was ap-
plied according to a previously described method [31]. Briefly, at the end of the 30 min
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digestion period, the pH was rapidly increased to 9 by addition of 1 M NaOH for com-
plete deprotonation. The pH increase was also performed with blank digestion buffer
including pancreatic extract (without formulation, PC, and NaTDC) to determine the
back-titration volume in the absence of lipolysis products. The latter volume was sub-
tracted from the total back-titration volume to obtain the value of FAtitr(back-titration).
The correction factor was calculated according to the formula:
Correction factor =
FAtitr(direct titration) + FAtitr(back-titration)
FAtitr(direct titration)
(6.1)
where FAtitr(direct titration) is the cumulative amount of FA titrated by 30 min of
digestion. The NaOH consumption caused by digestion of formulation lipids was finally
obtained by subtracting the consumption due to lipolysis of the blank digestion medium
(n=3). The extent of formulation digestion was calculated according to:
Extent of digestion =
FAtottitr
Theor. max. amount of FA in LBF
(6.2)
where FAtottitr is the cumulative amount of ionized and unionized FA liberated by 30
min of digestion. The theoretical maximal amount of FA in the LBF was calculated
assuming that each triglyceride molecule would liberate two FA and that diglyceride and
monoglyceride molecules initially present in the formulation liberate one FA. Cremophor
EL was assumed to be digested to an extent of 30% [203].
6.2.5.2 Quantification of lipolysis-triggered drug precipitation
The three formulations containing loratadine and carvedilol, respectively, were digested
and the amount of precipitated and solubilized drug was assayed in the digests. Thus,
after the 30 min digestion period, we immediately added a 4-BPBA solution (1 M in
methanol, 9 µL per ml of digest) to inhibit further lipolysis [215], re-adjusted the pH,
and ultracentrifuged the samples (80,000xg, 37◦C, 90 min) in a Centrikon T-1180 ul-
tracentrifuge equipped with a TFT-80.4 fixed-angle rotor (Kontron Instruments, Milan,
Italy). The aqueous phase was then diluted with acetonitrile and centrifuged (16,000xg,
15 min). The pellet was suspended in purified water, diluted in acetonitrile, and cen-
trifuged (16,000xg, 15 min). Finally, all samples were analyzed using high-performance
liquid chromatography (HPLC).
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6.2.6 Determination of drug solubility in the formulations and in di-
gestive media
Drug solubility was determined in the undiluted formulation at 37◦C. Excess solid drug
was added to a 2 ml aliquot of blank formulation and stored in hermetically sealed glass
vials during equilibration (37◦C, 450 rpm). After 24, 48, and 72 h the samples were
centrifuged (37◦C, 16,000xg, 30 min) and, after dilution in solvent, the supernatant was
analyzed by HPLC. Equilibrium was assumed when two consecutive solubility samples
varied by ≤5% w/w.
Furthermore, we determined drug solubility in the lipolysis medium containing drug-free
formulations prior to and after a 30 min digestion period. For the latter measurement,
enzyme inhibitor (4-BPBA, 1M in methanol, 9 µl per ml of digest) was added to the
medium after 30 min digestion and the pH was re-adjusted. Excess solid drug was
transferred to an aliquot of the lipolysis medium and was hermetically sealed in glass
vials. After an equilibration period of 4, 8, and 24 h (450 rpm, 37◦C), the samples were
centrifuged (16,000xg, 37◦C, 15 min). The supernatant was then diluted in solvent,
centrifuged (16,000xg, 15 min), and finally analyzed by HPLC. Whenever a lipid phase
was obtained upon centrifugation, the lipid and the aqueous phase were re-emulsified,
to measure the overall concentration of solubilized drug. Drug solubility experiments
were carried out in triplicate. Equilibrium was assumed when two consecutive solubility
samples varied by ≤5% w/w.
The maximal supersaturation ratios, SRM , of the drug-containing formulations in the
simulated intestinal media prior to and after digestion were calculated according to the
equation SRM = C/C∗, where C is the maximum concentration of solubilized drug and
C∗ was the solubility prior to and after 30 min lipolysis, respectively [26].
6.2.7 Physical characterization of precipitated drug
The precipitated drug following dispersion and the pellet phase that was obtained upon
digestion and ultracentrifugation of the drug-containing formulation, were analyzed by
X-ray powder diffraction (XRPD). The precipitate obtained after 1 h of dispersion was
collected by filtration using a 0.1 µm polycarbonate filter membrane and immediately an-
alyzed. To analyze the precipitate evolving during formulation lipolysis, the formulations
were digested in vitro for 30 min, and after enzyme inhibition and pH re-adjustment,
an aliquot was ultracentrifuged (80,000xg, 37◦C, 90 min). The pellet phase was im-
mediately isolated and an X-ray diffractogram was recorded. The same procedure was
followed with the pellet phase obtained from a 30 min lipolysis experiment with drug-
free formulation, which was spiked with an equal amount of pure drug (as used for the
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formulation preparation). Moreover, we recorded the X-ray diffractograms of crystalline
loratadine and carvedilol as a reference.
For X-ray analysis, we used a theta-theta X-ray powder diffractometer (R-XRD Phaser
D2, Bruker AXS GmbH, Karlsruhe, Germany) equipped with a Co and Cu KFL tube
(30 kV, 10 mA) as radiation source and a Lynxeye R© detector. The samples were scanned
in the angular range of 5◦ (2θ) to 40◦ (2θ) with a step size of 0.1◦ (2θ) and a count time
of 5 s per step.
6.2.8 Re-dissolution of precipitated drug
Re-dissolution of loratadine and carvedilol that precipitated during formulation lipolysis
was analyzed in an Erweka DT600 USP 2 paddle dissolution apparatus. Drug-free di-
gestion buffer (containing NaTDC and PC) was preheated in dissolution vessels (37◦C,
75 rpm) and the pH was adjusted to 7.5. The volume of the dissolution medium was
large enough to ensure sink conditions. After formulation lipolysis (30 min) and enzyme
inhibition, the digest was ultracentrifuged (80,000xg, 37◦C, 90 min) and the resulting
pellet phase was collected. The pellet was re-suspended in 5 ml digestion buffer and
added to the re-dissolution medium. Samples (2 ml) were removed after 1, 2, 5, 10, 20,
30, 40, 60, 120, and 180 min of re-dissolution, filtered through a polyvinyl difluoride
(PVDF) syringe filter (0.45 µm) and subsequently analyzed by HPLC.
Re-dissolution was studied with pellets obtained after lipolysis of the formulations con-
taining loratadine and carvedilol as well as with a reference pellet. This reference was
a pellet obtained from 30 min lipolysis of drug-free formulation, which was spiked with
an equal amount of pure crystalline drug. All experiments were conducted in triplicate.
6.2.9 Dynamic light scattering
We measured the particle size of the dispersed formulations before lipolysis initiation by
dynamic light scattering using a Zeta Sizer Nano ZS (Malvern Instruments, Malvern,
UK), equipped with a 4 mW He-Ne laser operating at a wavelength of 633 nm. Since
the formulations were highly diluted in an aqueous medium, the viscosity of water was
assumed. The scattering signal was detected at an angle of 173◦ and measurements were
performed at 37◦C. Each sample was measured in triplicate and the result was expressed
as intensity averaged particle diameter (nm).
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6.2.10 High-performance liquid chromatography (HPLC)
For HPLC analysis (Agilent Technologies 1200 Series) we used an autosampler (G1329A),
an isocratic pump (G1310A), and a variable wavelength detector (G1310A). A Zorbax R©
Eclipse Plus C18 (5 µm) column (Agilent Technologies, Santa Clara, CA, USA) was used
for all experiments. Loratadine and carvedilol were detected at wavelengths of 248 and
254 nm, respectively. Loratadine was eluted with 40% acetonitrile and 60% phosphate
buffer (20 mM, pH 2.5) and carvedilol with 35% acetonitrile and 65% acetate buffer
(20 mM, pH 2.5). All sample measurements were within the linear range of calibration.
6.3 Results
6.3.1 Characterization of the LBFs
Three different LBFs (F1, F2, and F3, see Table 6.1) in combination with two lipophilic,
weakly basic compounds (loratadine and carvedilol) were selected as model systems. All
formulations were self-emulsifying and dispersed rapidly in simulated intestinal medium.
The evolving systems ranged from a sub-micron emulsion to colloidal dispersions ex-
hibiting mean droplet diameters of 171.6 ± 11.5, 26.74 ± 0.04, and 34.34 ± 0.13 nm,
for formulations F1, F2, and F3, respectively (n=3).
The digestion profiles of the three model formulations are depicted in Figure 6.2. All
formulations were hydrolyzed in the presence of digestive enzymes. After 30 min of
digestion, formulations F1 and F2 were almost completely digested and formulation F3
was digested to the extent of ∼85.7%. Thus, all dispersions changed substantially over
the course of formulation digestion.
6.3.2 Determination of drug solubility and supersaturation ratio
The solubilities of loratadine and carvedilol were determined in the three undiluted for-
mulations, in pure lipolysis medium (without LBF and lipolytic enzymes), as well as
in the dispersed systems prior to and after lipolysis. The solubilities of loratadine and
carvedilol in pure lipolysis medium were 0.039 ± 0.001 and 0.049 ± 0.007 mg/ml, respec-
tively. The undiluted formulations demonstrated high solubilization capacities with drug
solubilities of 130.5 to 165.2 mg/g for loratadine and 78.4 to 145.4 mg/g for carvedilol
6.2. Comparatively lower drug solubilities were found with the dispersed formulations,
as expected. In dispersed, undigested formulations, loratadine solubilities were in the
range of 1.23 to 2.59 mg/ml, while carvedilol solubilities were between 0.602 and 1.506
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Figure 6.2: Titration profile of FA obtained during the 30 min lipolysis of formulations
F1, F2, and F3 (mean ± SD, n=3). The titration profiles were corrected with the
back-titration factor, and the NaOH consumption caused by the digestion of blank
digestion medium was subtracted. The extent of formulation digestion was ∼100% for
formulations F1 and F2, and ∼85.7% for formulation F3.
mg/ml. In digested formulations, loratadine solubilities were in the range of 0.63 to 0.79
mg/ml, while carvedilol solubilities were between 0.49 and 1.02 mg/ml.
While all pre-concentrates were below saturation (saturation ratio of 0.8), the dispersed
and digested formulations became supersaturated. We calculated the supersaturation
ratio SRM for each dispersed formulation, prior to and after 30 min lipolysis. SRM
is the ratio of the maximum drug concentration (that is attained in vitro) and drug
solubility [26, 77]. It is a measure of the driving force for drug precipitation; i.e., the
higher SRM , the higher the likelihood for drug precipitation. The dispersed, undigested
systems were slightly supersaturated with SRM values of 1.17 to 2.55. This was different
for the digested formulations, where the SRM increased in each formulation (Table 6.2).
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Drug supersaturation was most pronounced with formulation F3, resulting in a more
than three times higher SRM value at the end of lipolysis compared with that at the
beginning. With formulation F1, which liberated the largest amount of FA, the super-
saturation ratio almost doubled over the course of lipolysis. Finally, with formulation
F2, the increase in supersaturation were comparatively moderate (1.6 and 1.1 times the
SRM values prior to lipolysis, respectively).
Table 6.2: Drug solubility in the undiluted formulations and saturation ratios (mean
± SD) at the beginning and after a 30 min digestion period. The SRM is calculated for
the formulations containing drug at a concentration corresponding to 80% of solubility
(i.e., saturation of 0.8 in each pre-concentrate). The table also details the solid-state
of precipitating material during formulation dispersion and digestion.
Compound LBF Solubility, Supersaturation ratio, SRM Solid-state of precipitate
C * (mg/g) Dispersion Lipolysis Dispersion Lipolysis
Loratadine
F1 165.2 ± 3.3 2.23 ± 0.02 5.15 ± 0.08 No precip. Crystalline
F2 130.5 ± 5.0 2.02 ± 0.02 3.21 ± 0.10 Crystalline Crystalline
F3 156.2 ± 2.9 1.17 ± 0.02 4.16 ± 0.04 No precip. Crystalline
Carvedilol
F1 78.4 ± 5.6 2.55 ± 0.01 4.34 ± 0.44 No precip. Amorphous
F2 145.4 ± 3.7 2.29 ± 0.01 2.59 ± 0.16 Crystalline Amorphous
F3 139.6 ± 4.1 1.78 ± 0.04 5.63 ± 0.22 No precip. Amorphous
6.3.3 Drug solubilization upon dispersion without lipolysis
The drug solubilization capacity was first studied for each drug-loaded formulation upon
dispersion only. The dispersion medium was identical to the medium used for lipolysis
but without digestive enzymes. As seen in Figure 6.3a and b, formulations F1 and F3
were able to maintain the compounds in solution during the 1 h dispersion period. In
contrast, formulation F2 resulted in drug precipitation, and after 1 h, only 71.2 ± 6.9%
of loratadine and 61.6 ± 13.9% of carvedilol remained in solution.
Drug material that precipitated from formulation F2 was collected and analyzed using
XRPD. As seen in Figure 6.4, the angular range of peaks of precipitated loratadine
and carvedilol mostly corresponded to those of the reference patterns (pure, crystalline
drugs). Therefore, apparently, loratadine and carvedilol precipitated in a crystalline
form during dispersion.
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Figure 6.3: Percentage of solubilized loratadine (a) and carvedilol (b) after dispersion
of formulations F1 (©), F2 (4), and F3 () under non-digesting conditions (mean ±
SD, n=3). Only formulation F2 resulted in relevant precipitation of loratadine and
carvedilol after 60 min of dispersion.
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Figure 6.4: XRPD patterns of precipitated loratadine and carvedilol collected after 1
h of dispersion of formulation F2. The angular range of peaks of precipitated loratadine
and carvedilol corresponded to that of the reference pattern (pure, crystalline drug).
This result suggests that loratadine and carvedilol precipitated in the crystalline form
during dispersion of formulation F2.
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6.3.4 Drug precipitation under digesting conditions
The three formulations containing loratadine and carvedilol were digested for 30 min and
the amounts of precipitated drug determined after sample ultracentrifugation. Each for-
mulation resulted in extensive drug precipitation. For formulations with loratadine,
approximately 70% of the drug was precipitated after 30 min of digestion. Formula-
tions with carvedilol showed a slightly larger extent of precipitation, ranging from 78.2
to 91.8% (Fig. 6.5). No oil phase was visually detectable in ultracentrifuged samples,
which supports the observation that the formulations were almost completely digested
by the end of the experiment. With formulations F1 and F3, precipitation of loratadine
and carvedilol was only triggered by formulation digestion. Instead, with formulation F2,
the main trigger of drug precipitation was formulation dispersion, whereas the contribu-
tion of formulation digestion was moderate (2.6% and 16.6% of total drug precipitation
for loratadine and carvedilol, respectively).
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Figure 6.5: Amount of loratadine (left plot) and carvedilol (right plot) in the aqueous
and pellet phase obtained upon digestion of the three formulations F1, F2, and F3
(mean ± SD, n=3). Approximately 70% of loratadine was precipitated after 30 min
of digestion, whereas the extent of carvedilol precipitation was slightly higher (78.2 to
91.8%). The total extent of precipitation was very similar amongst the formulations of
a given drug and no oil phase was visually detectable in ultracentrifuged samples.
The pellet phases containing precipitated drug were further analyzed by XRPD. Fig-
ure 6.6 depicts the XRPD patterns of pure loratadine and carvedilol, of the pellets
containing precipitated drug, and of a reference pellet. This reference was the pellet ob-
tained after lipolysis of drug-free formulation spiked with crystalline drug. The XRPD
patterns of these reference pellets displayed the typical diffraction patterns of crystalline
loratadine and carvedilol, respectively. For the pellets with precipitated loratadine, the
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angular range of peaks corresponded to that of the reference pellet.
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Figure 6.6: XRPD pattern of the pellets obtained from the lipolysis of formulation F1,
F2, and F3 containing precipitated loratadine (upper plot) and carvedilol (lower plot).
As a reference, the XRPD pattern of pure crystalline drug, and of the blank pellets
containing the corresponding amount of crystalline drug (F1 ref., F2 ref., F3 ref.) were
recorded. The angular range of peaks of precipitated loratadine corresponded to that
of the reference patterns, suggesting that loratadine precipitated in crystalline form
during digestion. In contrast, the XRPD patterns of precipitated carvedilol revealed
no characteristic peak, suggesting that carvedilol precipitated in an amorphous form
during digestion.
In contrast, this characteristic peak pattern was almost absent in the pellet with precip-
itated carvedilol. Only slight peaks were observed in the XRPD pattern of pellets with
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precipitated carvedilol, especially with formulation F2. These peaks may indicate a crys-
tallization process, which was very slow compared to the observation period. However,
these XRPD patterns suggested that carvedilol mostly precipitated in the amorphous
state, while loratadine apparently precipitated in crystalline form during lipolysis.
Comparison of the precipitation behavior of the two drugs in the range of formulations
revealed that the extent of precipitation was very similar amongst the three formula-
tions for a given drug. Analogously, no formulation effect was seen for a given drug with
respect to the solid-state form of the precipitates.
6.3.5 Re-dissolution
To put the results of solid-state analysis into a biopharmaceutical perspective, we studied
the re-dissolution of the precipitates obtained upon lipolysis. The re-dissolution profiles
of the pellets containing precipitated drug and of the reference pellets spiked with the
corresponding amounts of the crystalline drugs are plotted in Figure 6.7.
The dissolution profiles of precipitated loratadine were very similar to the dissolution
profile of the reference pellet, which contained crystalline drug. Hence, almost 100% of
the drug re-dissolved within 60 min. In contrast, re-dissolution of precipitated carvedilol
was considerably faster in comparison with the reference pellet. The plots of formula-
tions F1 and F2 show that more than 90% of the precipitated carvedilol re-dissolved
within 30 min, while the crystalline drug in the reference pellet remained incompletely
dissolved after 180 min of re-dissolution. This result supports the finding that pre-
cipitated carvedilol differed from the crystalline drug. Interestingly, re-dissolution of
loratadine was comparatively fast, although it was in a crystalline state.
Considering loratadine and carvedilol separately, there was no pronounced influence of
the (digested) formulation on the drug dissolution profiles. However, an exception oc-
curred for the pellet of formulation F2 containing precipitated carvedilol. Re-dissolution
here was notably slower than with the precipitates of F1 and F3. This difference was
likely due to the difficulty in disintegrating the pellet phase of system F2, which formed
a rather dense aggregate during sample preparation.
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Figure 6.7: Re-dissolution profiles of loratadine (left) and carvedilol (right) in pellets
obtained from the lipolysis of formulation F1, F2, and F3. Filled symbols represent the
dissolution values of pellets containing precipitated drug, open symbols are reference
values of blank pellets spiked with crystalline drug (mean ± SD, n=3). The dissolution
profiles of precipitated loratadine were very similar to the dissolution profile of the ref-
erence pellet that contained crystalline drug. In contrast, the dissolution of precipitated
carvedilol occurred considerably faster than that of the reference pellet.
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6.4 Discussion
Several in vitro assays have been developed to simulate the precipitation of weakly ba-
sic drugs during gastrointestinal passage [213, 239, 240, 243, 244]. These are valuable
approaches for estimating a drug precipitation profile at intestinal pH in the presence
of bile salts and phospholipids. However, when a weak base is administered in an LBF,
the drug is not only surrounded by a simple aqueous environment. There are lipidic
excipients and hydrolysis products in close proximity to the drug that determine the
apparent solubilization capacity of the medium and may influence drug precipitation.
The purpose of this study was to analyze the precipitation behavior of lipophilic weak
bases formulated in different LBFs by considering the dispersion and digestion steps
separately. Loratadine and carvedilol were selected as model compounds and dissolved
in three different LBFs. The pre-concentrates had the same drug saturation ratio of
80% solubility (at 37◦C). However, upon formulation dispersion, there was a decrease in
solubilization capacity that resulted in a slightly supersaturated state. One formulation
(F2) exhibited some precipitation of both loratadine and carvedilol after 60 min of dis-
persion. The hydrolytic breakdown of formulation lipids notably increased the degree of
supersaturation, especially with formulations F1 and F3, which resulted in substantial
drug precipitation.
Interestingly, we observed partially different solid-state properties of the precipitates de-
pending on the experimental conditions. During dispersion without lipolytic enzymes,
both loratadine and carvedilol precipitated as crystalline materials. Formulation lipol-
ysis also led to the precipitation of crystalline loratadine, but in contrast, carvedilol
precipitated as an amorphous drug. It is interesting to compare these results with the
findings of Hsieh et al. [243], who described the supersaturation and precipitation be-
haviors of loratadine and carvedilol during potentiometric titration. The drugs were
initially dissolved in a simple aqueous medium (without excipients, phospholipids, and
bile salts) and pH-induced precipitation resulted in amorphous material for both lorata-
dine and carvedilol [243].
Compared with our study, these findings suggest that precipitation triggered by a pH-
change alone should be clearly differentiated from cases in which formulation lipids,
medium bile salts, and phospholipids influence the precipitation process. It is well
known from chemical engineering that the solid-state of a precipitated substance largely
depends on the given precipitation process and on solvent conditions [78]. For example,
a compound that precipitates because of a solvent change may have different solid-state
properties than the same drug precipitated by a pH-shift. During potentiometric titra-
tion in a simple aqueous medium, as it was in the studies of Hsieh et al. [243], the pH
gradient was the major trigger generating supersaturation and amorphous drug precip-
itation. However, as seen from our results, during biorelevant formulation processing
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there appears to be a complex interplay of factors that should be discussed in more
detail.
When a LBF reaches the gastrointestinal fluids, it first disperses to build fine oil droplets
or micellar structures. During this process, there is a partitioning of drug between oil
droplets, micellar species, and water, which is determined by the relative affinity of the
compound to these different phases. Drug partitioning into the aqueous phase deter-
mines the free fraction of drug that deprotonates in the basic environment (depending
on pKa). Therefore, the kinetics of drug partitioning is linked to the kinetics of deproto-
nation to free base, and thus it determines the rate of drug supersaturation. Compared
with precipitation in a simple aqueous medium, the use of biorelevant media also implies
the presence of several negatively charged counterions such as bile salts, maleate, and
chloride ions. These negatively charged species can interact with the base, determine
its solubility in the medium and, thus, the extent of drug supersaturation and kinetics
of precipitation. A further influence can occur with respect to the stability of supersat-
uration. When a system reaches a supersaturated state, it is naturally prone to drug
precipitation. However, the nucleation induction time is largely determined by the sta-
bility of this metastable state, and in a complex medium, it can be notably influenced
by the presence of endogenous and exogenous surfactants [55, 56, 70, 245].
When the formulation reaches the intestinal lumen, LBFs are generally digested by
lipolytic enzymes [31, 56]. The digestion of formulation lipids results in a substantial
transformation of the vehicle toward higher polarity. If the original lipid was a good
solvent for the drug, then this process can be viewed as a kind of solvent depletion and
is probably a major trigger for drug precipitation. In the case of a weak base there may
be an additional effect caused by charge interactions with negatively charged FA, which
are produced during hydrolysis of glycerides at the surface of oil droplets. Charged
lipolysis products are likely to be in close proximity to ionized weak bases, thereby fa-
voring molecular interactions. It must be kept in mind that this type of interaction is
particularly relevant during lipolysis and is not present during formulation dispersion
without digestion.
It is worth noting that the formulation performance in vivo is expected to be even more
complex. First, the unstirred water layer at the intestinal surface is characterized by
an acidic microclimate (pH 5.3-6.2) [246–248]. This lower pH favors protonation, and
hence, it can improve the solubilization of a weakly basic drug. Secondly, the absorp-
tion of drug through the intestinal membrane reduces the total drug concentration in
the intestinal lumen. This in vivo sink is particularly relevant for highly permeable
drugs, for which absorption leads to a fast decrease in drug supersaturation. Care is
therefore needed when predicting the extent of precipitation using one-compartmental
assays, such as the in vitro lipolysis test. For qualitative analyses of the precipitate, this
lack of absorptive sink is probably less critical. Moreover, the precipitation behavior of
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a weak base may also depend on the nutritional state. In the present study, we used a
state-of-the-art method for lipolysis testing, which simulated formulation performance
in the fasted state. The gastric passage was neglected, because formulation transfer
into the intestine is expected to be rapid. However, drug molecules may still migrate
out of oil droplets into the acidic bulk phase, even though the gastric residence time is
comparatively short. Partitioning of weak bases in the gastric environment has recently
been shown for cinnarizine in equilibrium [80], but the kinetics of such partitioning is
currently unknown. However, intestinal drug supersaturation and precipitation may be
influenced by such drug partitioning in the gastric environment.
Based on these considerations and on our experimental results it seems that, although
a particular chemical compound exhibits some intrinsic propensity to precipitate in ei-
ther crystalline or amorphous states [249], the solid-state of a drug precipitating in the
intestinal environment is hardly predictable a priori. The appropriate selection of ex-
perimental methods simulating the intestinal lumen is therefore of great importance, as
evidenced in recent the works of Psachoulias et al. The precipitation of ketoconazole
(without excipients) was analyzed in vivo [61], and a three compartment in vitro model
was developed to simulate the gastrointestinal transit of an aqueous ketoconazole so-
lution [240]. In the in vitro model, the gastric and intestinal compartments contained
an HCl solution (pH 2.5) and fasted state simulating intestinal fluid (FaSSIF-V2plus
[61], without digestive enzymes), respectively. The transfer of ketoconazole from the
gastric into the luminal compartment resulted in supersaturation and precipitation of
crystalline drug in vitro. In contrast, amorphous ketoconazole was isolated in luminal
aspirates after administration to humans. Therefore, the presence of lipids, digestive
enzymes and/or drug absorption clearly influenced the precipitation behavior of keto-
conazole in vivo.
Such ex vivo studies of precipitating material are of high interest. More research is
needed to clarify effects of sampling in vivo as well as in vitro. Sampling effects may
affect the determined precipitation kinetics and especially the lag time between sample
removal and solid-state analysis could be critical regarding a phase transition of the
solid-state. Similarly, the in vitro addition of enzyme inhibitor (4-BPBA) could influ-
ence the precipitation behavior of the drug so that more studies are needed to this end.
In this study the impact of formulation composition on drug precipitation was also an-
alyzed. The data revealed no specific influence of the formulation on the solid-state
properties of precipitated drug. Re-dissolution data indicated that carvedilol dissolved
considerably faster than the drug in the control experiment. In contrast, re-dissolution
of precipitated loratadine was slower and followed almost the same kinetics as the ref-
erence data. This result confirms the solubility advantage of the amorphous precipitate
compared with the crystalline material [60, 79]. A superior re-dissolution performance of
amorphous drug was also reported in recent studies [33, 80]. Larsen et al. analyzed the
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in vivo performance of LBFs with cinnarizine in dogs [80]. Although one formulation ex-
hibited amorphous precipitation in vitro, the corresponding oral bioavailability was not
lower than with the other formulations, which were able to prevent drug precipitation
in vitro. Therefore, these in vivo data may support the view of facilitated re-dissolution
from amorphous precipitates during intestinal transit. Other effects mentioned above,
such as the in vivo sink and stabilization of supersaturated drug, might also have con-
tributed.
Interestingly, re-dissolution of loratadine was rather fast compared with the re-dissolution
of crystalline carvedilol. It was therefore assumed that loratadine, although it is in a
crystalline state, would re-dissolve during intestinal transit. This is an important aspect:
even a crystalline precipitate would not directly indicate poor re-dissolution and erratic
drug absorption. The administered drug dose, drug permeability, and the kinetics of
drug precipitation and re-dissolution ultimately define the fraction of drug absorbed.
Based on these considerations, an improved biopharmaceutical understanding of drug
precipitation from LBFs may begin with characterizing its solid-state properties as well
as its re-dissolution kinetics.
6.5 Conclusions
The findings of the present study are of high practical importance for the development
of oral LBFs with weakly basic drug candidates. Apparently, weak bases do not gen-
erally precipitate in a specific form, but the resulting solid-state is largely depending
on compound properties as well as on in vitro testing conditions. The results also sug-
gested that a classification of weak bases according to their precipitation behavior in a
simple pH shift experiment can be only tentatively related to the precipitation of weak
bases from LBFs under dispersion/digestion conditions. The extent of drug precipitation
and consideration of solid-state properties is of critical importance in LBF development.
Therefore, solid-state characterization of precipitated drugs under different experimental
conditions should be routinely performed in formulation screening to better understand
the biopharmaceutical behavior of LBFs.
This study provided new insights into the likely fate of LBFs in the GI tract and such
improved understanding is highly needed to better predict LBF behavior in vivo. The
finding that the surrounding dispersive or digestive environment affects the solid-state
of a precipitate emphasizes the need for an improved mechanistic understanding of the
precipitation behavior from LBFs. More research should especially be directed to the
activation energy of solid-state phase transitions, as it may significantly determine the
resulting precipitate. It also appears very promising to include solid-state properties as
well as the re-dissolution behavior into physiologically-based pharmacokinetic models to
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improve the simulation of formulation performance in vivo. In addition to such physic-
ochemical excipient effects, an LBF can also influence biological processes such as drug
permeability, gastrointestinal transit time, and/or pre-systemic clearance. These aspects
should be considered when a new formulation is developed. A better understanding of
the complex interplay of basic drugs with lipid-based excipients and intestinal media is
certainly a key requirement to better design LBFs in the future.
Chapter 7
Comparison of high-resolution
ultrasonic resonator technology
and Raman spectroscopy as novel
PAT tools for drug quantification
in SEDDS
Summary
This study evaluates Raman spectroscopy and high-resolution ultrasonic resonator tech-
nology (URT) as analytical tools for drug quantification in self-emulsifying drug delivery
systems (SEDDS). The model drugs fenofibrate, indomethacin, and probucol were quan-
titatively assayed in different self-emulsifying formulations. We measured ultrasound
velocity and attenuation in the bulk formulationcontaining drug at different concentra-
tions. The formulations were also studied by Raman spectroscopy. We used both, an
in-line immersion probe for the bulk formulation and a multi-fiber sensor for measuring
through hard-gelatin capsules that were filled with SEDDS. Each method was assessed
by calculating the relative standard error of prediction (RSEP) as well as the limit of
quantification (LOQ) and the mean recovery.
Raman spectroscopy led to excellent calibration models for the bulk formulation as well
as the capsules. The RSEP depended on the SEDDS type with values of 1.5–3.8%,
Stillhart C. et al. Comparison of high-resolution ultrasonic resonator technology and Raman spec-
troscopy as novel PAT tools for drug quantification in SEDDS. Journal of Pharmaceutical and Biomedical
Analysis, 2012, 59, 29–37.
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while LOQ was between 0.04 and 0.35% (w/w) for drug quantification in the bulk. Sim-
ilarly, the analysis of the capsules led to RSEP of 1.9–6.5% and LOQ of 0.01–0.41%
(w/w). On the other hand, ultrasound attenuation resulted in RSEP of 2.3–4.4% and
LOQ of 0.10.6% (w/w). Moreover, ultrasound velocity provided an interesting analyti-
cal response in cases where the drug strongly affected the density or compressibility of
the SEDDS. We conclude that ultrasonic resonator technology and Raman spectroscopy
constitute suitable methods for drug quantification in SEDDS, which is promising for
their use as process analytical technologies.
7.1 Introduction
The American Food and Drug Administration (FDA) initiative on process analytical
technologies (PATs) has notably increased the interest in novel analytical methods for
pharmaceutical product analysis (US FDA PAT Guidance, 2004). A variety of meth-
ods for drug quantification in pharmaceutical formulations, such as infrared (IR) spec-
troscopy or high-performance liquid chromatography (HPLC), require extensive manual
sample preparation, are time-consuming, and usually destructive. This is in contrast
to the main PAT requirements asking for rapid and non-destructive analytical meth-
ods. Today we know about a couple of analytical techniques that are used for process
monitoring [250]. However, some processes and drug delivery systems are particularly
challenging, so that applied research is needed for the implementation of existing tech-
niques and the evaluation of novel methods.
A highly promising technique is based on ultrasound analytics, since sound waves can
propagate through turbid media of liquid and semi-solid pharmaceutical formulations.
Ultrasound technology has evolved over time and two main applications have been
established: acoustic resonance spectroscopy and high-resolution ultrasonic resonator
technology (URT). In spectroscopic analysis, ultrasound velocity and attenuation are
measured over a large frequency range. In contrast, URT utilizes a specific ultrasound
frequency to determine high-resolution ultrasound velocity and attenuation. Recently,
Medendorp et al. pioneered the use of acoustic resonance spectroscopy as a PAT tool
for drug quantification in semi-solids [251]. Similarly, Chen et al. measured the concen-
tration of a model drug and an excipient in acetone solution with this technique [252].
URT was also applied in process analytics [195, 253], but to the best of our knowledge
real-time monitoring of drug concentration in pharmaceutical formulations has never
been assessed. However, this technology bears great potential as a PAT tool for drug
quantification due to the rapid data collection without additional sample preparation,
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the relative low-cost instrumentation, the fast computing time, and the possibility of
flow-through measurement.
In contrast to the ultrasound-based method, Raman spectroscopy has already gained
some importance in several process analytical applications [254]. The high chemical
specificity of Raman spectroscopy is one of the key advantages over other tools such as
IR spectroscopy. An increasing number of Raman applications have been reported in
recent years. Many quantitative Raman methods focused on solid dosage forms such as
tablets, capsules, and powders [255–260]. In addition, Gotter et al. [261] described the
use of Raman spectroscopy for the quantification of a drug suspended in a simple semi-
solid formulation consisting of paraffin. More complex solid pharmaceutical formulations
were analyzed by Hargreaves et al. [255], who established Raman spectroscopy for quan-
titative analysis of multi-component pharmaceutical capsules. This study demonstrated
the suitability for quantifying three low-level excipients in the formulation as well as an
active pharmaceutical ingredient (API). To the best of our knowledge, more complex
semi-solid formulations such as SEDDS have not been investigated yet.
SEDDS are typically mixtures of up to five excipients (triglyceride oils, mixed glyc-
erides, lipophilic surfactants, hydrophilic surfactants, and water-soluble cosolvents) [9]
that undergo self-emulsification if they are exposed to water. Their ability to enhance
oral absorption of poorly water-soluble drugs led to a growing interest in formulation
research [9]. Some formulations, e.g., ritonavir (Norvir R©), saquinavir (Invirase R©), and
cyclosporine (Sandimmun Neoral R©), have already reached the market.
Since SEDDS provide particularly complex matrices, we aimed to use such formula-
tions to evaluate URT as well as Raman spectroscopy for API quantification. Particular
emphasis was placed on comparing the two methods with respect to their analytical
performance in the different systems. Moreover, we considered two optical Raman con-
figurations: one was intended for in-line measurement in the bulk solution and the other,
a multi-fiber sensor, was foreseen for drug quantification through hard-gelatin capsules
filled with SEDDS.
7.2 Materials and Methods
7.2.1 Materials
Polysorbate 80 and Miglyol 812 were purchased from Ha¨nseler AG (Herisau, Switzer-
land), Imwitor R© 742 and Imwitor R© 988 were supplied by Sasol Germany GmbH (Witten,
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Germany), and Cremophor R© RH 40 by BASF SE (Ludwigshafen, Germany). Fenofi-
brate, indomethacin, and probucol were all obtained from Sigma-Aldrich Chemie GmbH
(Buchs, Switzerland). Uncolored hard-gelatin capsules Licaps R© (size 1) were received
from Capsugel (Bornem, Belgium).
For the preparation of the simulated gastric media, we obtained sodium chloride from
Carl Roth GmbH (Karlsruhe, Germany), pepsin from Ha¨nseler AG (Herisau, Switzer-
land), sodium taurocholate from Prodotti chimici ed alimentari S.p.A. (Basaluzzo, Italy),
phosphatidylcholine from Lipoid GmbH (Ludwigshafen, Germany), and hydrochloric
acid (1 N) from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland).
7.2.2 Samples and analytics
Two different SEDDS consisting of polysorbate 80, Imwitor 988, Miglyol 812 (50/15/35;
PO), and Cremophor RH 40, Imwitor 742, Miglyol 812 (40/30/30; CO) were selected as
model formulations [48, 91]. For both formulations, we prepared a concentration series
with each of the three APIs fenofibrate (Fen), indomethacin (Ind), and probucol (Pro),
separately. Therefore, a total of six concentration series, each including 33 samples, were
studied.
The oils (Miglyol 812, Imwitor 742, Imwitor 988) and the surfactant (Cremophor RH 40
and polysorbate 80, respectively) were mixed on a magnetic stirrer at 40◦C until a clear
solution was obtained. Samples of different API concentrations were then prepared by
dissolving the drugs in the vehicle at room temperature using a magnetic stirrer.
In the analytical part of the experiment, the drug content was first determined in each
bulk formulation by Raman spectroscopy and URT. The formulations were then man-
ually filled into hard-gelatin capsules (∼70% volumetric filling degree). A multi-fiber
Raman probe was subsequently used for API quantification through the capsule to com-
pare in-line bulk analytics with a drug assay through the capsule material. Finally,
HPLC was used as the reference method for API quantification. A detailed description
of each analytical method is given in the following sections.
7.2.2.1 Solubility study
The solubility of the three APIs in PO and CO was determined in triplicate at room
temperature. An excess amount of API was added to the formulations and then the sus-
pensions were continuously mixed on a magnetic stirrer. To ensure that the equilibrium
was reached, the solubility was determined after 24 h, 48 h, and 72 h. Then, samples
were centrifuged at 2000 rpm for 30 min using an Eppendorf centrifuge (model 5415 C)
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to separate non-dissolved API from the vehicle. Finally, the drug concentration in the
supernatant was assessed by HPLC.
7.2.2.2 Characterization of diluted SEDDS
The model systems were characterized with respect to their self-emulsification behavior
upon dilution under physiological conditions. Therefore, formulations with and without
API were diluted at 37◦C (1:200 w/w) in a medium simulating the stomach in the fasted
state (FaSSGF). This medium had a pH of 1.6 and contained minor concentrations of
phosphatidylcholine (20 µM) and bile salts (80 µM) according to Vertzoni et al. [262].
The diluted samples were gently shaken for a few seconds to mimic the limited mixing
stress that occurs physiologically. We measured the particle size on a Zeta Sizer Nano
ZS (Malvern Instruments, Malvern, UK), equipped with a 4 mW He-Ne Laser operating
at a wavelength of 633 nm. The scattering signal was detected at an angle of 173◦, and
each sample was measured for 10 min. The result was expressed as intensity averaged
particle diameter (nm) and as polydispersity index (PDI).
7.2.3 Instrumental and analytical conditions
7.2.3.1 Raman spectroscopy
Raman spectra were recorded in the backscattering modus using a Raman RXN1 an-
alyzer (Kaiser Optical Systems, Inc., Ann Arbor, MI) equipped with a charge-coupled
device (CCD) camera and a diode laser operating at a wavelength of 785 nm. Mea-
surements were carried out with a laser power of 400 mW, and background Rayleigh
scattering was removed by a holographic filter during spectra acquisition.
We recorded the Raman spectra of the bulk formulations with a single-fiber optic probe
(spot size 0.007 mm2) by direct immersion of the probe head into the formulation. The
vials were wrapped in aluminum foils to avoid the influence of external light on the
detection of Raman scattering. To collect Raman spectra through the capsules, a multi-
fiber PhAT probe was used. This sensor had a non-contact sampling optic device with
a laser spot diameter of 6 mm. Scattered radiation was then collected by an array of 50
optical fibers and delivered to the CCD detector. Capsules were positioned on an iris
holder to locate each capsule at the same position and to avoid displacement during the
measurement. A sample holder consisting of a black metal block shielded the samples
from external light.
The reference spectra of the pure drugs in powder form and of the empty hard-gelatin
capsule were recorded with a non-contact probe. This optics utilizes a single fiber for
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excitation and another for collection, and provides a sampling area of 0.007 mm2 such
as the immersion probe.
Spectra were acquired at a resolution of 4 cm−1 and processed for subsequent data anal-
ysis using the iC Raman Instrument software (Version 3.0, Mettler-Toledo AutoChem
Inc., Columbia MD).
7.2.3.2 Ultrasonic resonator technology
High-resolution URT is based on the calculation of the attenuation, A (s2/m) and veloc-
ity, U (m/s) of a sound wave propagating through a sample [263]. In a homogenous liquid
the velocity of a sound wave is determined by the density, ρ and the adiabatic compress-
ibility, κ of the fluid. The mathematical relationship is described by the Newton-Laplace
equation:
U =
1√
κ · ρ (7.1)
Urick [107] generalized this relation to mixtures of different components. Therefore,
sound velocity in the mixture U12 can be described as (using the subscripts 1 and 2 for
the pure components):
1
U212 · ρ12
=
φ1
U21 · ρ1
+
φ2
U22 · ρ2
(7.2)
where φ is the volume fraction and ρ is the density of the two components with the
labeled subscripts.
In the ultrasonic experiments, we measured sound velocity U as well as acoustic atten-
uation A. The latter parameter summarized several contributions to energy loss during
sound propagation. It is inversely proportional to the square of sound frequency f, as
described by the following equation:
A =
α
f2
(7.3)
The term α refers to the acoustical attenuation factor that describes the absorption of
a sound wave with amplitude a traveling a distance x through a medium (a0 = initial
amplitude):
α = −1
x
· ln
(
a
a0
)
(7.4)
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Ultrasonic velocity and attenuation were measured using the ResoScan R© System (TF
Instruments Inc., Monmouth Junction, NJ). The ResoScan was equipped with two iden-
tical parallel resonator cells having a path length of 7.0 mm (ground wave λ0 = 14
mm) with a fundamental frequency of approximately 10 MHz. Since ultrasonic velocity
is strongly temperature-dependent, a Peltier-element-controlled thermostat ensured a
highly stable temperature in the resonator cavities (resolution 1 mK, stability ≤ ± 5
mK). Ultrasound velocity was measured in a range of 1100–1900 m/s and ultrasonic
attenuation was measured between 10−14 and 10−13 s2/m.
To remove air bubbles, we centrifuged all samples prior to the ultrasonic analysis. Thus,
an Eppendorf centrifuge (model 5415 C) was employed for 2 min at 2000 rpm. A sam-
ple of about 200 µl was then carefully transferred to the resonator cavities. Since we
measured the difference in ultrasound velocity (∆U ) and attenuation (∆A) between ac-
tive formulations and placebo formulations, the API-containing formulation was injected
into one of the cells, while the placebo formulation was filled in the other. Once thermal
equilibrium was reached in both cells, we started the measurement. The analysis was
done in triplicate at room temperature.
7.2.3.3 Reference measurements
The drug content of each sample was determined by HPLC. HPLC (Agilent Technologies
1200 Series) analysis was performed with an isocratic pump (G1310A), an autosampler
(G1329A), and a variable wavelength detector (G1314B). All measurements were per-
formed on a LiChrospher R© 60, RP select B 125-4 (5 µm) column (Merck, Darmstadt,
Germany) at a flow rate of 1 ml/min. Before measuring, the samples were diluted with
water at a ratio of 1:200, except CO/Pro samples, which were diluted with acetoni-
trile:water (96:4). The HPLC conditions are detailed in Table 7.1.
Table 7.1: Overview of HPLC methods used for API quantification.
API Mobile phase Injection volume UV detection
Fen Acetonitrile - ammoniumacetate buffer (pH 3.5; 25
mM) (65:35, v/v)
20 µl 287 nm
Ind Phosphoric acid (50 mM) - acetonitrile (40:60, v/v) 5 µl 260 nm
Pro Acetonitrile-water (96:4, v/v) 10 µl 241 nm
Chapter 7. URT and Raman spectroscopy as PAT tools 142
7.2.3.4 Density measurements using Coriolis mass flow technology
Density of the six formulations (Fen/CO, Ind/CO, Pro/CO, Fen/PO, Ind/PO, and
Pro/PO) at five different drug concentrations (0.5, 1, 2, 3, and 4 % w/w) was measured.
We used the Mass Sense Density Meter (Integrated Sensing Systems Inc., Ypsilanti
MI, USA) which was equipped with a microelectromechanical system (MEMS) density
sensor. This technology used a micromachined tube which was driven into resonance
electrostatically while its motion was sensed capacitively by two metal electrodes. The
density ρ of the liquid was deduced from the Coriolis force as described by the following
equation:
ρ =
1
V
·
[(
Ks
4 · pi2 · f2
)
−mt
]
(7.5)
where V is the internal volume of the resonant tube, mt is the tube mass, Ks is the
spring constant of the tube, and f is the resonance frequency of the tube [264]. The
density was measured in the range from 0.6 to 1.3 g/ml with an accuracy of ±0.001 g/ml
and values were determined in triplicate at room temperature.
7.2.4 Data analysis
Raman spectra were analyzed by partial least square (PLS) regression. This method
establishes a relationship between a set of dependent variables Y and a set of inde-
pendent variables X (in our case the reference concentration obtained by HPLC and
the Raman spectra, respectively). The method performs a principal component analysis
based on the independent variable matrix and maximizes the correlation with the depen-
dent variable matrix at the same time. This multivariate analysis was performed using
the software iC Quant (Version 1.0, Mettler-Toledo AutoChem Inc., Columbia MD).
All spectral data were mean-centered. Further pre-processing steps comprised baseline
correction and normalization to unit length.
URT data were analyzed by univariate regression plotting of ∆U and ∆A, separately,
versus the reference concentrations obtained by HPLC.
The limit of quantification, LOQ (% w/w), was calculated according to the Interna-
tional Conference of Harmonization (ICH) guidelines [265]. Thus, a calibration curve
was modeled using a set of 6–10 samples containing API within an order of magnitude
of the estimated quantification limit. Based on the standard deviation σ and the slope
S of the calibration curve, the LOQ was expressed as:
LOQ =
10 · σ
S
(7.6)
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Samples with an API concentration above the calculated LOQ were used for model cali-
bration and validation. Simple and time-saving quantification methods are preferred for
process analytical applications. Therefore, we aimed to assess the predictive power of
the calibration models that were constructed with a small number of calibration points.
We used calibration sets comprising 5–7 samples, while the remaining samples were used
to validate the models. This division between calibration and validation samples was
maintained for all models.
Relative standard error of prediction, RSEP (%) was calculated according to the equa-
tion:
RSEP =
√√√√√√√
n∑
i=1
(cpi − cai )2
n∑
i=1
(cai )
2
· 100 (7.7)
where n is the number of samples, ca the actual concentration (detected by HPLC), and
cp the predicted concentration (by the model).
Mean recovery (%) was established for each model according to the equation:
Mean recovery =
1
n
·
n∑
i=1
cp
cp
· 100 (7.8)
7.3 Results and discussion
7.3.1 SEDDS characterization
We studied two model SEDDS with different drugs for the evaluation of URT and Ra-
man spectroscopy. The model systems were named according to the surfactant so that
for the formulation with polysorbate 80, PO was assigned and for the formulations with
Cremophor RH 40, the label CO was given. In both systems, a concentration series of
the drugs fenofibrate, indomethacin, and probucol was prepared. Table 7.2 shows the
main characteristics of the test systems.
The model compounds demonstrated different solubilities in the formulations, but in all
cases a wide range of concentrations was enabled, which was beneficial considering the
aim of the study. Furthermore, the presence of drug did not strongly alter the dilu-
tion characteristics of the SEDDS. This anticipated self-emulsification of the lipid-based
formulations (PO and CO), both with and without API, was verified. We analyzed
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samples diluted in gastric medium simulating fasted state in vivo by dynamic laser light
scattering. The mean particle diameter of all formulations was in the range of typical
SEDDS [9], as seen in Table 7.2. The CO formulations even formed rather small par-
ticles, so that these systems were basically self-microemulsifying drug delivery systems
(SMEDDS). Larger swollen micelles were obtained from the dilution of the polysorbate
formulations. Furthermore, PO systems were generally more polydisperse upon dilution
as opposed to the CO formulations. However, such differences were not considered to
be of relevance for the scope of the current analytical research.
Table 7.2: Characterization of lipid formulations used in the study
Formulation Concentration range
[%, w/w] (number of
samples)
Solubilitya ± SD
[%,w/w]
Particle diameterb (PDI)
[nm]
PO - - 123.1 (0.269)
PO/Fen 0.01–8.00 (33) 8.58 ± 0.02 138.6 (0.219)
PO/Ind 0.01–4.00 (33) 5.63 ± 0.02 93.3 (0.252)
PO/Pro 0.01–8.00 (33) 11.34 ± 0.01 135.0 (0.192)
CO - - 31.2 (0.078)
CO/Fen 0.01–8.00 (33) 14.14 ± 0.11 35.9 (0.069)
CO/Ind 0.01–4.00 (33) 4.61 ± 0.02 34.9 (0.063)
CO/Pro 0.01–8.00 (33) 11.90 ± 0.14 34.8 (0.054)
a API concentration measured after 72 h (25◦C).
b Dilution ratio: 1:200 (w/w) in FaSSGF; temperature: 37◦C; API concentration: 8% (w/w) for
formulations with Fen and Pro, 4% (w/w) for formulations with Ind.
7.3.2 Raman spectroscopy
Fig. 7.1 shows the Raman spectra of pure APIs (Fen, Ind, and Pro) and excipients
(Polysorbate 80, Cremophor RH 40, Imwitor 988, Imwitor 742, Miglyol 812, and the
empty capsule). We analyzed these APIs in powder form as well as the empty gelatin
capsule with a single-fiber non-contact optic probe. The spectra of the different ex-
cipients were instead collected using the immersion probe. All API spectra had some
distinct Raman bands in the ranges of 1000–1500 cm−1 and 2700–3200 cm−1. In some
of these ranges, the different excipients exhibited a comparatively lower Raman activity.
To evaluate Raman spectroscopy as a method for drug quantification, we first recorded
the spectra of the six concentration series, each with 33 samples, directly from the bulk
formulation. Subsequently, following a manual filling of the formulation into hard-gelatin
capsules, additional spectra were determined through the capsules using the PhAT probe.
Despite the partially overlapping spectral ranges of pure APIs and excipients, each for-
mulation revealed at least one region where the signal intensity was highly specific for
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the API. In these regions, increasing drug concentrations showed peaks with increasing
heights as well as areas. This was observed for both measurements in the bulk and
through the capsules, as seen in Fig. 7.2 and Fig. 7.3. Based on these preliminary ob-
servations, backscatter Raman spectroscopy appeared to be promising for quantitative
determination of the model drugs in SEDDS.
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Figure 7.1: Raman spectra of pure APIs and excipients.
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Table  2
Characterization of lipid formulations used in the study.
Formulation Concentration range
measured [%, w/w]
(number of samples)
Solubilitya ± SD [%, w/w] Particle
diameterb
(PDI) [nm]
PO – – 123.1 (0.269)
PO/Fen 0.01–8.00 (33) 8.58 ± 0.02 138.6 (0.219)
PO/Ind 0.01–4.00 (33) 5.63 ± 0.02 93.3 (0.252)
PO/Pro 0.01–8.00 (33) 11.34 ± 0.01 135.0 (0.192)
CO  – – 31.2 (0.078)
CO/Fen 0.01–8.00 (33) 14.14 ± 0.11 35.9 (0.069)
CO/Ind 0.01–4.00 (33) 4.61 ± 0.02 34.9 (0.063)
CO/Pro 0.01–8.00 (33) 11.90 ± 0.14 34.8 (0.054)
a API concentration measured after 72 h (25 ◦C).
b Dilution ratio: 1:200 (w/w) in FaSSGF; temperature: 37 ◦C; API concentration: 8% (w/w)  for formulations with Fen and Pro, 4% (w/w) for formulations with Ind.
the different excipients exhibited a comparatively lower Raman
activity.
To evaluate Raman spectroscopy as a method for drug quan-
tification, we first recorded the spectra of the six concentration
series, each with 33 samples, directly from the bulk formulation.
Subsequently, following manual filling of the formulation into
hard-gelatin capsules, additional spectra were determined through
the capsules using the PhAT probe. Despite the partially overlap-
ping spectral ranges of pure APIs and excipients, each formulation
revealed at least one region where the signal intensity was  highly
specific for the API. In these regions, increasing drug concentra-
tions showed peaks with increasing heights as well as areas. This
was observed for both measurements in the bulk and through the
capsules, as seen in Figs. 3 and 4. Based on these preliminary obser-
vations, backscatter Raman spectroscopy appeared to be promising
for quantitative determination of the model drugs in SEDDS.
PLS analysis was then performed on the complete data
set, while the number of PLS components was  determined by
cross-validation. Different calibrations constructed on API-specific
spectral ranges did not greatly affect the obtained models.
Therefore, we always considered the entire spectral ranges of
500–3300 cm−1 (bulk formulation) and 500–1800 cm−1 (capsules)
for multivariate analysis.
Table 3 lists the values of LOQ, RSEP, and mean recovery of drug
quantification in the different formulations. Interestingly, the LOQ
values obtained from drug quantification in the capsules were in the
range of values obtained from the measurements in the bulk solu-
tion. This similar sensitivity was mainly due to the optical devices
specifically used for these two  analytical tasks. Drug quantification
in the capsules required the use of the PhAT probe. This system, hav-
ing 50 collected optical fibers, provided a sampling area (28.3 mm2)
that was about 40–900 times larger than that present in conven-
tional dispersive and FT-Raman, so that it had higher sensitivity to
scattered radiation than the single-fiber probe. On the other hand,
the prediction errors of the calibration models were equal or even
smaller for the drug assays in the bulk formulation compared to the
capsules. This result can also be inferred from the plots of actual vs.
predicted concentrations (Figs. 5 and 6). There was a tendency of
slightly higher R2 for drug quantification in the bulk as compared to
the capsule (0.9973–0.9995 vs. 0.9732–0.9991). Such a subtle effect
was likely to contribute to some increase in prediction error of drug
quantification in the capsules, which was mostly attributable to
the experimental setup. Since the laser beam diameter of the PhAT
probe slightly exceeded the capsule width, there was some signal
n ise resul ing in an undulating baseline as seen on the spectra
in (Figs. 3 and 4, spectra on the right side). This effect was fur-
ther enhanced by the transparency of the samples coupled with
the short distance covered by the laser beam, leading to a signal
noise coming from the background of the sample.
Regarding the different SEDDS types, drug quantification in PO
formulations led to clearly higher prediction errors than those
based on CO. This tendency was particularly pronounced for the
quantification in capsules, where the predictive ability in PO
systems was up to three times lower compared to CO-based for-
mulations (RSEP 3.5–6.5% vs. 1.9–2.4%). Even though the type of
SEDDS affected RSEP, all values were sufficiently low to fulfill the
Fig. 3. Raman spectra of CO formulations collected in the bulk (left) and through the capsules (right). The 33 spectra of each concentration series are combined in each
illustration, Raman signals generated from APIs are highlighted.
Figure 7.2: Raman spectra of CO formulations collected in the bulk (left) and through
the capsules (right). The 33 spectra of each concentration series are combined in each
illustration, Raman signals generated from APIs are highlighted.
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Fig. 4. Raman spectra of PO formulations collected in the bulk (left) and through the capsules (right). The 33 spectra of each concentration series are combined in each
illustration, Raman signals generated from APIs are highlighted.
general acceptance criteria of performance parameters in analytical
validation [22]. The obtained results encouraged the use of Raman
spectroscopy as an accurate method for API quantification in com-
plex semi-solid formulations. Together with the intrinsic Raman
activity of the analyzed substance, it was the type of lipid mixture
that apparently influenced the predictive ability of the method.
With respect to the PAT feasibility, the immersion probe can
be directly employed as in-line setup for real-time monitoring of
the intermediate product (i.e. the capsule fill mass). Raman spec-
troscopy was very promising for drug quantification through the
capsules as well. However, optimization of the instrument setup
might even improve its usefulness as a PAT method. Despite the
advantages of the large sampling area, the laser beam area should
not exceed the capsule size to reduce background noise within
Raman backscattering. Moreover, the analytical procedure was not
as fast as the manufacturing of the capsules. Since only a defined
portion of the capsules can be transferred to the sample holder, the
analysis of the final product was performed at-line.
A similar approach was adopted by Johansson et al. [9],
where the transmission and the backscatter mode of Raman spec-
troscopy were compared for the quantitative analysis of tablets
and capsules. Spectra were recorded with the PhAT probe. This
study demonstrated that transmission Raman leads to even more
robust calibration models for solid pharmaceutical formulations
as compared to backscatter Raman. In fact, the transmission setup
allowed the entire tablet thickness to be analyzed, which was an
improvement when compared to the backscatter mode, where
only about 10% of a typical tablet was  sampled (sampling depth
of approximately 5 mm)  [9]. The homogenous drug mixtures and
transparent capsules used in our study provided an advantageous
situation for the backscattering setup so that only limited improve-
ment could be expected from a Raman transmission mode. This
expectation was  supported by the relatively low RSEP obtained
from our experiments. Backscatter Raman demonstrated robust
models for this type of drug delivery systems.
3.3. URT
In addition to using Raman spectroscopy, we analyzed the six
concentration series by ultrasound velocimetry. However, since the
ResoScan® system was only suitable for analyzing liquid samples,
API quantification in capsules was not performed. We  determined
ultrasound velocity and attenuation as relative values. Thus, two
sample cells were always filled, whereby the placebo formulation
was filled in the first cell (cell 1) and the drug-containing formula-
tion in the second cell (cell 2). The differences in ultrasound velocity
!U and attenuation !A  between the two samples were obtained by
subtracting the values measured in cell 1 from the values measured
in cell 2, and used for univariate analysis.
Generally, there was  a linear relationship for both acoustic
responses as a function of API concentration (Fig. 7). We  noticed
the tendency of !A  to be more sensitive to drug concentration
Table 3
Prediction of API concentration in capsules and in the bulk formulation using Raman spectroscopy.
Formulation Bulk formulation Capsules
LOQ [%, w/w] RSEP [%, nominal] Recovery ± 95%
CI [%, nominal]
LOQ [%, w/w] RSEP [%, nominal] Recovery ± 95%
CI [%, nominal]
PO
Fen 0.20 2.32 99.1 ± 1.3 0.05 3.55 99.8 ± 3.3
Ind  0.04 3.83 101.6 ± 2.9 0.41 6.54 99.6 ± 4.8
Pro  0.35 3.18 102.0 ± 3.6 0.06 4.52 102.7 ± 2.8
CO
Fen 0.10  1.99 99.5 ± 2.7 0.34 1.87 100.5 ± 2.1
Ind  0.09 2.96 100.2 ± 1.7 0.01 2.05 100.0 ± 1.1
Pro 0.25  1.48 100.9 ± 1.6 0.02 2.40 99.2 ± 2.8
Figure 7.3: Raman spectra of PO formulations collected in the bulk (left) and through
the capsules (right). The 33 spectra of each concentration series are combined in each
illustration, Raman signals generated from APIs are highlighted.
PLS analysis was then performed on the complete data set, while the number of PLS
components was determined by cross-validation. Several calibration models constructed
on API-specific spectral ra ges did not greatly affect the obtained models. Therefore,
we always consider d the entire sp ctral ranges of 500–3300 cm−1 (bulk formulation)
and 500–1800 cm−1 (capsules) for mul ivariate an lysis. Table 7.3 lists the values of
LOQ, RSEP, a d m an r covery of drug quantification in the different formulations.
Interesting y, the LOQ values obtained from drug quantification in t e capsules were in
the range of v lues obtain d from the measurement in the bulk solution. This similar
sensitivity w s mainly ue to the o tical devices specifical y us d for these two analytical
tasks. Drug quantification in the capsules requir d the use of the PhAT probe. Thi
system, having 50 collect d optical fiber , provided a sampling area (28.3 mm2) that w s
Table 7.3: Prediction of API concentration in the bulk formulation and in capsules
using Raman spectroscopy.
Formulation
Bulk formulation Capsules
LOQ RSEP Recovery
± 95% CI
LOQ RSEP Recovery
± 95% CI
PO/Fen 0.20 2.32 99.1±1.3 0.05 3.55 99.8±3.3
PO/Ind 0.04 3.83 101.6±2.9 0.41 6.54 99.6±4.8
PO/Pro 0.35 3.18 102.0±3.6 0.06 4.52 102.7±2.8
CO/Fen 0.10 1.99 99.5±2.7 0.34 1.87 100.5±2.1
CO/Ind 0.09 2.96 100.2±1.7 0.01 2.05 100.0±1.1
CO/Pro 0.25 1.48 100.9±1.6 0.02 2.40 99.2±2.8
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about 40–900 times larger than that present in conventional dispersive and FT-Raman,
so that it had higher sensitivity to scattered radiation than the single-fiber probe. On
the other hand, the prediction errors of the calibration models were equal or even smaller
for the drug assays in the bulk formulation compared to the capsules. This result can
also be inferred from the plots of actual versus predicted concentrations (Fig. 7.4 and
7.5). There was a tendency of slightly higher R2 for drug quantification in the bulk
as compared to the capsule (0.9973–0.9995 versus 0.9732–0.9991). Such a subtle effect
was likely to contribute to some increase in prediction error of drug quantification in the
capsules, which was mostly attributable to the experimental setup. Since the laser beam
diameter of the PhAT probe slightly exceeded the capsule width, there was some signal
noise resulting in an undulating baseline as seen in the spectra (Fig. 7.2 and Fig. 7.3,
spectra on the right side). This effect was further enhanced by the transparency of the
samples coupled with the short distance covered by the laser beam, leading to a signal
noise coming from the background of the sample.
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Figure 7.4: Drug quantification in PO formulations by Raman spectroscopy in the
bulk formulation (top) and through the capsules (bottom).
 = calibration data set, ♦ = validation data set.
Regarding the different SEDDS types, drug quantification in PO formulations led to
clearly higher prediction errors than those based on CO. This tendency was particularly
pronounced for the quantification in capsules, where the predictive ability in PO systems
was up to three times lower compared to CO-based formulations (RSEP 3.5–6.5% versus
1.9–2.4%). Even though the type of SEDDS affected RSEP, all values were sufficiently
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Figure 7.5: Drug quantification in CO formulations by Raman spectroscopy in the
bulk formulation (top) and through the capsules (bottom).
 = calibration data set, ♦ = validation data set.
.
low to fulfill the general acceptance criteria of performance parameters in analytical
validation [266]. The obtained results encouraged the use of Raman spectroscopy as an
accurate method for API quantification in complex semi-solid formulations. Together
with the intrinsic Raman activity of the analyzed substance, it was the type of lipid
mixture that apparently influenced the predictive ability of the method.
With respect to the PAT feasibility, the immersion probe can be directly employed as
in-line setup for real-time monitoring of the intermediate product (i.e., the capsule fill
mass). Raman spectroscopy was very promising for drug quantification through the
capsules as well. However, optimization of the instrument setup might even improve its
usefulness as a PAT method. Despite the advantages of the large sampling area, the laser
beam area should not exceed the capsule size to reduce background noise. Moreover, the
analytical procedure was not as fast as the manufacturing of the capsules. Since only a
defined portion of the capsules can be transferred to the sample holder, the analysis of
the final product was performed at-line.
A similar approach was adopted by Johansson et al. [257], where the transmission
and the backscatter mode of Raman spectroscopy were compared for the quantitative
analysis of tablets and capsules. Spectra were recorded with the PhAT probe. This
study demonstrates that transmission Raman leads to even more robust calibration
models for solid pharmaceutical formulations as compared to backscatter Raman. In
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fact, the transmission setup allows the entire tablet thickness to be analyzed, which is an
improvement when compared to the backscatter mode, where only about 10% of a typical
tablet is sampled (sampling depth of approximately 5 mm) [257]. The homogenous drug
mixtures and transparent capsules used in our study provided an advantageous situation
for the backscattering setup so that only limited improvement could be expected from a
Raman transmission mode. This expectation was supported by the relatively low RSEP
obtained from our experiments. Backscatter Raman demonstrated robust models for
this type of drug delivery systems.
7.3.3 URT
In addition to using Raman spectroscopy, we analyzed the six concentration series by
ultrasound velocimetry. However, since the ResoScan system was only suitable for ana-
lyzing liquid samples, API quantification in capsules was not performed. We determined
ultrasound velocity and attenuation as relative values. Thus, two sample cells were al-
ways filled, whereby the placebo formulation was filled in the first cell (cell 1) and the
drug-containing formulation in the second cell (cell 2). The differences in ultrasound ve-
locity ∆U and attenuation ∆A between the two samples were obtained by subtracting
the values measured in cell 1 from the values measured in cell 2, and used for univariate
analysis.
Generally, there was a linear relationship for both acoustic responses as a function of
API concentration (Fig. 7.6). We noticed the tendency of ∆A to be more sensitive
to drug concentration compared to ∆U. The drugs fenofibrate and probucol exhibited
smaller quantification limits and prediction errors with ∆A as response, when compared
to calibration models built on ∆U (Table 7.4). Indomethacin was different, and the
special character of this drug was further underlined by the results of ∆U calibration.
The largest ∆A variation was induced by indomethacin and probucol, and this was
likely to result in lower LOQs, as observed with these formulations when compared with
systems with fenofibrate (Table 7.4). Nevertheless, the analytical performance of ∆A
was in a similar range as that of Raman spectroscopy. This was a remarkable result in
the context of ultrasound attenuation as a monitoring parameter in complex lipid-based
formulations.
Fig. 7.6 shows the double plots of ∆U and ∆A as a function of drug concentration.
The values of ∆A generally higher with increasing drug concentrations. The extent of
increase and thus the slope of the linear models were mainly affected by the drug type,
while there was barely any difference between the formulation types.
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Figure 7.6: Variation of ∆U (©) and ∆A (4) with drug concentration.
With both fenofibrate and probucol, ∆U decreased with increasing drug concentrations.
Furthermore, ∆U calibration models of these two drugs led to particularly high values
of LOQ and RSEP. Interestingly, analytical performance was different in the case of
indomethacin where ultrasound velocity even increased with drug load. For better un-
derstanding of this finding, consider Eqs. 7.1 and 7.2. Thus, any change in ultrasound
speed is attributed to differences in apparent density or compressibility of the mixture.
It was therefore of interest to study how the density of the formulations was affected by
different drug amounts.
Five drug concentrations (range 0.5–4 % w/w) were compared with respect to density
Table 7.4: Prediction of API concentration in the bulk formulation using URT: eval-
uation based on ∆U and ∆A
Formulation
∆U ∆A
LOQ RSEP Recovery
± 95% CI
LOQ RSEP Recovery
± 95% CI
PO/Fen 1.48 5.43 98.5±6.4 0.40 2.33 101.4±1.9
PO/Ind 0.14 1.08 100.6±1.6 0.20 3.26 101.8±3.5
PO/Pro 2.05 5.43 98.5±3.6 0.13 4.42 103.9±4.2
CO/Fen 2.29 5.34 98.0±4.3 0.64 3.51 97.0±2.9
CO/Ind 0.80 1.35 99.4±1.6 0.48 2.36 97.9±1.8
CO/Pro 1.24 3.44 100.6±2.9 0.39 3.00 101.9±3.7
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changes (Fig. 7.7). The results indicated that density in the mixture increased with
drug load in all cases. As inferred from the slopes m, the density increase was particu-
larly pronounced for SEDDS containing indomethacin (0.027 [mInd] versus 0.005–0.015
[mPro, mFen]). Increasing density would theoretically lead to decreasing values of ∆U,
provided that the drug concentration does not change the apparent bulk compressibility
in the mixture. The unusual finding for indomethacin could therefore only be explained
with a dominating drug effect on the apparent bulk compressibility which appears to
have. outweighed the increasing density induced by indomathacin. This drug strongly
affected the structure of the lipid mixture, and reduced compressibility originated from
a perturbation of the liquid-crystalline structure by the drug. Drugs with a strong effect
on the structuring of SEDDS are suitable candidates for analytics based on ultrasound
velocity.
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7.4 Conclusions
Raman spectroscopy and URT were well suited for rapid and non-destructive drug quan-
tification in complex lipid-based formulations. Therefore, both methods have a high
potential for implementation as PAT tools in real-time monitoring the production of
SEDDS or other lipid mixtures. These methods are not only useful in process analysis
but may also be used when simple and rapid calibration is required, e.g., during for-
mulation development where the composition of the formulations may be varied. Since
the development of a formulation-specific method is time-consuming, rapid calibration
is clearly advantageous.
Raman spectroscopy has an advantage over URT because it even detects impurities and
degradation products. However, the modern ultrasound method has proven to be sim-
ple and fast, while showing excellent calibration performance with API quantification
in SEDDS. Specifically, the response of ultrasound attenuation resulted in high sensi-
tivity and good predictability. Therefore, ∆A bears the advantage of broad application
as a parameter for drug quantification, while ∆U is particularly suitable for predicting
drug concentrations if a pronounced influence of the drug is exerted on the apparent
compressibility or density of the mixture.
Chapter 8
Final remarks and outlook
The prediction of formulation performance in vivo is a key requirement for the rational
and effective development of novel formulations. The present thesis aimed at improving
the biopharmaceutical understanding of LBF performance in the GI tract using in vitro
assays, advanced analytical tools, and mathematical modeling.
The quality of biopharmaceutical studies depends on the availability of adequate ana-
lytical techniques. There has been an increasing realization that LBF processing in the
GI tract is highly dynamic and that conventional analytical tools often fail in detecting
these changes accurately. This is particularly true for drug precipitation during LBF
dispersion and digestion. Real-time analytics has therefore become a desirable goal, but
its application to biopharmaceutical tests was shown to be challenging. This is due,
on the on hand, to the complexity and the intrinsic turbidity of testing media. On the
other hand, the low absolute concentration of analyte is often below the detection limit
of conventional instrumentation.
We identified Raman spectroscopy as an excellent technique for biopharmaceutical test-
ing of LBFs. The chemical specificity and the ability to differentiate between physical
states were two main advantages. Additionally, it provided highly time-resolved data,
which was appropriate for studying the kinetics of drug precipitation in more detail. In
this context, we also found evidence of the experimental drawbacks of off-line techniques
for precipitation detection. Ultracentrifugation was the state-of-the-art method for de-
tecting drug precipitation during in vitro lipolysis so far. However, we observed that the
lag time between sample removal and analysis can lead to further drug precipitation.
Care is therefore needed when applying such off-line procedures for the analysis of fast
dynamic processes.
Raman spectroscopy bears great potential for further application in biopharmaceutical
LBF testing. It is primarily a research tool and may provide major opportunities for
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studying drug solubilization during LBF processing on a mechanistic basis. However, the
technique could also be implemented in industrial formulation development. A potential
direction is the use of Raman spectroscopy in high-throughput formulation screening,
and for this purpose, miniaturization of in vitro assays and of Raman tools should be
considered.
Certain biopharmaceutical processes involving LBFs remain hardly accessible using in
vitro methods. For example, it is technically difficult to simulate an absorptive sink
during formulation lipolysis. We proposed an alternative approach, which was based on
the combination of in vitro lipolysis with mathematical modeling. This was the very
first approach that enabled to study formulation digestion in an absorptive environment.
It provided clear evidence that the extent of supersaturation in the intestinal lumen is
considerably lower than during in vitro lipolysis. Hence, standard in vitro lipolysis may
overpredict the extent of drug precipitation, whereas formulation digestion in vivo is
probably less critical than assumed so far. This improved biopharmaceutical under-
standing provided leads to rationally select appropriate in vitro models for LBF testing.
Mathematical modeling proved also helpful for improving the mechanistic understand-
ing of drug solubilization during LBF dispersion and digestion. For example, the non-
interacting model of drug solubilization showed that a loss in excipient interactions can
lead to extensive drug precipitation upon dispersion of a formulation. Such an approach
may be helpful to identify critical drug loadings in LBFs. Similarly, we introduced an
heuristic approach to model drug solubilization during LBF digestion. This model al-
lowed the determination of the kinetics of lipolysis-triggered drug precipitation and drug
solubilization in the GI tract.
These advancements may substantially improve the mechanistic understanding of for-
mulation performance in vivo. Moreover, excellent opportunities are provided regarding
the optimization of physiologically-based models involving LBFs. A drug precipitation
step could be included and, to this end, the complex interplay between formulation lipol-
ysis, drug absorption, and the kinetics of precipitation should be further investigated.
Additionally, it would be desirable to consider biological effects of drug and excipi-
ents (e.g., the influence on efflux mechanisms and on the lymphatic drug transport) in
physiologically-based models. Such holistic approaches are a key requirement for better
predicting the oral bioavailability of LBFs.
Hence, the present thesis allowed an important step forward toward an accurate predic-
tion of LBF performance in vivo. Analytical advancements and mathematical models
provided new insights into the formulation processing in the GI environment. The find-
ings were highly encouraging and evidenced that LBFs still bear a great potential for
the oral delivery of poorly water-soluble compounds.
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